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General introduction and  
outline of the thesis
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GeneRAl InTRoDuCTIon
Aspergillus is a mould fungus found ubiquitously in the environment, but most abun-
dantly in soil and water. It continuously forms spores, which become airborne once 
they came into contact with the surrounding air and are dispersed easily due to their 
high hydrophobicity [1-3]. We inhale several hundred conidia per day that continuously 
interact with our immune system [2, 4]. We evolved a sophisticated host defence system 
that both controls and tolerates the fungal burden [5]. A dysregulated host response 
towards Aspergillus, either being hyper- or hypo-reactive, is the cause for developing 
Aspergillus-related disease [6].
THe ASPERGILLUS sPeCIes
Many species belong to the Aspergillus family, but the species A. fumigatus is the most 
prevalent disease-causing agent [3]. Many factors contribute to this fact: A. fumigatus 
grows and survives under a wide range of environmental conditions [7], it adapts very 
effi  ciently to the nutrients in immunocompromised hosts and is able to colonize the 
lung of allergic patients; due to their size the conidia (2-3 μm diameter) can reach the 
alveoli easily [3, 8-10]. Interestingly, in allergic and invasive pulmonary aspergillosis 
the prevalence of diff erent Aspergillus spp. is quite similar. While A. fumigatus is the 
most commonly isolated strain followed by A. fl avus, species like A. niger, A. terreus or 
A. nidulans are much less prevalent [11-13]. Studying the Aspergillus-host-interaction 
requires appreciation of both the pathogen and the host cell(s) it encounters. The cell 
wall of the Aspergillus conidium consists of an outer hydrophobic rodlet layer and an in-
ner polysaccharide core, which can biochemically be separated into an alkali-insoluble 
fraction containing β-(1,3)-glucan covalently bound to chitin and galactomannan (GM) 
and an alkali-soluble fraction composed of a linear chain of α-(1,3)glucan linked GM 
β-1,4-linked homopolymer of  
N-acetylglucosamine (GlcNAc) 
Chi$n	
β-glucans	
Manno-	
proteins	
Cell		
membrane	
GM/GAG	
figure 1: The polysaccharide cell wall of the Aspergillus conidium with special attention to chitin
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or galactosaminogalactan (GAG) [14] (Figure 1). The rodlet layer shields the resting As-
pergillus conidium from recognition by the immune cells [15]. Once the different types 
of polysaccharides are exposed, their interaction with the immune system differs [14]: 
while a pro-inflammatory response has been associated with β-(1,3)-glucan recognition, 
an anti-inflammatory function has been described for GAG [16, 17], and both anti- and 
pro-inflammatory responses have been described for chitin [18-21].
fRoM InnATe To ADAPTIve IMMune ResPonses In AsPeRGIllosIs
Once an Aspergillus conidium is inhaled, a whole network of host cells consisting of lung 
epithelial cells, macrophages, NK cells and neutrophils will respond fast, but nonspecifi-
cally to the invading fungus. Conserved structures present on invading microorganisms 
are recognized by pattern recognition receptors (PRRs), and activation of subsequent 
signalling pathways leads to secretion of innate cytokines that initiate the differentiation 
of naïve T cells towards T helper cells. PRRs allow innate immune cells to initiate differ-
ent responses dependent on the microorganism it encounters, a concept that was first 
postulated in 1989 by Charles Janeway [22]. In 1991 the Toll gene was found to regulate 
anti-fungal immunity in Drosophila [23], and in 1996 Toll-like-receptors (TLRs) were de-
scribed in humans as the first class of PRRs, discoveries for which the Nobel prize was 
awarded in 2011 [24, 25]. Over decades several other classes of PRRs such as NOD-like 
receptor (NLRs), C-type lectins receptors (CLRs) and RIG-I-like receptors (RLRs) have 
been discovered. Once those receptors have regognized the corresponding pathogen 
associated molecular pattern (PAMP) downstream signalling cascades consisting of 
various kinases or adapter molecules get actived. For example, the dectin-1 receptor 
signals after binding of β-(1,3)-glucan via Syk kinase and the adapter molecule CARD9. 
Activation of the transcription factor NF-κB results in transcription of genes encoding 
for pro-inflammatory cytokines, such as pro-IL-1β. Once a second signal is provided the 
inflammasome containing the caspase-1 gets activated and pro-IL-1β is cleaved into the 
active IL-1β. This pro-inflammatory cytokine machinery underlies a tight regulation to 
prevent from overshooting cytokine stimulation. Crosstalk and co-signalling between 
different receptors and pathways can explain the variety of different types of immune 
responses. Via this mechanism fungal PAMP binding the corresponding PRR can direct 
the adaptive immune response [26]. Although less fast, the initiation of a specific and 
durable adaptive immune response is crucial for successful clearance of the pathogen. 
After recognition of Aspergillus by cells of the innate immune system such as alveolar 
macrophages, cytokines produced by innate cells will lead to the differentiation of naïve 
CD4+ cells into different T helper (Th) subsets (Figure 2).
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Plasticity of immune cells is an effi  cient mechanism of the immune system to adapt to 
diff erent conditions quite rapidly. It has been shown that the type of cytokines present 
in the environment determines the direction of the diff erentiation of the cell, resulting in 
the Th subsets Th1, Th2, Th17, Th22 or Th9, some of them having plasticity [27].
IL-12 and IL-18 initiate the diff erentiation towards Th1; a strong Th1 response has been 
associated to be protective for invasive aspergillosis [28]. In contrast, IL-4 triggers Th2 
diff erentiation characterized by the production of IL-4, IL-5 and IL-13, cytokines that have 
been shown to drive pathology in allergic bronchopulmonary aspergillosis by inducing 
mucus production, mast cell activation and eosinophilia [29]. A strong Th2 response 
is detrimental for successful fungal clearance [28]. Less clear is the role of the more 
recently described Th17 cells. In the presence of IL-1β and IL-23, Th cells can diff erentiate 
into Th17 cells that are characterized by the production of the cytokines IL-17 and IL-22. 
On the one hand, Th17 cells were shown to mediate antifungal control at the site of the 
mucosa; on the other hand they have been associated with harmful eff ects [30]. In addi-
tion, another distinct subpopulation of CD4+ T helper cells, the Th22 cells characterized 
by their production of IL-22 and TNFα, play an important role in mucosal host defence 
[31]. Another more recently described T helper subset are Th9 cells: in the presence 
of IL-4 and TGFβ a naïve T cell diff erentiates into a Th9 cell, which promotes allergic 
infl ammation [32, 33]. Interestingly, also Th17 cells have been described to be a source 
for IL-9. TGFβ and IL-1β can induce both IL-9 and IL-17 in T cells that play an important 
role in driving pathology in autoimmune diseases [34, 35]. Moreover, in this context, the 
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figure 2: Schematic overview: from innate to adaptive host defence in aspergillosis. Defi ciency due to 
Th1 and possibly Th17 leads to invasive aspergillosis (IA), while overwhelming Th2 reaction can cause 
allergic bronchopulmonary aspergillosis (ABPA). AMPs (antimicrobial peptides).
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regulatory T cells are an important counterpart suppressing Th1, Th2 and Th17-mediated 
infl ammation in the Aspergillus-specifi c host response.
ClInICAl synDRoMes AssoCIATeD wITH ASPERGILLUS AnD oTHeR 
oPPoRTunIsTIC PATHoGens
As already mentioned, a healthy immune system can easily handle the tremendous 
amount of inhaled Aspergillus conidia. Patients with underlying diseases severely aff ect-
ing the immune response are prone to develop fungal diseases or other opportunistic 
infections. The clinical spectrum of Aspergillus-associated diseases ranges from allergic 
bronchopulmonary aspergillosis (ABPA), an allergic reaction in a chronically colonized 
lung, to localized infections such as chronic pulmonary aspergillosis or to invasive as-
pergillosis (IA), [36] (Figure 3).
AbPA
Fungal pathogens have been linked to allergy causing agents for the fi rst time by Storm 
Van Leeuwen in 1925 [1] and cases with ABPA have been reviewed for the fi rst time 
1952 by Hinson et al. [37]. A hypersensitive reaction to Aspergillus is the core immu-
nopathological mechanism underlying ABPA. While asthma with fungal sensitization 
aff ects roughly 33% of severe asthma patients, ABPA is less common. Around 10% of 
cystic fi brosis (CF) patients and 2% of asthma patients suff er from APBA [38]. The typical 
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figure 3: Clinical spectrum of Aspergillus-associated diseases (adapted from Denning et al. Clinical 
and Translational Allergy 2014)
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diagnostic criteria of ABPA comprise asthma, immediate skin reactivity to Aspergillus 
antigens, serum IgE > 1000 ng/ml and facultative central bronchiectasis [39]. Mainstays 
of the therapy are a general immunosuppressive treatment with oral administration of 
corticosteroids next to antifungal therapy with itraconazole, which has been shown to be 
beneficial for ABPA patients [40].
loCAlIzeD ASPERGILLUS InfeCTIons
Especially pre-formed cavities such as bronchiectases in the lung or the sinus of the 
skull base are preferential localisations for localized Aspergillus infections, such as as-
pergilloma in the lung or skull base osteomyelitis [36, 41]. As long as Aspergillus does not 
invade surrounding blood vessels, theses infections can present without any symptoms. 
Otherwise haemoptysis or headache and nerve palsy, respectively, are common symp-
toms. These patients are not generally immunocompromised, but rather have specific 
immune defects with the consequence that aspergillomas can exist not rarely for over 
years before being noticed [36].
InvAsIve AsPeRGIllosIs
Neutropenia is the most common risk factor for the development of IA especially affect-
ing patients, who underwent an organ or bone-marrow transplantation [42]. Diagnosis 
remains challenging, since fungal cell wall components measured in the blood, such as 
galactomannan and β-glucan, are difficult to detect during the early stage of disease and 
immunological parameters are often unreliable due to the severe immunosuppression 
in patients that develop IA [43]. Despite early and adequate treatment with Amphotericin 
B or azoles the mortality of IA remains very high, ranging from 30% - 60% depending on 
the grade of immunosuppression and the grade of dissemination of the IA [42].
CAnDIDIAsIs
Aspergillus is not the only fungal pathogen that has been associated with allergic syn-
dromes and infections in immunodeficient patients: a whole range of different fungal 
species other than Aspergillus can lead to allergic bronchopulmonary mycosis or in-
vasive infections [44]. Also clinical syndromes presenting with Candida infections that 
are associated with allergic phenotype are known. Candida is a commensal of the body 
and an opportunistic pathogen. It can cause infections in immunocompromised patients 
such as patients undergoing organ or bone marrow transplantation or suffering from 
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haematological malignancies [45]. Furthermore, another group of patients has recently 
been described to be on high risk to develop mucosal Candida infection: patients with 
an IL-17 deficiency [46]. Patients with a loss-of-function mutation in the STAT3 gene, lead-
ing to lower activity of RORγT, the transcription factor mediating the differentiation of a 
naïve CD4 cells towards a Th17 cell, suffer from hyper IgE syndrome (HIES). Clinically, 
they present with a higher susceptibility for infections, such as recurrent staphylococ-
cal skin or pulmonary infections as well as chronic mucocutaneous candidiasis (CMC), 
but also with an allergic phenotype; they suffer from eczema, eosinophilia and high IgE 
serum levels [47]. Another cause of CMC, a gain-of-function mutation in the STAT1 gene 
leading to a STAT1 hyperphosphorylation and complete lack of IL-17 producing cells, has 
recently been identified [48, 49]. In contrast to the HIES patients, CMC patients do not 
present with an allergic phenotype.
non-TubeRCulous MyCobACTeRIA
The lung of patients with cystic fibrosis (CF) is often colonized with Aspergillus as well as 
with opportunistic bacteria, such as non-tuberculous mycobacteria (NTM) [50]. Similar 
to Aspergillus, NTMs are ubiquitously in soil and water and infections are commonly 
associated with underlying immunodeficiencies. Especially defects affecting the IFNγ-
signalling, such as polymorphisms in the IFNγ, IL-12 or STAT1-pathway or even autoan-
tibodies against IFNγ cause a high susceptibility to NTM infections [51]. In addition to 
CF patients, patients with the Lady Windermere syndrome are at high risk to develop 
NTM infections. These patients present with a unique marfanoid body phenotype and 
demonstrate a skewed immune response with lower IFNγ and TGFβ levels [52, 53]. There 
are interesting clinical and immunological parallels between these clinical syndromes 
associated with opportunistic fungal and mycobacterial infections.
In conclusion, clinical presentations caused by fungal and other environmental op-
portunistic pathogens are mainly determined by the immunological status of the host. 
Deviations from the normal status into either a hyper-reactive or an immunocompro-
mised status are associated with allergic or invasive aspergillosis, respectively. Little is 
known about the exact underlying immunopathology. The aim of this thesis is to use a 
multidisciplinary approach and to combine genetic, immunological and clinical knowl-
edge to increase our knowledge of the dysregulated pathways and immunophenotypes 
associated with these diseases.
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ouTlIne AnD AIMs of THe THesIs
Fungus associated molecular patterns and human pattern recognition receptors have 
a continuous interplay that is essential for preventing infections. In this thesis I aim to 
identify the recognition pathways and T helper responses involved in the host response 
in allergic and invasive aspergillosis, as well as opportunistic infections often associ-
ated with an altered immune status. By studying genetic polymorphisms as well as 
immunological mechanisms underlying the various opportunistic infections we can gain 
knowledge to develop more target-specific immune-modulatory therapies to supple-
ment conventional treatment regimens that are often limited in their effectiveness and 
accompanied with severe side-effects.
ASPERGILLUS ReCoGnITIon AnD InITIATIon of T HelPeR ResPonses
Once an Aspergillus conidium is inhaled it first encounters the innate immune cells of 
the respiratory tract. Many studies have been performed to identify pattern recognition 
receptors and different cell populations orchestrating the antifungal immune response 
to efficiently clear the invading pathogen. How these receptors and cells form a complex 
network in the Aspergillus-specific immune response is reviewed in Chapter 2.
To successfully clear the fungal invaders the first step is the successful recognition of 
fungal PAMPs by human PRRs. Polysaccharides are crucial components of the fungal 
cell wall. While for many of them, such as β-glucans and mannose, human PRRs had 
been identified, there is controversy about the receptor(s) recognizing the polysaccha-
ride chitin. On the one hand chitin has been described not to be immunogenic [21], on 
the other hand a profound anti-inflammatory capacity mediated via mannose receptor 
and TLR9 [18] has been attributed to chitin. Since few studies have been performed in 
human cells to date, we studied the immunological properties and PRRs of Aspergillus 
chitin in the human context, see Chapter 3.
Following the innate immune response against Aspergillus, specific adaptive cytokine 
combinations are induced which stimulate different Th responses. Thereby, different 
PRRs trigger different Th responses, which are again associated with a different clinical 
presentation of aspergillosis. A strong Th1 response has been associated with a suc-
cessful fungal clearance and Th17 responses represented by the production of IL-17 and 
IL-22 were associated with either detrimental or protective effects. In contrast, elevated 
Th2 responses are associated with allergic symptoms and Aspergillus is a potent inducer 
of allergic reactions causing ABPA. Which receptors, lymphocyte subsets and regulating 
cytokines are involved in the Th1 and Th17 responses, is displayed in Chapter 4. 
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To characterize the whole range of Th responses in aspergillosis we studied pattern 
recognition pathways leading to Aspergillus-specific Th2 responses. In Chapter 5, we 
investigated the PRRs leading to a Th2 cytokine bias of the Aspergillus-specific host 
response, and we characterized the Th cytokine profile of ABPA patients compared to 
healthy controls and asthma patients sensitized with Aspergillus.
Several fungal infections have been associated with mutations in genes encoding 
for anti-fungal immune responses that result in dysregulation of certain cytokines. 
The search for unknown genetic variations can be crucial to better understand fungal 
diseases. Only a few studies have been performed to date, which identify the genetic 
background in ABPA patients [54]. Therefore, we have studied the genetic background 
of patients with ABPA in an Indian cohort and compared this genetic background with 
patients with asthma, as well as with healthy controls from the same geographic region 
(Chapter 6).
After successful recognition, Aspergillus conidia are phagocytosed and intracellularly 
killed in phagolysosomes mediated by the low pH and a high concentration of reactive 
oxygen species (ROS) produced by the NADPH-oxidase. Patients with chronic granu-
lomatous disease (CGD), who lack the NADPH-oxidase, are at great risk for Aspergillus 
infections [55]. Although A. fumigatus is the most commonly isolated Aspergillus species 
in CGD patients, A. nidulans is much more prevalent in these patients compared to other 
immunocompromised patients, e.g. after stem cell transplantation. In Chapter 7, we aim 
to identify differences in phagocytosis and killing as well as in the induction of cytokines 
and ROS molecules between A. fumigatus and A. nidulans, which might help to explain 
the higher prevalence of A. nidulans in CGD patients.
T HelPeR DefICIenCIes In ClInICAl seTTInGs
Aspergillus typically affects the lung and only rarely the bone and even less com-
monly the skull base. While IA or ABPA patients usually have an immunocompromised 
or hyperreactive immune response, respectively, the immune defect in patients with 
Aspergillus skull base osteomyelitis (SBO) was unknown. In Chapter 8, we investigated 
whether these patients demonstrate a certain immunological profile that would explain 
their higher susceptibility to Aspergillus skull base infections.
In addition to ABPA there are more fungus-related immunological disorders associ-
ated with an allergic phenotype, such as HIES. In contrast to ABPA patients, who present 
with the classical asthmatic symptoms caused by Aspergillus allergens, in HIES patients 
with a STAT3 LOF mutation, the skin is primarily affected. They present on the one hand 
with allergic skin symptoms such as atopic features, namely eczema, eosinophilia and 
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high IgE levels, but also with skin infections, such as chronic mucocutanous candidiasis 
and staphylococcal skin abscesses [47]. These patients demonstrate a deficient Th17 
response, which is also a characteristic feature of CMC patients with a STAT1 GOF muta-
tion. HIES and CMC have very similar clinical phenotypes and underlying immunological 
defects. In Chapter 9, we compare the allergic immune responses against Aspergillus, 
Candida and S. aureus of HIES and CMC patients to investigate how in the setting of an 
IL-17 deficiency the allergic Th2 and Th9 responses are modulated and whether there 
would be differences that might explain an allergic phenotype in HIES which is not pres-
ent in CMC.
Opportunistic pathogens cause pulmonary infections only in patients with immu-
nological deficiencies. Similar to Aspergillus, non-tuberculous mycobacteria (NTM) 
can cause chronic colonisation and pulmonary infection in immunodeficient patients 
and they are often present together, most obviously in patients with CF. In contrast to 
a healthy lung, the lungs of CF patients has a very diverse microbiome consisting of 
environmental pathogens such as Aspergillus and NTMs. The majority of CF patients 
is chronically colonized with Aspergillus, which leads to the full clinical picture of ABPA 
in 10% of the cases [38]. In addition, the CF lung is chronically colonized with NTMs 
[56]. However, a strict distinction between infection and colonisation is difficult. Similar 
pathways in cytokine signalling have been associated with both fungal as well as NTM-
associated diseases, especially IFNγ-signalling defects [57]. We therefore investigated 
immune responses of different patient groups with NTM infection. In Chapter 10, we 
compared the immunological profile of three CF patients infected with M. abscessus 
with a group of non-CF patients with pulmonary NTM infections to rule out whether the 
CF patients demonstrate deficiencies in M. abscessus-specific Th responses that might 
explain their higher susceptibility to M. abscessus.
NTM infections are not only seen in patients with CF, but have been reported more 
frequently from patients exhibiting a unique body phenotype with elongated fingers, 
scoliosis and pectus excavatum comparably to patients with Marfan syndrome. This 
phenotype is called ‘Lady Windermere syndrome’ [53]. In Chapter 11, we investigated 
the possible genetic cause for the syndromal physical phenotype and the failure in the 
clearance of NTM infections. We also studied whether these patients demonstrate a 
distinct cytokine production compared to healthy controls. We performed whole-
exome-sequencing in 11 patients and their family members and performed functional 
validation assays.
Finally, a summary of the new findings and a conclusion of this thesis are presented 
in Chapter 12.
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AbsTRACT
A large variety of fungi are present in the environment, among which a proportion 
colonizes the human body, usually without causing any harm. However, depending on 
the host immune status, commensals can become opportunistic pathogens that induce 
diseases ranging from superficial non-harmful infection to life-threatening systemic 
disease. The interplay between the host and the fungal commensal flora is being or-
chestrated by an efficient recognition of the microorganisms, which in turn ensures a 
proper balance between tolerance of the normal fungal flora and induction of immune 
defence mechanisms when invasion occurs. Pattern recognition receptors (PRRs) play 
a significant role in maintaining this balance due to their capacity to sense fungi and 
inducing host responses such as the induction of proinflammatory cytokines involved in 
the activation of innate and adaptive immune responses. In the present review we will 
discuss the most recent findings regarding the recognition of C. albicans and A. fumiga-
tus and the different types of immune cells that play a role in antifungal host defence.
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InTRoDuCTIon
During the last few decades the prevalence of fungal infection has considerably in-
creased, especially due to the immunosuppressive treatments in cancer therapy, trans-
plantation, and the HIV epidemics (1). Moreover, pathogenic fungi are able to rapidly 
adapt and become resistant to antifungal agents (2). The human commensal Candida 
albicans and the environmental fungus Aspergillus fumigatus are facultative pathogens, 
which in immunocompetent individuals do not cause infection. However, immunocom-
promised patients are prone to systemic fungal infections in which mortality rates can 
rises up to 60% (3). While the clinical presentation of candidiasis and aspergillosis dif-
fers, the mechanisms needed to control infection including the pattern recognition and 
inflammatory networks share many characteristics.
PATTeRn ReCoGnITIon ReCePToRs In funGAl InfeCTIon
Both Candida and Aspergillus undergo a continuous morphology switch between yeasts 
and hyphae, resulting in differential exposure of fungal pattern associated molecular 
patterns (PAMPs). C. albicans cell wall contains carbohydrate polymers and glycopro-
teins, comprising mainly chitin, β-1,3- and β-1,6-glucan and O- and N-linked mannan. 
The Aspergillus cell wall is predominantly composed of chitin, α-glucans, β-(1,3)-(1,4)-
glucans, and galacatomannans. One important feature of the Aspergillus conidial cell 
wall is the outer layer of hydrophobic rodlets. During swelling of the conidial cell wall 
and subsequent germination, the hydrophobic layer changes into a hydrophilic structure 
exposing polysaccharides. During the course of fungal infection and invasion, the first 
crucial step in mounting effective immune responses is the recognition of the invaders 
by the host. Various PRRs on differential cell populations will recognize fungal invaders 
and trigger bona fide signalling pathways and cellular responses (Figure 1).
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C-type lectin receptors (CLRs)
Mannans present in the outer layer of Candida and Aspergillus cell wall come in direct 
contact with the host and can be recognized by the C-type lectin receptors (CLRs). Man-
nose receptor (MR), primarily present on macrophages, recognizes Candida N-mannan 
(4), and further induces IL-17 (5). MR has also been shown to recognize Aspergillus co-
nidia and induces proinflammatory cytokines (5). Dectin-2, which is mainly expressed 
on DCs, macrophages and neutrophils recognizes Candida α-mannan and also triggers 
IL-17 (6). In addition to its role in modulating Th responses, Dectin-2 has also been 
associated with ROS production, as well as phagocytosis and killing of C. glabrata (7). 
figure 1: Recognition of C. albicans and A. fumigatus by innate immune cells
The pattern recognition receptors Dectin-1, Dectin-2, Dectin-3, FC gamma receptor (FcRγ), Mannose 
Receptor (MR), Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Nonintegrin (DC-SIGN), 
Mincle, Mannan-Binding Lectin (MBL), Complement Receptor 3 (CR3), Galectin-3, Cluster of Differentiation 
36 (CD36), Toll-Like Receptors (TLRs), NACHT, LRR, and PYD domain–containing protein 3 (NLRP3), and 
Nucleotide-binding Oligomerization Domain–containing protein 2 (NOD2) recognize the fungal cell wall 
components β-glucan, α-mannan, β-mannan, N/O-mannan, phospholipo-mannan (PLM), glucuronoxylo-
mannan (GXM), chitosan, chitin, or fungal DNA and RNA. These signals activate canonical or non-canonical 
nuclear pathways, with the subsequent induction of an immune response, such as secretion of cytokines, 
chemokines, initiation of phagocytosis or inflammasome activation.
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Dectin-2 forms heterodimers with Dectin-3, leading to proinflammatory responses upon 
C. albicans infection (8). Dectin-2 is also important for the Aspergillus-specific immune 
response, being upregulated upon recognition of the fungus. Its expression is restricted 
to the population of monocyte-derived macrophages (9).
Galectin-3 on macrophages recognizes β-mannans (10), and induces a protective anti-
fungal response in murine macrophages through the secretion of TNFα. Moreover, mice 
deficient in galectin-3 are more susceptible to disseminated candidiasis (11). Mincle is a 
CLR expressed on monocytes and neutrophils, yet with an unknown ligand. In murine 
models Mincle was responsible for inducing protective responses against C. albicans, 
mainly by the initiation of TNFα production; mice deficient in this receptor were drastically 
susceptible to systemic candidiasis (12). However, the role of Mincle in Aspergillus rec-
ognition is still unknown. DC-SIGN is present on dendritic cells as well as macrophages, 
and recognizes Candida N-linked mannan (13), and can bind and internalize Aspergillus 
conidia (14). It induces a cascade of cytokines that activate T helper cells in order to 
differentiate and initiate adaptive immune responses. Mannose-binding lectin (MBL) is 
a soluble CLR that also binds mannan modulating the recruitment of phagocytes and 
proinflammatory responses against Candida (15).
β-1,3- and β-1,6-glucan is shielded by the mannoproteins in C. albicans yeast, but it is 
exposed on budding yeast, and Candida hyphae. Dectin-1, a well-described CLR present 
on macrophages and monocytes, binds to a long β-1,3-glucan chain (16) inducing cyto-
kines as well as internalization of the fungus upon formation of a “phagocytic synapse” 
(17). Resting Aspergillus conidia do not present abundant β-glucans on their surface 
either, which might account for the redundant role of Dectin-1 in induction of different 
Th subsets in experimental in vitro-models (18, 19). Inhibition of Dectin-1 on alveolar 
macrophages did not affect phagocytosis of resting A. fumigatus conidia (20). In contrast, 
alveolar macrophages stimulated with germinated conidia produce innate cytokines via 
the Dectin-1 pathway (21). Dectin-1 was described to be involved in both clinical spectra 
of aspergillosis: in an invasive aspergillosis mouse model, IL-17 production was mediated 
by Dectin-1 and was dependent on IL-23 (22); in an allergic mouse model Dectin-1 was 
demonstrated to drive pulmonary pathology via IL-22 production (23). Corticosteroids 
blocked Aspergillus-induced autophagy via the Dectin-1/Syk pathway (24), and cortico-
steroid resistant asthma was associated with detrimental IL-17 and IL-22 production (25), 
suggesting a strong role for autophagy and Dectin-1 to drive pathology in severe forms of 
asthma. Dectin-1 polymorphisms were not associated with disseminated candidiasis in 
humans, but were associated with Candida colonization, while susceptibility to invasive 
aspergillosis was dependent on dectin-1 polymorphisms (26, 27). In conclusion, CLRs 
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play an important role in mediating immunity against Candida and Aspergillus through 
inducing Th derived cytokines and mediating uptake of the fungus.
Toll like receptors (TLRs)
TLRs have been extensively studied in the context of fungal recognition. TLRs play a 
significant role in a murine model of disseminated candidiasis and together with IL-1 
receptor activate several potent antifungal-signalling mechanisms (28). TLR2-/- mice 
were reported to have an increased susceptibility to disseminated candidiasis that could 
be attributed to a decreased secretion of TNFα and MIP-2 and impaired recruitment 
of neutrophils. In contrast, others have shown that TLR2-/- mice are more resistant to 
systemic candidiasis exhibiting an increased chemotaxis and IFNγ secretion, while IL-10 
was significantly impaired. Interestingly, the recruitment of monocytes was enhanced 
in TLR2-/- mice, suggesting an increase in the candidacidal activity in these mice (29). 
TLR4-/- mice were more susceptible to systemic candidiasis due to an impaired secre-
tion of KC and decreased neutrophil recruitment resulting in a higher fungal burden in 
the kidneys (30). However, TLR1 polymorphisms, but not TLR2 and TLR4 polymorphisms 
have been associated with human susceptibility to C. albicans infection (27). TLR4-/- mice 
were more susceptible to Aspergillus infections and TLR4 polymorphisms were associ-
ated with invasive aspergillosis (28, 31). Immunosuppression of TLR2-/- mice resulted 
in higher susceptibility to Aspergillus infections (32), however polymorphisms in TLR2 
were not associated with invasive aspergillosis (26). The intracellular receptor TLR3 
recognizes fungal nucleic acids. TLR3 had a protective role against Candida as a muta-
tion in the L412F variant of TLR3 led to lower activation of NF kB and decreased levels 
of IFNγ, resulting in increased susceptibility to cutaneous candidiasis (33). TLR3-/- and 
TRIF-/- mice were found to be susceptible to invasive pulmonary aspergillosis, and TLR3 
polymorphisms have been associated with invasive aspergillosis (26, 34), suggesting 
an important role of TLR3 in mediating protection against Aspergillus infection as well. 
Conclusions on the role of TLR7 and TLR9 in fungal infection have not been consistent, 
and no polymorphisms in TLR7 and TLR9 have been associated to date with invasive 
aspergillosis or candidiasis (26, 27).
NOD-Like receptors (NLRs)
NOD1 and NOD2 are intracellular NLRs that recognize bacterial peptidoglycans. Chitin-
mediated responses, such as the induction of IL-10, were found to be dependent on 
NOD2 as well as TLR9 and MR (35). However, there is presently only in-vitro data to 
support a role for NOD2 in fungal infection, no in-vivo studies in NOD2 mice have been 
performed and no studies have been performed on the role of NOD1 in fungal infection. 
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The best-characterized NLR is NLRP3, which is a component of the inflammasome. 
Mice deficient in NLRP3 were more susceptible to Candida infections (36-38). One study 
showed involvement of NLRP3 in anti-Aspergillus host defence in-vitro, however dis-
seminated aspergillosis has not been studied in NLRP3 deficient mice (39).
InflAMMAToRy neTwoRks
Recognition of fungal associated molecular patterns by PRRs will lead to the initiation of 
an efficient host defence that is mandatory to clear the invading fungus. Several popula-
tions of cells are involved that orchestrate this clearance (Figure 2).
figure 2: Inflammatory networks of the innate immune response against Aspergillus
1) Inhaled Aspergillus conidia reaching the alveoli, are endocytosed by the lung epithelial cells, in which they 
survive or escape from via hyphal formation. Epithelial cells react upon fungal growth with expression of pro-
inflammatory cytokines. 2) Once internalized in alveolar macrophages and monocytes, Aspergillus conidia are 
phagocytosed, which is prevented by hyphal formation. Acidification in the phagolysosomes is essential for 
the killing of A. fumigatus conidia. Reactive oxygen species (ROS) are produced to effectively kill and eradi-
cate Aspergillus. A defect ROS system of macrophages and monocytes like in CGD is associated with defect 
autophagy resulting in pro-inflammatory cytokine production. 3) Upon invasion, neutrophils are recruited 
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Epithelial cells
The epithelium constitutes a mechanical barrier against invading fungi. C. albicans is 
in permanent contact with epithelial cells and infection with tissue invasion is associ-
ated with morphological changes of yeast into hyphae. Candida hyphae can penetrate 
the epithelial cells through two distinct mechanisms: induced endocytosis and active 
penetration. Epithelial cells respond to Candida with activation of NFκB and cytokine 
production when two pathways are induced; the second pathway, namely MPK1 and 
c-Fos activation, was dependent on hyphal formation. In this way conidia are tolerated 
and germination is seen as a danger signal in which the epithelium plays an important 
initial step to induce a protective inflammatory network (40). Aspergillus species are not 
typical commensals. Lung epithelium not only acts as an efficient barrier, it can also 
phagocytose Aspergillus conidia. Although primary epithelial cells from the respira-
tory tract phagocytose Aspergillus conidia, the killing capacity of these cells is low (41). 
However, they can control outgrowth, and in addition potent antifungal drugs such as 
posocanazol can accumulate in the membranes of lung epithelial cells and in this way 
might contribute to efficient exposure of antifungal drugs during Aspergillus infection. 
Thus epithelial cells can play an important role in fungal infection by restricting fungal 
outgrowth and initiate potent antifungal host responses.
Monocytes and Macrophages
Residential macrophages are phagocytes that are essential in mediating the first steps 
of an effective antifungal host defence. Fungi have evolved strategies to escape these 
initial first steps. Candida can inhibit phagolysosome maturation and production of NO 
by pro-inflammatory cytokines produced by macrophages and monocytes or by IL-17 expressed in RORγt+ 
neutrophils and acting on the IL-17RC receptor via an autocrine feed-back loop. Aspergillus conidia are in-
tracellular killed by the ROS system, while Aspergillus conidia and hyphae bind to neutrophils extracellular 
traps (NETs), which mainly consist of neutrophil DNA and antimicrobial proteins like calprotectin, inhibiting 
the fungal growth without killing. 4) Natural killer (NK) cells are activated by the germinated and hyphal forms 
of Aspergillus and mediate the killing via perforin release or directly via IFNγ. Next to that, IFNγ enhances 
conidial killing by macrophages. 5) The role of innate lymphoid cells (ILCs) in the lung during invasive as-
pergillosis is largely unknown. Invariant (i) NKTcells are directly activated by asperamide B derived from 
Aspergillus and cause together with IL-13, derived from Th2 cells, allergic airway responses. 6) Monocyte-
derived dendritic cells (DC) recognize Aspergillus conidia and hyphae resulting in upregulation of CD80+ and 
CD86+ and the production of IL-8 and IL-12p70. DCs shape adaptive Th responses after migration to the 
lymphnode. Aspergillus conidia induce preferentially, Th1/Treg responses and Aspergillus hyphae Th17/Th2 
responses. DCs, high positive for TNF, mediate differentiation into the Th17 direction with production of IL-17 
and low positive for TNF into the Th2 direction with production of IL-13. 7) As last step of invasion Aspergillus 
can overcome the endothelium and reach the blood stream. All growth forms of Aspergillus activate plate-
lets, which activate monocytes to produce IL-8. Activated platelets are capable to inhibit hyphal formation.
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by macrophages, while Aspergillus can inhibit phagolysosome acidification (20). In addi-
tion, fungi can change the characteristics of macrophages; Candida infection can induce 
a more anti-inflammatory phenotype enhancing fungal survival by switching M1 macro-
phages to a M2 phenotype (42). Recently, the importance of residential macrophages to 
control disseminated fungal infection was elegantly demonstrated. A deficiency in accu-
mulation of residential macrophages in the kidney due to a deficiency in the chemokine 
receptor CX3CR1 led to renal failure and death. Moreover, patients with a polymorphism 
leading to a decreased function in CX3CR1 were more susceptible to disseminated can-
didiasis. These data highlight the essential role of residential macrophages, in particular 
in the kidney to control disseminated fungal infection (43). In addition to macrophages, 
monocytes can also phagocytose spores and inhibit germination. Monocytes have a 
potent conidial killing capacity and are essential in the first 48h to control disseminated 
candidiasis (44). Moreover, monocytes can rapidly differentiate into dendritic cells that 
transport spores to draining lymph nodes, where they prime and expand A. fumigatus-
specific T helper cells (45). In addition, monocytes can augment neutrophil conidiacidal 
activity and play a crucial role in controlling disseminated fungal infection (46).
Neutrophils
Neutrophils are essential to clear fungal invasion, which is underscored by the observa-
tion that immunosuppression with prolonged neutropenia is a major risk factor for inva-
sive fungal infections. Various neutropenic mouse models have clearly demonstrated 
a significant role for neutrophils in disseminated fungal infection. Mice depleted of 
alveolar macrophages prior to pulmonary aspergillosis recruited neutrophils normally 
and were able to restrict hyphal tissue invasion, while neutrophil depletion prior to or 
within 3 h after infection resulted in high susceptibility (47). Neutrophils use oxidative and 
non-oxidative killing mechanisms, which are both essential in Candida and Aspergillus 
infections. The oxidative burst is produced by the enzymes NADPH oxidase and my-
eloperoxidase. NADPH-oxidase deficiency results in the disease chronic granulomatous 
disease (CGD), which is associated with an extraordinary increased susceptibility to 
invasive mold infection, highlighting the importance of NADPH-oxidase in controlling 
fungal infection. Another specific feature of neutrophils is their capacity to rapidly re-
lease granules that mediate extracellular killing. Those granules contain, next to NADPH 
oxidase and myeloperoxidase other proteins with antimicrobial properties, like lyso-
zymes, lactoferrins, elastases, defensins, gelatinases or cathepsin G (48). In a cell-free 
supernatant of de-granulated neutrophils of CGD patients a normal amount of iron-free 
lactoferrin was found, which was capable to decrease fungal growth (49). Additionally, 
neutrophil elastase and cathepsin B were described to have antifungal activity and elas-
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tase was found to contribute to neutrophil extracellular traps (NETs) (50). NETs, which 
are composed of DNA that forms large fibrillar structures that can bind pathogens and 
antimicrobial peptides, provide a mechanism to combat hyphae that are too big to be 
phagocytosed. It was demonstrated that Candida can be captured by NETs, however it 
did not contribute to efficient killing (51). Similarly, NETs were able to limit fungal growth, 
but not to kill Aspergillus conidia and hyphae (50, 52). Bianchi et al. have demonstrated 
that NET formation is deficient in CGD patients and that NET formation can be restored 
by gene-therapy resulting in successful neutrophil-dependent elimination of A. nidulans 
conidia and hyphae. The neutrophil-associated calprotectin was identified to inhibit 
growth of A. nidulans in the NETs of CGD mice after gene therapy (53). The antifungal 
activity of calprotectin is not restricted to Aspergillus; it was also identified as the main 
component in NETs controlling Candida growth in vivo and in vitro (54). CGD is not only 
characterised by a deficiency in neutrophil killing and NET formation. The NADPH oxi-
dase is also present in monocytes and macrophages, and has been shown to be also 
important for controlling fungal infection (55).
In addition, macrophages and monocytes deficient in NADPH-oxidase have a defect 
in autophagy, an intracellular mechanism that can control Aspergillus outgrowth (56). 
Whereas autophagy appears to be crucial for Aspergillus infection, it seems redundant in 
candidiasis, although initially it was reported that mice deficient in autophagy were more 
susceptible to Candida infection (57, 58). A selective killing defect by neutrophils for C. 
albicans, but not for A. fumigatus, was found in CARD9 deficient neutrophils resulted 
in abnormal ultrastructural phagolysosomes and massive hyphal outgrowth, which was 
independent of ROS production and release of azurophilic granules. Neutrophils were 
found to display two independent killing mechanisms; ROS-dependent that was crucial 
for clearing opsonized Candida and CARD9 dependent that was crucial for unopsonized 
Candida (59). This suggests that neutrophils have an unknown killing mechanism that is 
specific for Candida initiated by CARD9.
IL-17 is a potent mediator of neutrophil recruitment. Next to T helper cells and innate 
lymphoid cells, neutrophils themselves have been reported as a source for IL-17, in a 
Dectin-1 and IL-23 dependent manner, and RORγT positive neutrophils exposed to IL-23 
and IL-6 express the receptor IL-17RC (60). This suggests an autocrine feedback-loop 
in recruiting neutrophils to the site of the fungal infection. Mice deficient in IL-17 sig-
nalling are more susceptible to systemic candidiasis. However, patients with an IL-17 
deficiency suffer from mucosal candidiasis, but do not develop invasive candidiasis, and 
are not more susceptible to invasive mould infection. It is still an open question to what 
extend IL-17 determines neutrophil faith and function at the mucosa. In a mouse model 
of oropharyngeal candidiasis IL-17RA-/-and IL-23-/- mice depleted for neutrophils 
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showed higher fungal burden compared to non-neutropenic animals, suggesting that 
IL-17 deficiency does not result in a complete neutrophil function at the site of infection 
(61). In addition, the recruitment of neutrophils by vaginal epithelial cells producing S100 
alarmins was independent of IL-17 production (62).
Dendritic cells
Dendritic cells (DCs) achieve a crucial patrolling function. They are located in the mucosa 
and migrate to the draining lymph nodes to activate T cells. DCs stimulated with the fun-
gal pathogens Aspergillus and Candida showed increased activation markers like CD80 
and CD86, as well as IL-8 and IL-12p70 production (63). Moreover, DCs played a crucial 
role for the host response against Candida via the production of type-I IFNβ in a Dectin/
Syk/IRF5 dependent pathway (64-66). DCs are mainly involved in activation and shaping 
T helper (Th) responses. During pulmonary Aspergillus infection conidial transport from 
the lung to the lung draining lymph nodes, priming of CD4+ T cell responses and the 
prevention of the pulmonary fungal burden was mediated by monocyte derived CD11b+ 
DC population in a murine model (45). Aspergillus conidia triggered a protective Th1 
and Treg responses, whereas Aspergillus hyphae triggered an anti-inflammatory Th2/
Th17 profile (67). The protective DC responses were dependent on the PI3K/Akt/mTOR 
pathway, while the anti-inflammatory DCs depended on STAT3/IDO activation (67).
The direction of the airway inflammation in mice into either Th2 or Th17 was dependent 
on TNFα produced by monocyte-derived DCs: BALB/c mice showed a high amount of 
TNFα-producing DCs promoting Th17 responses with subsequent neutrophils recruit-
ment, while C57BL/6 mice displayed a low amount of TNFα producing DCs, associated 
with high IL-5 levels and eosinophilia (68). Plasmacytoid DCs (pDCs) represent a specific 
subset of DCs, and in the context of fungal infections have not been studied in great ex-
tend. In a mouse model of invasive aspergillosis a specific influx of pDCs was observed, 
and depletion of pDCs resulted in an increased susceptibility to invasive aspergillosis. In 
vitro analysis showed that hyphal growth was inhibited by pDCs in a contact-independent 
manner. Interestingly, pDCs produced inflammatory cytokines, such as IFNα and TNFα 
that were independent of TLR9 (69). In contrast, pDCs in a vaginal candidiasis model 
were suggested to mediate tolerance, since pDCs that were were present in the draining 
lymph nodes of the infection lacked the upregulation major histocompatibility complex 
class II, CD80, CD86, and CD40 (70). This could points to a crucial difference in pDC 
responses induced by Aspergillus or Candida that might be dependent on the site of 
infection.
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Innate lymphoid cells
Recently, a novel population of innate lymphocytes called innate lymphoid cells (ILCs) 
has been identified. ILCs are analogous to Th helper subsets, but differ because they 
lack the T cell receptor. They have been named according to their cytokine profile. ILC1 
cells express T-bet and produce IFNγ, ILC2 cells express GATA3 and produce IL-5 and 
IL-13, and ILC3 cells express RORγt and produce IL-17 and IL-22. Only a few studies so far 
have deciphered a role for innate lymphoid cells in the host defence against Aspergillus 
or Candida. The IL-17 producing ILC3 cells have been described as being important in 
the defence against and the control of pathogens at the mucosal barrier. C. albicans is a 
potent inducer of IL-17 (71) and mice lacking IL-17 are highly susceptible to Candida infec-
tions (72). As described earlier, patients with an IL-17 deficient phenotype such as hyper 
IgE syndrome (73) and patients with chronic mucocutaneous candidiasis (74), suffered 
from mucosal candidiasis, but the lack of IL-17 in these patients has been predominantly 
attributed to Th17 cells. Innate lymphoid cells would supply a faster source of IL-17 than 
the adaptive Th17 cells, and they represent an additional important source of IL-17.
The first clues that ILCs play an important role in controlling fungal infection and colo-
nization come from experimental mouse models. Fungal control in a murine model of 
oral candidiasis was mediated by IL-17 secreting ILCs and both, ILC depleted RAG-/- and 
RORC+ ILC-/- mice completely failed to control fungal outgrowth (75). The relevance of 
ILCs in mediating pulmonary host responses in the lung was demonstrated in a study 
where Candida airway exposure was able to protect against Pseudomonas aeruginosa-
induced lung injury, an effect that was dependent on pulmonary ILCs that expressed 
IL-22 (76). It has been demonstrated that ILCs play a role in the pathogenesis of asthma 
and allergic reactions, and the contribution of GATA3+ ILCs to allergic reactions medi-
ated by Aspergillus has recently been studied in patients with chronic sinusitis. These 
patients showed a significant proliferation of GATA3+ ILCs and increased GATA3+ ILCs 
responsiveness to IL-33 induced by Aspergillus extract which resulted in an increased IL-
13 production (77). Interestingly, also invariant NKT (iNKT) cells were found to contribute 
to airway hyperactivity in an IL-33 dependent manner, directly activated by the Aspergil-
lus glycosphingolipid Asperamide B (78). This might explain one mechanism via which 
Aspergillus can directly induce allergic responses in an immunocompetent host, and 
suggests a critical role for ILCs in fungal-induced allergic reactions. The role of ILCs in an 
immunosuppressive status during invasive fungal infection still needs to be investigated.
Natural Killer Cells
Natural Killer (NK) cells contribute to the rapid innate immune response against invad-
ing pathogens in an antigen-independent manner, mainly by recognizing infected cells 
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and induce cell death of the infected cell. NK cells also contribute to the host defence 
against fungal infections. The additional depletion of NK cells in a T/B-cell-deficient 
SCID mice increased the susceptibility to systemic candidiasis, while it had no (or even 
an opposite) effect in immunocompetent mice (79). NK cells might substitute for specific 
functions of B and T cells when these cells are absent, which is in line with the obser-
vation that NK cell activation by Candida results in the production of high amounts of 
GM-CSF, IFNγ and TNFα; cytokines that are also produced by T cells. Although phago-
cytosis by NK cells did not inhibit hyphal growth of Candida, antifungal activity against 
Candida was observed that was mediated by extracellular perforin production by NK 
cells (80). Comparably, NK cells could kill Aspergillus hyphae via a perforin-mediated 
mechanism, while Aspergillus conidia were not affected (81). Bouzani et al. also showed 
that only germinated morphological forms of Aspergillus were able to stimulate NK cells 
to produce high amount of IFNγ. However, in contrast to Voigt et al. and Schmidt et al., 
they propose a perforin-independent killing mechanism, since they observed that the 
killing was mediated via a soluble factor (82). NK cells are potent producers of IFNγ, and 
IFNγ is crucial for controlling Aspergillus infection, which is highlighted by the fact that 
IFNγ knock-out mice displayed an increased susceptibility to invasive aspergillosis. In 
a murine model of invasive aspergillosis, in which neutrophils were depleted, NK cells 
were the major population of cells that were able to secrete IFNγ and to control fungal 
growth in the lung during early infection. The depletion of NK cells in IFNγ-deficient mice 
did not result in increased severity of the infection, while depletion of NK cells in wild 
type mice resulted in a similar increases susceptibility to infection that was observed 
in IFNγ-deficient mice. These data strongly suggest that in neutropenic conditions the 
protective IFNγ responses during early invasive aspergillosis are critically dependent on 
NK cells. (83).
Platelets
Classically, platelets, mediate blood coagulation after interruption of the endothelium. 
In addition, platelets are capable to mediate innate immune functions, especially during 
bloodstream infections. Although in vitro studies failed to show the capacity of C. albicans 
to aggregate human platelets, in vivo platelets bound to C. albicans and were activated 
after bloodstream injection in a murine model (84). Platelets produced peptides like 
Rantes or platelet factor 4 with antimicrobial activity against Candida and platelet-rich 
plasma inhibited the growth of Candida (85). In Aspergillus infection, the production of 
the proinflammatory IL-8 from human monocytes is enhanced by platelets activated by 
Aspergillus hyphae, and all Aspergillus morphotypes had the capacity to activate plate-
lets (86). This seems to be an interesting feedback-loop, since Aspergillus germination 
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and hyphal formation was inhibited by activated platelets (87). Interestingly, not only the 
direct contact of the platelets to Aspergillus was necessary, also Aspergillus cell culture 
supernatant was able to activate platelets, suggesting a potentially harmful contribution 
to systemic infection by increasing thrombotic status during invasive aspergillosis (87).
ConClusIons AnD fuTuRe PeRsPeCTIves
During past years fungal pathogens have been of rising interest especially due to the 
increasing number of immunocompromised patients. In order to combat fungal infec-
tions, the human immune system needs to be able to efficiently sense the fungal patho-
gen, and to activate a plethora of immune cells that are able to engulf and clear the 
pathogen. In this regard PRRs are of significant importance. Numerous studies revealed 
beneficial as well as detrimental roles of different TLRs in fungal infections. Furthermore, 
several studies on murine models are contradictory, probably due to the differences 
in the experimental setup, mouse strains that are used, as well as differences in fungal 
strains. Although many PRRs that recognize fungal PAMPs have been identified, there is 
still a large amount of unexplored PRRs that could contribute to antifungal host defence. 
Moreover, the interactions that have been described between PRRs point to an even 
more complex dynamic cell wall recognition system on immune cells. The knowledge 
that there could be many fungal PRRs that are dynamically expressed and have the 
capacity to interact with each other indicates that understanding fungal recognition at 
the host cell membrane needs further studies and will be challenging and complex.
Fungal recognition as well as the interplay between the innate immune cells forms 
the initial inflammatory network that is needed to control fungal infection. A better 
understanding of the role of epithelial cells in fungal infection has led to an increased 
awareness that non-classical immune cells, such as epithelial cells, endothelial cells 
and platelets, also play a crucial role in the orchestration of an efficient antifungal host 
response. In addition, new subsets of immune cells, such as innate lymphoid cells have 
come to stage and NK cells have gained interest in their contribution to control fungal 
infection. These new players next to the traditional and well-known professional phago-
cytes such as neutrophils and monocyte/macrophages open up relevant new ques-
tions. To what extend does immunosuppression with corticosteroids affect these new 
players? And in turn does this influence the function of the classical phagocytes? Does 
NADPH-oxidase deficiency influence effective epithelial and endothelial antifungal host 
responses? In addition, recent studies have suggested an innate immune memory in 
NK cells as well as in monocytes, which opens new horizons regarding the host-fungus 
interactions. Hence, not only CLRs, but also some TLRs were shown to mediate immune 
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responses to a microbe, upon a second encounter, by either strengthening or diminish-
ing host responses by the means of host chromatin remodelling that can shape the host 
immune response (88, 89), making these receptors interesting candidates for further 
investigation as potential targets for vaccines.
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AbsTRACT
Chitin is an important cell wall component of Aspergillus fumigatus conidia of which 
hundreds are inhaled on a daily basis. Previous studies have shown that chitin has both 
anti- and pro-inflammatory properties; however the exact mechanisms determining the 
inflammatory signature of chitin are poorly understood, especially in human immune 
cells.
Human peripheral blood mononuclear cells were isolated from healthy volunteers 
and stimulated with chitin from Aspergillus fumigatus. Transcription and cytokine pro-
duction of the pro-inflammatory IL-1β and the anti-inflammatory IL-1Ra were measured 
by qPCR or ELISA from the cell culture supernatant, respectively. Chitin induced an 
anti-inflammatory signature characterized by the production of IL-1Ra in the presence of 
human serum, which was abrogated in immunoglobulin depleted serum. Fcγ-receptor-
dependent recognition and phagocytosis of IgG-opsonized chitin was identified as a 
novel IL-1Ra-inducing mechanism by chitin. IL-1Ra production induced by chitin was de-
pendent on Syk kinase and PI3K activation. In contrast, co-stimulation of chitin with the 
PRR ligands lipopolysaccharide, Pam3Cys or muramyl dipeptide, but not β-glucan, had 
synergistic effects on the induction of pro-inflammatory cytokines by human PBMCs. In 
conclusion, chitin can have both pro- and anti-inflammatory properties, depending on 
the presence of pathogen associated molecular patterns and immunoglobulins, thus 
explaining the various inflammatory signatures reported for chitin.
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IMPoRTAnCe
Invasive and allergic aspergillosis are increasing health care problems. Patients get 
infected by inhalation of the airborne spores of Aspergillus fumigatus. A profound knowl-
edge of how Aspergillus and its cell wall components are recognized by the host cell 
and which type of immune response it induces is necessary to develop target-specific 
treatment options with less severe side-effects compared to treatment options to date. 
There is controversy in the literature about the receptor for chitin in human cells. We 
identified the Fcγ-receptor and Syk/PI3K-pathway via which chitin can induce anti-
inflammatory immune responses by inducing IL-1 receptor antagonist in the presence 
of human immunoglobulins, but also pro-inflammatory responses in the presence of 
bacterial components. This explains why Aspergillus does not induce strong inflamma-
tion just by inhalation and rather fulfills an immune-dampening function. While in a lung 
co-infected with bacteria, Aspergillus augments immune responses by shifting towards 
a pro-inflammatory reaction.
InTRoDuCTIon
Conidia of the opportunistic fungus Aspergillus fumigatus are responsible for allergic 
syndromes, especially allergic bronchopulmonary aspergillosis. This occurs especially 
in patients with asthma or cystic fibrosis, who are chronically colonized with Aspergil-
lus (1). Several Aspergillus proteins are known as allergens, driving pathology in allergic 
bronchopulmonary aspergillosis. In addition to proteins, the polysaccharide chitin is 
also known to induce allergy by causing accumulation of interleukin (IL)-4 expressing 
innate immune cells (2). Humans do not produce chitin, but express proteins that can 
degrade or bind chitin, such as chitinases and chitinase-like proteins, respectively (3). 
Polymorphisms in chitinase genes (4) or elevated serum levels of chitinase-like proteins 
have been associated with asthma (5), although the exact mechanism describing how 
chitinases and chitin interact with immune cells and trigger immune responses is not yet 
completely understood.
Chitin is one of the major fibrillar components of the Aspergillus cell wall, and is 
covalently bound to β-(1,3)-glucans (6). While in a resting conidium polysaccharides 
are shielded by a rodlet and melanin layer, during germination chitin is exposed on 
the mycelium surface and can interact with cells of the innate immune system (6). 
Aspergillus cell wall polysaccharides serve as pathogen associated molecular patterns 
(PAMPs), which are recognized by pattern recognition receptors (PRRs) to induce an in-
nate immune response with consequent induction and shaping of an adaptive immune 
response (7). While β-(1,3)-glucan is known as the ligand for dectin-1 (8), recent studies 
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propose different identities of the chitin recognition receptor and the induced immune 
response. Schlosser et al. identified FIBCD1 as a high-affinity chitin binding receptor of the 
intestine that controls immune responses against ingested parasites and fungi (9). Ad-
ditionally, chitin was described to have pro-inflammatory properties by inducing IL-17 via 
the Toll-like receptor (TLR)2 pathway (10) in murine cells, and a recent study suggested 
recognition of chitin via the mannose receptor (MR) on the surface of the phagocytes 
and by the nucleotide-binding oligomerization domain (NOD)2 and TLR9 receptors in 
the cytoplasm, leading to the induction of the anti-inflammatory cytokine IL-10 in mouse 
macrophages (11). No pattern recognition receptor or signalling pathway triggered by 
chitin has been identified in human immune cells to date. In the present study, we aimed 
to elucidate the immunological properties of chitin isolated from the A. fumigatus cell 
wall and its receptor in human peripheral blood mononuclear cells, and the mechanism 
and circumstances under which chitin can switch between anti-inflammatory immune 
responses towards pro-inflammatory responses.
MeTHoDs:
Volunteers and patients
Blood was collected from healthy volunteers or patients by venous blood puncture. 
Two NOD2-deficient individuals had the homozygous NOD2 insertion of a cysteine at 
position 1007 (rs2066847) that results in a frameshift of the coding sequence, which was 
analysed and described previously (12). Serum was used from two patients with a defi-
ciency in Mannose binding lectin (MBL) with serum MBL levels below 0.04 mg/L. One 
patient had the autosomal recessive mutation in FERMT3, the gene encoding kindlin-3 
leading to the leukocyte adhesion deficiency type III (13, 14).
Ethics statement
All experiments were performed and conducted in accordance to Good Clinical practice, 
the Declaration of Helsinki, and the approval of the Arnhem-Nijmegen Ethical Commit-
tee (nr.2010/104). Blood from volunteers and patients was taken after written informed 
consent was obtained.
PRR ligands, blockers and other stimuli
E.coli lipopolysaccharide (LPS) (1 ng/mL) (TLR4 ligand, E. coli serotype O55:B5, Sigma-
Aldrich St. Louis, MO USA), Pam3Cys (1 μg/mL) (TLR2 ligand, EMC microcollections, 
Tübingen, Germany), N-acetylmuramyl-ananyl-D-isoglutamine (MDP) (5 μg/mL) (NOD2 
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ligand, Sigma-Aldrich). Fungal cell wall β-(1,3)-glucan (10 μg/mL) (dectin-1 ligand) was 
kindly provided by Prof. David L Williams (East Tennessee State University, Johnson City, 
TN, USA). This polysaccharide was isolated from C. albicans yeast and it was verified it 
was exempt of proteins. The suspension contained water-insoluble microparticles (1-5 
μm) (15).
The dectin-1 inhibitor GE2 was a kind gift of Prof. Gordon Brown (University of Aberdeen, 
Scotland). Bartonella quintana LPS was prepared and purified as described elsewhere 
(16) and used as a TLR4 inhibitor (100 ng/mL) (17); isotype control mouse IgG1 (10 μg/
mL) (eBioscience, Halle-Zoersel, Belgium); anti-TLR2 (10 μg/mL) (eBioscience); isotype 
control goat IgG (10 μg/ml) (R&D Systems Minneapolis, MN, USA); isotype control mouse 
IgG1κ (10 μg/mL) (Biolegend, San Diego, CA, USA); anti-human mannose receptor (MR) 
(anti-human CD206, 10 μg/mL) (Biolegend); isotype control goat IgG (10 μg/ml) (R&D 
Systems Minneapolis, MN, USA); anti-human β2-integrin (anti-CR3) (10 μg/ml) (R&D 
Systems); isotype control mouse IgG2b (10 μg/mL) (R&D Systems Minneapolis, MN, 
USA); anti-human CD32 (anti-Fcγ Receptor II) (10 μg/mL) (Stemcell Technologies SARL, 
Grenoble, France); Wortmannin (100ng/mL, dissolved in DMSO) (Sigma), R406 Syk-
kinase inhibitor (5 μM, dissolved in DMSO) (Invivogen, Toulouse, France); cytochalasin D 
(10 μg/mL, dissolved in DMSO) (Sigma-Aldrich); polymyxin B (2 μg/mL) (Sigma-Aldrich), 
2-hours pre-incubation with chitin at 37°C; Human Immunoglobulins for intravenous 
administration (IVIG) (Nanogam, Sanquin, Amsterdam, The Netherlands) was dialysed 
in PBS before use. Mannose binding lectin (MBL) was purified from human plasma, as 
described in a previous study (18).
Purification and characterization of chitin from the A. fumigatus cell wall
Chitin was isolated from the A. fumigatus cell wall (A. fumigatus CEA17_ΔakuBKU80 strain 
(19); mycelia collected after 20 h growth at 37°C in the liquid Sabouraud medium) accord-
ing to the method described earlier (20, 21). However, the resultant chitin showed ~3% 
β-(1,3)-glucan contamination when checked by gas chromatographic analyses (22). This 
contamination which could have important immunological consequences, was cleared 
upon recombinant endo-β-(1,3)-glucanase treatment. In brief, chitin preparation (5 mg 
in 0.5 mL of 50 mM acetate buffer, pH 6.0) was treated with endo-β-(1,3)-glucanase 
(20 µL containing 5 µg protein) at 37°C for overnight followed by centrifugation and 
checking the supernatant for reducing sugar released by p-aminobenzoic acid assay 
using 4-hydroxy-benzhydrazide (23). This was repeated till no more reducing sugar was 
released into the supernatant. Further, the chitin preparation was washed thoroughly 
with sterile water and the absence of β-(1,3)-glucan was confirmed by gas chromato-
graphic analysis. The degree of acetylation in the chitin preparation was determined 
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by three different methods: the Cibacron brilliant red 3B-A dye binding method (24), a 
UV spectrophotometry method using dual standards [glucosamine (GlcN) hydrochloride 
and N-acetyl-glucosamine (GlcNAc)] For UV analysis, the chitin was solubilized upon 
ultra-sonication. A stock aqueous chitin suspension (1 mg/mL) was prepared by ultra-
sonication using a probe-sonicator (Soniprep 150, MSE, London, UK). The sonicator was 
set to 50% power and 50% tune reaching 16 amplitude microns for 30 seconds. The 
sonication reduced the molecular weight while not affecting the degree of acetylation 
(25, 26) and a Fourier Transform Infrared Spectroscopy (FT-IR) method using the absorp-
tion ratio A1655/A3450 (27, 28)
For FT-IR, dry chitin was suspended uniformly between IR window and spectrum was 
recorded (1400-4000 cm-1) in a JASCO FT/IR-6100 apparatus, subtracting the spectra of 
air.
Experiments were performed with four different batches of chitin purified from the A. 
fumigatus mycelial cell wall with a final concentration of 10 µg/mL.
To determine the size of the chitin particles, chitin suspension was subjected to Flow 
cytometry (FC500 Flow cytometer, Beckman Coulter) and compared with reference 
beads of 0.1 μm, 0.25 μm (Thermo Scientific), 3, 6 and 10 μm (Flow-Check Pro Fluoro-
spheres, Beckman Coulter). The data were analyzed using Kaluza (Analysis Version 1.3, 
Beckman Coulter).
PBMCs isolation
Venous blood was drawn in 10 mL EDTA tubes. The blood was diluted 1:1 with Phos-
phate Buffered Saline (PBS). Subsequently PBMCs were isolated using Ficoll-paque (GE 
healthcare, Zeist, The Netherlands) density gradient centrifugation. The PBMCs layer 
was collected and washed twice in cold PBS. Cells were reconstituted in RPMI+, con-
sisting of RPMI-1640 culture medium (Dutch modification, Gibco, Invitrogen, Breda, The 
Netherlands) supplemented with 10 µg/mL gentamicin, 10 mM L-glutamine and 10 mM 
pyruvate (Gibco). The cells were counted with a particle counter (Beckmann Coulter, 
Woerden, The Netherlands) and the concentration was adjusted to 1x107 cells/mL.
PBMCs stimulation
PBMCs were plated in a 96-well plate (Corning, NY, USA) at a final concentration of 
2.5x106/mL in an end volume of 200 μL per well. Stimulations were performed in the 
presence of 10% human serum, either not depleted or depleted for all immunoglobulins 
(BBI solutions, Cardiff, UK). Serum was either complement active, if not otherwise indi-
cated, or heat-inactivated by incubation for 30 minutes at 56°C in a water bath according 
to a commonly used protocol (29). After 1 hour pre-incubation with inhibitor or medium, 
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stimuli or medium were added. Cells were incubated at 37°C with 5% CO2, after 24 hours, 
supernatants were collected and stored at -20°C.
Cytokine measurements
IL-1β, tumor necrosis factor (TNF)α, IL-6, IL-8, IL-10 and IL-1Ra were measured in the cell 
culture supernatants using commercial ELISA kits (IL-1β, TNFα and IL-1Ra: R&D Systems; 
IL-6, IL-8 and IL-10: Sanquin) according to the instructions supplied by the manufacturer.
Pulldown assay of chitin-binding immunoglobulins in human serum
To deplete serum from chitin-binding immunoglobulins, 1 mL of RPMI supplemented 
with 10% serum containing either 1 mg chitin from a stock concentration of 10 mg/mL or 
the equal amount of distilled water (for mock treatment) was incubated overnight at 37°C 
and shaken at 130 rpm. On the next day, the chitin containing or mock treated suspen-
sion was centrifuged (20 minutes, 14000 rpm, room temperature) and the supernatant 
without beads was recovered. The depletion efficacy was checked by a chitin-binding 
IgG ELISA.
Chitin-binding IgG ELISA
A polystyrene 96-well plate was coated with 10 μg/mL chitin (100 μL per well) over-
night at room temperature. After washing and blocking with PBS with 1% bovine serum 
albumin (BSA) for 1 hour, wells were incubated with 10% serum in RPMI+, mock treated 
serum and depleted serum for 1 hour. IgGs bound to chitin were detected by using an 
anti-human IgG (whole particle) labelled with peroxidase in a concentration of 1:1000 
(Sigma-Aldrich). Enzymatic reaction was started by adding the TMB and H2O2 containing 
substrate, which was stopped after 10 minutes by 10% sulphuric acid solution. The optic 
density was measured by photometric ELISA reader.
Quantitative PCR (qPCR)
RNA was isolated from 1x106 PBMCs after stimulation for 4 hours and 24 hours with 
Aspergillus chitin either in the presence of medium or 10% human serum using Trizol 
reagent (Invitrogen) according to a protocol supplied by the manufacturer. RNA (500 
ng) was reverse transcribed into cDNA using the iScript cDNA synthesis kit (Hercules, 
Bio-Rad Laboratories, CA). Quantitative PCR (qPCR) analysis was performed using SYBR 
Green Master Mix (Applied Biosystems, Carlsbad, CA) and the Applied Biosystems 
7300 real-time PCR system. As PCR protocol the following conditions were used: 2 
minutes 50°C, 10 minutes 95°C followed by 40 cycles at 95°C for 15 sec and 60°C for 
1 minute. For the amplification of hIL-1Ra the primers 5’- GCCTCCGCAGTCACCTAAT-3’ 
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and 5’- TCCCAGATTCTGAAGGCTTG-3’ and for the amplification of hIL-1β the primers 
5’- GCAACTGTTCCTGAACTCAACT-3’ and 5’- ATCTTTTGGGGTCCGTCAACT-3’ were 
used. To correct for differences in loading concentrations of RNA between the different 
conditions, qPCR results were corrected with the housekeeping gene β2 microglobulin 
(β2m) amplified using the primers 5’- ATGAGTATGCCTGCCGTGTG-3’ and 5’-CCAAATGC-
GGCATCTTCAAAC-3’. Primer efficacy was evaluated using a standard curve. IL-1Ra Ct 
values were compared with the β2m Ct by calculating the delta Ct and the fold-change 
was calculated relative to the RPMI-stimulated to determine the effect of stimulation 
with chitin on IL-1Ra expression.
Statistical analysis
The Wilcoxon signed rank test was used to determine differences between stimulation 
with and without inhibitors or between different sera. A p-value of < 0.05 was considered 
statistically significant (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001). Graphs represent 
cumulative results of all performed experiments and are presented as mean ± standard 
error of the mean (SEM). Data were analyzed with GraphPad Prism v 5.0.
ResulTs
Aspergillus fumigatus cell wall chitin produces IL-1Ra in the presence of serum
The chitin samples purified from A. fumigatus cell wall contained 70% of the particles 
showing sizes less than 0.5 µm (Fig 1; and a degree of acetylation of ~91% (Supplemental 
Figure 1). Purity of the chitin was ensured: first, the 3% of β-(1,3)-glucan still remaining 
bound to chitin after the final chemical extraction was removed by an endo-β-(1,3)-
glucanase treatment (see materials and methods section); second, the absence of 
endotoxin contaminations were ensured by the pre-treatment of chitin suspension with 
polymyxin B. In order to identify immunological function of chitin, human PBMCs were 
stimulated in vitro with chitin in the presence or absence of human serum. The pro-
inflammatory cytokines IL-1β, TNFα, IL-6 (Fig 2A) were not detectable in the cell culture 
supernatant by ELISA in presence or absence of chitin. In addition, the anti-inflammatory 
IL-10 was not induced by chitin, neither on protein level (Fig 2A) nor on transcription 
level, while LPS and LPS with chitin induced high transcription of IL-10 (Fig 2B). Although 
IL-8 was high in presence of chitin and serum, serum without chitin also induced a high 
level of IL-8, indicating that this high level of IL-8 is not due to the presence of chitin (Fig 
2C). However, chitin induced significant amounts of IL-1Ra compared to the medium 
control (Fig 3A), in a dose-dependent manner (Fig 3B). A kinetic analysis of IL-1Ra mRNA 
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expression showed that IL-1Ra transcription peaked after 4 hours of exposition of cells 
to chitin (Fig 3C). The absence of transcription of IL-1β confi rmed the lack of detection 
of this cytokine in the culture supernatant (Fig 2A). In conclusion, serum was required 
for the induction of IL-1Ra transcription and release by PBMCs upon chitin stimulation.
figure 1: Characterisation of chitin particles purifi ed from Aspergillus mycelium
Chitin particles were measured by fl ow cytometry and compared with reference beads; the distribution of 
chitin particles was calculated. Mean and standard deviation of 5 independent measurements of three dif-
ferent batches of Aspergillus chitin are depicted.
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figure 2: Aspergillus chitin does not induce pro-infl ammatory cytokines or the anti-infl ammatory 
cytokine IL-10
(A) IL-1β, TNFα, IL-6, IL-10 (n=6) and (C) IL-8 – production (n=8), and (B) IL-10 transcription (n=3) , were mea-
sured (A+C) either in the cell culture supernatant, or (B) in mRNA, of PBMCs of healthy controls that were 
stimulated (A+C) with Aspergillus chitin either the presence of medium (black bars) or human serum (withe 
bars) or (B) with Aspergillus chitin, LPS and LPS with Aspergillus chitin.
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Dectin-1, TLR2, TLR4, MR and NOD2 are not involved in chitin-induced IL-1Ra 
induction
Subsequently, we aimed to identify the receptor that recognizes chitin that mediates IL-
1Ra production by stimulation of PBMCs with chitin. Blocking dectin-1 with GE2 antibody 
did not aff ect the chitin-induced IL-1Ra production (Fig 4A). In addition, blocking TLR2 
or TLR4 also did not infl uence the IL-1Ra production by chitin (Fig 4B, C). Since MR and 
NOD2 have been described as recognition receptors for Candida albicans derived chitin 
(11), we stimulated PBMCs with chitin and human serum in the presence of a MR neutral-
izing antibody as well as stimulated PBMC of NOD2 defi cient patients with chitin and the 
NOD2 ligand MDP. Blocking MR did not result in signifi cant diff erences of the production 
of IL-1Ra (Fig 4D), and as depicted in Fig 4E, MDP-stimulation did not result in any IL-1Ra 
production in the NOD2 defi cient patients, while chitin induced IL-1Ra in equal amounts 
as in the healthy control. In conclusion, chitin-induced IL-1Ra is Dectin-1-, TLR2- and 4-, 
MR- and NOD2-independent.
figure 3: Chitin induces IL-1Ra-release and transcription of IL-1Ra, but not IL-1β in the presence of 
human serum
(A) IL-1Ra production measured in the cell culture supernatant of PBMCs of healthy controls after 24 hours-
stimulation either in the presence of RPMI (white bars) or human serum (black bars) (A) with 10 μg/ml 
Aspergillus chitin (n=9) or (B) with the diff erent dosages 1,10 and 100 μg/ml Aspergillus chitin in the presence 
of human serum (n=3). (C) IL-1β and IL-1Ra transcription was measured by qPCR after 4-hours stimulation in 
the presence of human serum (n = 3). Statistical analysis was performed using a (A) Wilcoxon signed rank test 
or (C) paired t test (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001).
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Immunoglobulin opsonisation mediates chitin-induced IL-1Ra
Since none of the PRRs known to recognize fungi was identifi ed as the receptor for 
the recognition of chitin to induce IL-1Ra while human serum was crucial, we engaged 
additional experiments to decipher the role of diff erent components present in human 
serum. In the presence of heat-inactivated serum IL-1Ra was still induced, although 
figure 4: Dectin-1, TLR2, TLR4, MR and NOD2 are not involved in the chitin-induced IL-1Ra
Chitin-induced IL-1Ra in culture supernatants of PBMCs of healthy volunteers stimulated in the absence 
or presence of a neutralizing antibody or molecule, (A) like GE2 for blocking dectin-1 (n = 5), (B) αTLR2 for 
blocking TLR2 (n=6) and (C) Bartonella LPS for blocking TLR4 (n=8), and (D) αMR for blocking the mannose 
receptor (n=12), (E) or of two NOD2 defi cient patients. IL-1Ra was measured in the cell culture supernatant 
by ELISA. Statistical analysis was performed with the Wilcoxon Signed Rank test (*=p < 0.05, ** = p < 0.01 and 
*** = p < 0.001).
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there was a lower induction of IL-1Ra compared to non-heat-inactivated serum (Fig 5A). 
Since MBL is an important polysaccharide-binding component, we stimulated PBMCs 
of healthy controls with chitin in the presence of MBL deficient serum. However, IL-1Ra 
was still induced by sera exempt of MBL (Fig 5B). CR3 is a known receptor recognizing 
complement-opsonized particles (30) and β-glucan (31, 32). IL-1Ra production was not 
abolished and even significantly increased when CR3 was blocked (Fig 5C). To further 
validate this finding and avoid a masking effect of the blocking antibodies inducing 
IL-1Ra in combination with chitin, PBMCs isolated from a Kindlin-3 (which is crucial for 
maximal CR3 signalling (33))-deficient patient were stimulated with chitin. Comparable 
to CR3 blocking, Kindlin-3 deficiency did not result in diminished IL-1Ra levels (Fig 5D).
In contrast to the partial effects observed with heat-inactivation of the serum, the in-
duction of IL-1Ra by chitin was completely abolished when serum was depleted of all 
immunoglobulins (Fig 5E). This result suggested that IgGs are responsible for the IL-1Ra 
induction by chitin. To demonstrate this, human immunoglobulins (IVIGs) were added to 
the immunoglobulin free serum, wherein IL-1Ra production could be restored in a dose-
dependent manner, indicating that immunoglobulins are required for the induction of 
IL-1Ra by chitin (Fig 5F). Fcγ receptors recognize the Fc part of IgG and thus recognize 
IgG opsonized pathogens and particles. An Fcγ Receptor II (FcγRII) neutralizing antibody 
significantly reduced chitin-induced IL-1Ra production (Fig 5G). To further elucidate 
whether chitin was directly bound and opsonized by IgG, we incubated 10% diluted 
serum or 1 mg/ml IVIGs in a polystyrene plate coated with chitin and subsequently 
detected bound IgG with an anti-Fc-antibody. A significant amount of IgGs bound to 
chitin in both samples (Fig 5H). To further elucidate whether the IL-1Ra induction was 
caused by immunoglobulins binding specifically to chitin, human serum was depleted 
from chitin-binding immunoglobulins. The efficacy of the pull-down experiment was 
tested by ELISA resulting in a reduction of 73,5 % of chitin-binding antibodies (Fig 5I). 
Stimulation of PBMCs with chitin in the presence of serum depleted of chitin-binding 
IgGs resulted in a similar significantly lower IL-1Ra induction (Fig 5J).
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figure 5: Complement and immunoglobulin opsonisation mediate the chitin induced IL-1Ra
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Chitin-induced IL-1Ra is dependent on actin polymerisation and signals via 
Spleen tyrosine kinase and PI3Kinase
Having identified opsonisation with IgG as the main mechanism for the IL-1Ra induction 
by chitin, we further deciphered whether phagocytosis and the down-stream signalling 
of Fcγ-receptor are needed for the induction of IL-1Ra by chitin. We stimulated PBMCs 
with chitin and human serum and blocked either the actin polymerisation with cytocha-
lasin D (Fig 6A) or the downstream-signalling kinases of the Fcγ-receptor spleen tyro-
sine kinase (Syk) (Fig 6B) or PI3Kinase (Fig 6C) or the combination of Syk and PI3Kinase. 
All resulted in a significant reduction of IL-1Ra, while IL-1Ra was completely abolished 
when Syk and PI3K were blocked simultaneously (Fig 6D). Taken together these findings 
indicate that recognition and phagocytosis via the Fcγ-receptor with subsequent Syk 
kinase and PI3Kinase activation mediates the IL-1Ra induction by chitin.
Chitin synergizes with Syk-independent-PRR pathways leading to IL-1β 
production that is dependent on immunoglobulins, Syk and PI3Kinase
Since the immune system is probably never confronted in nature with the highly purified 
chitin alone, but rather in the setting of different PRR ligands of the A. fumigatus conidia 
and hyphal cell wall, we stimulated PBMCs with chitin in the absence and presence of 
serum in combination with NOD2, TLR2, TLR4 and dectin-1 ligands. In the absence of 
serum no cytokines were induced. All non-Syk dependent PRR pathways stimulated 
with ligands, such as MDP (NOD2 pathway), Pam3Cys (TLR2 pathway) and LPS (TLR4 
pathway) synergized with chitin to induce an higher IL-1β and TNFα production, while 
stimulation with β-glucan (dectin-1/Syk pathway) combined with chitin did not induce 
IL-1β (Fig 7A), TNFα (Fig 7B) or IL-6 (Supplemental Fig 1). In contrast, chitin did not have 
PBMCs of healthy volunteers were stimulated with RPMI or chitin in the presence of (A) poolserum (PS) or 
heat-inactivated poolserum (HI PS) (n=11) (B) MBL deficient serum with and without additional purified MBL 
(n=3), (C) isotype control or CR3 neutralizing antibody (n= 8). (D) PBMCs of a Kindlin-3 deficient patient or two 
controls were stimulated with chitin. (E) PBMCs of healthy volunteers were stimulated with RPMI or chitin 
in the presence of poolserum or immunoglobulin depleted serum (Ig-) (n = 11), or (F) Ig depleted serum 
supplemented with decreasing concentrations of human immunoglobulins (IVIGs) (1mg/mL, 100μg/mL, 
10μg/mL) (n = 6). (H+I) Binding of IVIGs to chitin was determined in by coating an ELISA plate with chitin and 
a secondary incubation with (H) 10% poolserum or 1 mg/ml IVIGs or (I) 10% poolserum after mock treat-
ment or after pull-down of chitin-binding immunoglobulins and the OD was measured (n= 6). (G+J) PBMCs 
of healthy volunteers were stimulated with RPMI or with chitin in the presence of (G) an anti- FcγRII antibody 
or the isotype control (n=3), or (J) in the presence of mock treated poolserum or with poolserum depleted 
from chitin-binding immunoglobulins. (A-F, G and J) IL-1Ra was measured in the cell culture supernatant by 
ELISA. Statistical analysis was performed with the Wilcoxon Signed Rank test (*=p < 0.05, ** = p < 0.01 and *** 
= p < 0.001).
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synergistic eff ects on the LPS-induced IL-1Ra production; instead LPS combined with 
chitin induced IL-1Ra additively (Supplemental Fig 3). Next, we wanted to elucidate 
whether similar pathways responsible for IL-1Ra induction by chitin were mediating the 
synergistic response of chitin with other PAMPs. Using heat-inactivated serum we ob-
served a signifi cant higher ratio of LPS versus LPS/chitin-synergistic induction of IL-1β, 
while this ratio was signifi cantly lower in the presence of Ig-depleted serum. Further 
heat-inactivation of the Ig-depleted serum did not change the ratio (Fig 7C). In addition, 
blocking Syk and PI3Kinase in PBMCs reduced the synergistic eff ect of chitin on LPS 
stimulation signifi cantly, and the combination of both blockers completely inhibited 
the eff ect (Fig 7D). Collectively, these data suggest synergism induced by chitin is also 
immunoglobulin/FcγR dependent, and provide evidence for crosstalk between chitin-
induced FcγR signalling and other PRR pathways, with the exception of dectin-1.
figure 6: Chitin-induced IL-1Ra is dependent on actin polymerisation and signals via Syk and PI3Kinase
(A-D) PBMCs of healthy volunteers were stimulated with RPMI or chitin in the presence of (A) cytochalasin D 
actin depolymerisation agent (n = 13), (B) the Syk kinase inhitibor R406 (n = 10), (C) Wortmannin (n = 11) PI3K 
inhibitor or (D) the combination of R406 and Wortmannin (n=5), and IL-1Ra was measured in the cell culture 
supernatant by ELISA. Statistical analysis was performed with the Wilcoxon Signed Rank test (*=p < 0.05, ** = 
p < 0.01 and *** = p < 0.001).
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figure 7: Chitin synergizes with not-Syk-activating PRR ligands leading to high IL-1β production 
dependent on immunoglobulins, Syk and PI3Kinase
PBMCs of healthy volunteers were stimulated with (A+B) chitin, mdp, Pam3Cys, LPS, β-glucan and with the 
combination of PRR ligands with chitin in the absence or presence of human poolserum (n = 5-18), or (C+D) 
with LPS and LPS together with chitin, either (C) in the presence of heat-inactived (HI) poolserum, Ig depleted 
serum (Ig-) or heat-inactivated Ig depleted serum (HI Ig-) (n=9), or (D) after blocking Syk kinase or PI3Kinase 
or the combination of both (n = 5-7). (C+D) The ratio between LPS-induced IL-1β and chitin + LPS-induced IL-
1β was calculated. (A-D) IL-1β or TNFα (B) were measured in the cell culture supernatant by ELISA. Statistical 
analysis was performed with the Wilcoxon Signed Rank test (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001).
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DIsCussIon
No pattern recognition receptor or signalling pathway activated by chitin has been iden-
tified in human immune cells to date, and immunostimulatory capacities range from ab-
sence of effects, to anti-inflammatory, and even pro-inflammatory properties (34). In the 
present study, we describe a mechanism by which chitin can induce immune responses 
in human immune cells and identify that chitin has both anti-inflammatory properties 
by inducing IL-1Ra and pro-inflammatory effects by inducing IL-1β/TNFα in synergy 
with Syk-independent PRR pathways. Interestingly, none of the previously proposed 
chitin receptors such as TLR2, MR, NOD2 or dectin-1 were involved in the induction of 
IL-1Ra in human PBMCs, but phagocytosis, recognition via the FcγRII with subsequent 
Syk- and PI3K-signalling of IgG opsonized chitin was identified as the signalling pathway. 
Strikingly, the effect was only observed with chitin particles in the presence of immu-
noglobulins. Therefore, we propose that chitin has a dual immunological function by 
dampening and controlling immune responses together with immunoglobulins via the 
induction of IL-1Ra on one hand, and orchestrating pro-inflammatory responses when 
chitin is presented in combination with PAMPs the other hand.
Purified Aspergillus chitin does not induce any pro-inflammatory cytokines in PBMCs 
both in the absence or presence of human serum. This is in line with former studies of 
Mora-Montes et al. and Bueter et al. (20, 34), which described chitin as an immunologically 
inert particle, not inducing TNFα, IL-1β, IL-6 or IL-10 production (20) or inflammasome 
activation (35). This was observed in several cell types, such as murine bone-marrow de-
rived macrophages, M1 and M2 macrophages, as well as mouse peritoneal cells, mouse 
bone-marrow derived DCs and human PBMCs (35). Recently, it has been reported that 
chitin derived from different fungal species or crab shells induced IL-10 and TNFα in 
human PBMCs in a dose dependent manner (11). Several differences could account for 
this conflicting observation. The chitin particles in our study were mostly smaller than 1 
μm, while the previously described IL-10 inducing chitin was between 1 and 10 μm (11). 
In addition, the use of Aspergillus to isolate chitin, and the different chitin purification 
method could account for the differences observed in cytokine responses. The presence 
of a contaminant even at low dose in the chitin sample can have a significant effect on 
the response to chitin since we have shown that polysaccharides can have an opposite 
effect than chitin on the immune response when tested in combination with chitin.
While former studies focused on IL-10 as a potent anti-inflammatory cytokine, less atten-
tion has been paid to another potent endogenous anti-inflammatory cytokine, namely 
IL-1Ra. In this study stimulation of PBMCs with chitin in the presence of human serum 
resulted in IL-1Ra transcription and production. The fine-tuned balance of pro- versus 
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anti-inflammatory cytokines of the IL-1 family is important during systemic inflamma-
tion and several reports point to a crucial role for a balanced IL-1 response to prevent 
Aspergillus-induced pathology (36-38).
Since the MR has previously been reported to be involved in chitin-induced immune 
responses in mice (11), we investigated mannose-binding lectin, which shares homology 
with the MR, as well as blocked the MR on PBMCs. However, MBL and MR were not 
involved in IL-1Ra induction by chitin. Although CR3 plays a crucial role in mediating 
adaptive T cell responses against Aspergillus conidia (17, 39), this receptor was also 
not involved in chitin-induced IL-1Ra. Moreover, stimulation of PBMCs of a kindlin-3 
deficient patient (defective CR3 signalling (33)) with chitin revealed an intact IL-1Ra 
pathway. These data suggest that CR3 and MBL are not involved in chitin-induced IL-1Ra 
production. However, the fact that IL-1Ra induction by chitin was partly dependent on 
heat-inactivation suggests a role for complement system in the induction of IL-1Ra by 
chitin. Since Agarwal et. al. had shown in an earlier study that chitin is a poor inducer of 
the alternative complement pathway (40), the role of complement activation seen in this 
study could be caused by activation of the classical pathway. Elucidating this should be 
part of future studies.
In contrast to complement, immunoglobulins were essential for mediating the induc-
tion of IL-1Ra induced by chitin. Chitin showed direct interaction with immunoglobulins 
and the replenishment of IVIGs in Ig-depleted serum restored IL-1Ra induction. In ad-
dition, IL-1Ra was significantly lower when serum was depleted from chitin-binding im-
munoglobulins, suggesting that anti-chitin-specific IgGs mediates the IL-1Ra induction. 
Fcγ receptors can be activated by binding to immunoglobulin opsonized particles and 
subsequent internalisation, and receptor clustering (41). FcγRII has low affinity for mono-
meric IgG and only recognizes IgG complexes (42, 43), which might be similar to the ones 
artificially created by the binding of many IgG to long chitin molecules. Blocking FcγRII 
resulted in a significant decrease of the induction of IL-1Ra by chitin, suggesting that 
chitin opsonized with IgGs triggers FcγII receptor signalling, subsequently leading to 
IL-1Ra. Moreover, we identified that IL-1Ra induction of opsonized chitin was dependent 
on phagocytosis, Syk and PI3K activation.
Other polysaccharides present in the cell wall of Aspergillus, such as galactosamino-
galactan and β-glucan can also induce IL-1Ra (36, 44). However, both polysaccharides 
do not require human serum for the induction of IL-1Ra. Interestingly the induction of 
IL-1Ra by β-glucan was shown to be independent of dectin-1, but dependent on PI3K 
(45). Therefore, it might be that the PI3K-Akt pathway is the final common pathway es-
sential for IL-1Ra induction by polysaccharides, but that this pathway can be induced 
via different mechanisms depending on the ligand. Furthermore, it has been shown 
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that insoluble fibrillar polysaccharides can induce potent inflammatory responses by 
engaging multimerization of pattern recognition receptors (PRRs) and formation of su-
pramolecular PRR complexes, which is known as the fibril hypothesis (46). We observed 
striking effects when cells were stimulated with opsonized chitin in the presence of other 
PRR ligands. Ligands for TLR2, TLR4 and NOD2 mediated potent synergistic effects on 
pro-inflammatory cytokines such as IL-1β. Interestingly, the combination of chitin with 
β-glucan, the ligand for dectin-1, did not induce IL-1β production, not even in the pres-
ence of human serum. Recently, crosstalk between Fcγ-receptors with other TLRs has 
been described (42). Vogelpoel et al. observed synergism with TLR2 and TLR4 ligands, 
but not with dectin-1 ligands, which is in line with the data from our study. Whether this 
is because Fcγ-receptors and dectin-1 both signal via Syk-PI3K-Akt needs to be further 
elucidated (47, 48). Since the synergism was dependent on IgGs and PI3K signalling, it 
is tempting to speculate that independent of a specific receptor, opsonized polysac-
charides can induce potent synergistic pro-inflammatory responses via Fcγ-receptor 
activation when other pro-inflammatory ligands are present.
Studying the role of chitin-specific antibodies during aspergillosis might lead to new 
insights that could be relevant for the clinical setting. Indeed, an increase in anti-chitin 
antibodies have been shown in immunocompetent patients with chronic pulmonary as-
pergillosis and allergic aspergillosis (Raj and Latgé, unpublished). The role of the level of 
antibodies on the immune response towards chitin should be investigated in the future.
Another important question is how the opsonisation of chitin with specific antibodies 
could influence disease severity. Only little data exist, however Kin et. al. have shown 
that antibodies against bacterial polysaccharides can bind to chitin and dampen the 
overall immune response to chitin (49). In addition, since we provide evidence that chitin 
induces a different immune response when tested alone or with other PAMPs and since 
we know that the different polysaccharides of A.fumigatus will activate differently inflam-
matory responses, it is now of interest to test the effect of combinations of the cell wall 
polysaccharides to see if these combination are neutral, antagonist or synergistic.
In conclusion, we identified a novel mechanism through which chitin has strong 
anti-inflammatory effects and in the setting of other PAMPs can boost pro-inflammatory 
responses (Fig 8). These responses were critically dependent on immunoglobulins, Fcγ 
receptor signalling and phagocytosis. These data might explain, why the responses 
reported by chitin are so diverse. Moreover, since immunoglobulins might also influ-
ence other polysaccharide-induced immune responses, future studies need to focus 
on immunoglobulins and FcγR signalling when investigating fungal or fungal-cell wall 
component-induced immune responses.
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figure 8: Model of chitin-induced anti-infl ammatory IL-1Ra and pro-infl ammatory IL-1β responses
IgG-opsonized chitin is recognized by the Fcγ-receptor and uptake induced via the Syk/PI3K-pathway, 
which results in isolated induction of IL-1Ra. In the presence of other Syk-independent PRR ligands, like 
P3Cys, LPS and MDP IgG-opsonized chitin induces IL-1β in a synergistic manner.
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supplemental figure 1: Measurement of the degree of acetylation of chitin
With IR, UV spectrometric and dye binding measurements diff erent batches of chitin showed degree of 
acetylation ranging between 89-94%. An average value of 91% for four diff erent batches of chitin is presented.
supplemental figure 2: IL-6 induction after co-stimulation with other PRR ligands
PBMCs of healthy volunteers were stimulated with chitin, mdp, Pam3Cys, and with the combination of PRR 
ligands with chitin in the absence or presence of human poolserum (n = 5-18).
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supplemental figure 3: No synergy of chitin and LPS for IL-1Ra
PBMCs of healthy volunteers were stimulated with chitin, LPS and with the combination of chitin and LPS 
in the presence of human poolserum (n = 6). IL-1Ra was measured in the cell culture supernatant by ELISA. 
Statistical analysis was performed with the Wilcoxon Signed Rank test.
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AbsTRACT
T-helper cell responses induced by Aspergillus fumigatus have been extensively inves-
tigated in mouse models. However, the requirements for differentiation and the charac-
teristics of A. fumigatus-induced human T-helper (Th) cell subsets remain poorly defined. 
We demonstrate that A. fumigatus induces Th1 and Th17 subsets in human PBMCs. 
Moreover, we show that the cytokine IL-22 is not restricted to a specific T-helper subset, 
in contrast to IL-17A. The pattern recognition and cytokine pathways that skew these 
Aspergillus-induced T-helper responses are TLR4- and IL-1-, IL-23-, and TNFα- depen-
dent. These pathways are of specific importance for production of the cytokines IL-17A 
and IL-22. Additionally, our data reveals that the dectin-1/Syk pathway is redundant, and 
TLR2 has an inhibitory effect on Aspergillus-induced IL-17A and IL-22 production. Nota-
bly, blocking complement receptor 3 (CR3) significantly reduced Aspergillus-induced 
Th1 and Th17 responses, and this was independent on the activation of the complement 
system. CR3 is a known receptor for β-1,3-glucan, however blocking CR3 had significant 
effects on T-helper responses induced by heat-killed Aspergillus conidia, which have 
minimal β-glucan expression on their cell surface. Collectively, these data characterize 
the human T-helper subsets induced by Aspergillus, demonstrate that the capability to 
produce IL-22 is not restricted to a specific T cell subset, and provide evidence that CR3 
might play a significant role in the adaptive host defence against Aspergillus, although 
the ligand and its action remains to be elucidated.
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InTRoDuCTIon
The primary line of defence against Aspergillus fumigatus is mediated by neutrophils and 
other cells of the innate immune system (1). In addition to the innate immune response, 
adaptive T-helper (Th) responses also play a crucial role during invasive aspergillosis (IA). 
The Th1 response is associated with a protection in IA (2). However, conflicting data are 
reported regarding the role of Th17 responses in the host defence against A. fumigatus. 
A protective role for IL-17 is described by Werner et al. who showed that dectin-1-/- mice 
have decreased IL-17 production, and subsequently reduced A. fumigatus clearance 
(3, 4). In contrast, other studies show that IL-17 promotes inflammation and reduces 
resistance to the fungal infection (5, 6). Although these studies have investigated the 
role of IL-17 in mice, our group has previously reported that the human host response 
against A. fumigatus is mainly driven by the Th1 response, rather than the Th17 response 
(7). In addition, human mononuclear cells have been shown to express a primarily Th1 
biased cytokine profile in response to stimulation with Aspergillus (8), and when Th2 
responses are being suppressed enhanced protective Th1 response develop in mice 
(9). Furthermore, mice are resistant to A. fumigatus when proper IL-12 dependent Th1 
responses are induced (9, 10).
Even though various reports have focused on Th1 and Th17 responses against A. 
fumigatus, a role for the cytokine IL-22, which is a characteristic cytokine of the Th17 re-
sponse, has not been addressed in human host responses. Recently, a protective role for 
IL-22 was demonstrated in the early host defence against A. fumigatus in a murine model 
of invasive pulmonary aspergillosis (11). Furthermore, the induction of IL-22 contributes 
to lung pathology in a murine model of allergic bronchopulmonary aspergillosis (ABPA) 
(12). In the host defence IL-22 is primarily responsible for the induction of anti-microbial 
peptides (13) and is mainly produced by CD4+ T-cells, Natural Killer (NK) cells and NKT-
cells (13-19). Within the CD4+ population, IL-22 is mainly produced by cells of the Th17 
lineage (13), but also T-cells that are specialized in the production of IL-22 and TNFα; 
named Th22 cells (19).
Still, little is known about which cells mainly produce IL-17 (IL-17A), IFNγ and/or IL-22, 
and which recognition pathways and cytokines play a role in the induction of these cy-
tokines in response to A. fumigatus in humans. In the present study we investigated the 
A. fumigatus-induced characteristic T-helper cytokines IL-17, IL-22, and IFNγ in PBMCs 
to elucidate which human cells primarily produce these cytokines, and which pattern 
recognition receptors and cytokines are involved in the induction of these cytokines in 
response to A. fumigatus.
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MeTHoDs
Healthy volunteers and patients
Blood samples from healthy controls and patients were obtained after written informed 
consent. Three patients with homozygous Y238X mutations in exon 6 of CLEC7A gene 
(the gene encoding dectin-1) provided blood samples. In these patients diminished 
dectin-1 expression and failure to induce a cytokine response to β-glucan was demon-
strated previously (20).
Aspergillus
A clinical isolate of Aspergillus fumigatus V05-27, which was previously characterized (21), 
was used for all stimulations. Conidia and hyphae were prepared and heat-inactivated 
(HI) as described previously (22). A concentration of 1x107/mL was used in the experi-
ments.
β-1,3-glucan immunofluorescence of heat inactivated Aspergillus
To determine β-1,3-glucan expression after heat inactivation of Aspergillus. The HI 
conidia and hyphae were incubated for 30 minutes with mouse anti-β-1,3-glucan (Bio-
supplies, Bundoora, Australia). Subsequently the Aspergillus was washed and antibodies 
directed to β-glucan that were bound to Aspergillus were secondarily stained by goat 
anti-mouse alexa488 (Invivogen) according to the protocol supplied by the manufacturer. 
Immunofluorescence was observed at 400x magnification using a Zeiss Axio imager 
M1 fluorescence microscope, equipped with MRm camera (Carl Zeiss, Sliedrecht, The 
Netherlands).
PBMC isolation
Venous blood was drawn into 10 mL EDTA tubes, and PBMCs were isolated as described 
previously (21). In brief, blood was diluted in phosphate buffered saline (PBS) (1:1) and frac-
tions were separated by Ficoll (Ficoll-Paque Plus, GE healthcare, Zeist, The Netherlands) 
density gradient centrifugation. Cells were washed twice with PBS and resuspended in 
RPMI-1640 culture medium (Gibco, Invitrogen, Breda, The Netherlands) supplemented 
with 10 µg/mL gentamicin, 10mM L-glutamine and 10mM pyruvate (Gibco). The cells 
were counted using a particle counter (Beckmann Coulter, Woerden, The Netherlands) 
and the cell concentration was adjusted to 5x106/mL.
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CD4/CD56 cell depletion
To deplete the CD56 or CD4 cells from isolated PBMCs, cells were labelled using 
magnetic beads coated with anti-CD56 or anti-CD4 (MACS Miltenyi, Bergisch Gladbach, 
Germany). Subsequently, the cells were depleted over a depletion column according to 
the protocol supplied by the manufacturer. As control for the isolation procedure PBMCs 
were also runned over the columns without labelling with magnetic beads.
PBMC stimulation
PBMCs were plated in 96-well round bottom plates (Corning, NY, USA) at a concentration 
of 2.5x106/mL in a volume of 200 mL. They were either not stimulated or stimulated with 
1x107/mL HI conidia or hyphae for 24 hours or 7 days at 37°C and 5% CO2. All stimulations 
were performed in medium containing 10% human serum, which was obtained from a 
serum pool of healthy volunteers.
Pattern recognition receptors were inhibited in PBMCs by pre-incubation for 1 hour 
with specific inhibitors. LPS derived from Bartonella quitana was used to block TLR4 at 
a final concentration of 20 ng/mL (23). B. quitana LPS was extracted and purified as de-
scribed previously (24). Mouse anti-humanTLR-2 (eBioscience, Halle-Zoersel, Belgium) 
and control mouse IgG1 (eBioscience), anti-human integrin β2 (αCR3) and control goat 
IgG (R&D systems Minneapolis, MN, USA) were used in a final concentration of 10 μg/mL. 
Laminarin was kindly provided by Professor David Williams of Tennessee University and 
was used in a final concentration of 50 ng/mL to inhibit dectin-1. Syk kinase inhibitor was 
purchased from Calbiochem (Merck, Darmstadt, Germany) and was used in a concentra-
tion of 50 nM. In order to check the blockade of the PRRs, PBMCs were stimulated with 
the TLR4 ligand LPS (10 ng/mL) from Escherichia coli serotype O55:B5 (Sigma Chemical 
Co, St Louis, MO, USA); or with the TLR2 ligand Pam3Cys (1 μg/mL) (EMC microcollec-
tions, Tübingen, Germany). Inhibition of dectin-1 and Syk was validated by stimulation 
with HI C. albicans (1x106/mL). After 24 hours of stimulation at 37°C and 5% CO2 IL-1β 
was measured by ELISA. All blockades resulted in a significant reduction of cytokine 
production (Supplementary figure 1A, B).
The cytokine pathways of IL-1, IL-23 and TNFα were investigated using supplementa-
tion of the cultures with recombinant human (rh) IL-23 (50 ng/mL) and rhTNFα (10 and 
100 ng/mL) (R&D Systems). IL-1 receptor signalling was blocked by its natural receptor 
antagonist (Ra) IL-1Ra (10 μg/mL) (Amgen, Inc., Thousand Oaks, CA, USA), and IL-23 was 
blocked with mouse anti-human IL-23p19 (10 μg/mL) (R&D systems). sTNFRII (Enbrel) and 
human anti-human TNFα (Humira) were kindly provided by Dr. Renoud Marijnissen and 
Dr. Marije Koenders of the department of Rheumatology Radboud University Nijmegen 
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Medical Centre the Netherlands, and were used to block TNFα in a final concentration 
of 100 μg/mL.
Cytokine measurements
IL-17A, IL-22, IFNγ, IL-1β and IL-23 were measured using commercially available ELISAs 
(R&D systems or eBioscience) according to the protocol supplied by the manufacturers.
Intracellular IL-17, IL-22, and IFNγ flowcytometry
Following 7 days stimulation, PBMCs were stimulated 4-6 hours with PMA (50 ng/mL) 
(Sigma-Aldrich), ionomycin (1 μg/mL) (Sigma-Aldrich) and Golgiplug (BD Biosciences, 
Breda, the Netherlands) according to the protocol supplied by the manufacturer. Cells 
were stained extracellular using PeCy7-conjugated anti-CD4 (BD Biosciences), PeCy7-
conjugated anti-CD8 (Biolegend, San Diego, CA, USA) or PeCy7-conjugated anti-CD56 
(Beckman Coulter) antibody. Subsequently the cells were fixed and permeabilized 
with Cytofix/Cytoperm solution (eBioscience) according to the protocol supplied by 
the manufacturer. Following permeabilization the cells were stained intracellular with 
alexa647 conjugated anti-IL-17 (BD Biosciences), PE conjugated anti-IL-22 (R&D systems) 
and FITC conjugated anti-IFNγ (eBioscience) according to the protocol supplied by the 
manufacturers. The cells were measured on a FC500 flowcytometer (Beckman Coulter) 
and the data were analysed using CXP analysis software v2.2 (Beckman Coulter).
Statistical Analysis
Differences in IL-17, IL-22, and IFNγ production and the percentage of CD4+ cells be-
tween the medium and Aspergillus stimulated samples were analysed with the Mann-
Whitney-U test. Data of stimulations with and without inhibitors of PRRs, cytokines, or 
cytokine inhibitors were subjected to statistical analysis with the Wilcoxon signed rank 
test. A p-value of <0.05 was considered statistically significant, with p<0.05 = *, p<0.01 = 
**, and p<0.001 = ***. All experiments were performed at least twice and data represent 
cumulative results of all experiments performed and are presented as mean ± standard 
error of the mean (SEM) unless indicated otherwise. Data were analysed using GraphPad 
Prism v 5.0. The proportional Venn diagram was drawn using the eulerAPE application 
v2.0.3. (25, 26)
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ResulTs
The proinflammatory adaptive cytokine response to A. fumigatus
We investigated the capacity of A. fumigatus conidia and hyphae to induce the cyto-
kines IL-17A, IL-22 and IFNγ. Stimulation with conidia and hyphae induced a significant 
production of the Th1 cytokine IFNγ in human PBMCs, whereas IL-17A was induced in 
low amounts. Both conidia and hyphae also induced IL-22 in human PBMCs (Figure 1A).
To determine which cell populations expand after stimulation with Aspergillus, we 
performed flowcytometry analysis. We initially focused on CD4+ cells, since T-helper 
cells are generally considered to be the main producers of IL-17A, IL-22 and IFNγ. 
PBMCs that were not stimulated with conidia showed relatively small populations of 
IL-17A+ and IL-22+ CD4 cells (1.2% SD 0.7 and 1.7% SD 0.9 respectively), whereas the IFNγ+ 
CD4 cell population was 10.7% (SD 3.9). Stimulation with conidia induced a significant 
expansion of the IL-17A+, IL-22+ and IFNγ+ CD4 T-cell population (Figure 1B). By gating on 
the Aspergillus-induced IL-17A+, IL-22+ and IFNγ+ cells we observed that the majority of 
IL-17A+ and IL-22+ cells were CD4+ cells. However, approximately half of the IFNγ+ cells 
were negative for CD4 (Figure 1C). Subsequently, extracellular staining with the NK-cell 
marker CD56 and the cytotoxic T-cell marker CD8 revealed that a significant proportion 
of to the IFNγ+ population was CD56+ and CD8+ (figure 1D). The remainder of the IL-17A+ 
cells was positive for CD8+ only. No CD56+ IL-17A+ cells were found (figure 1D). However, 
despite the fact that a fraction of the IL-22+ cells was positive for CD8 or CD56, still ap-
proximately 9% of the IL-22+ was negative for all the investigated surface markers (figure 
1D). Interestingly, we found that the populations of CD8+ and CD56+ cells that were IFNγ+ 
were already present in unstimulated PBMCs, and did not expand upon stimulation with 
A. fumigatus (figure 1E).
CD4 cells are the primary cellular source of Aspergillus-induced Il-17A, Il-22 and 
Ifnγ
To demonstrate that CD4+ cells are the major contributors to Aspergillus-induced IL-17A, 
IL-22 and IFNγ, we depleted CD4+cells from PBMCs and compared this with normal 
PBMCs. Depletion of CD4+ cells resulted in a complete loss of IL-17A production. Fur-
thermore, IL-22 and IFNγ production were also significantly reduced, in most donors, to 
undetectable levels (figure 1F). Since several reports indicate that NK-cells can produce 
IL-22 (14, 16-18), we also investigated the contribution of CD56+ cells. Depletion of CD56+ 
cells had no significant effect on IL-17A, IL-22 and IFNγ production (Figure 1G).
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figure 1 Induction of IL-17A, IL-22, and IFNγ by A. fumigatus, and the cellular source of these 
cytokines
(A) IL-17A, IL-22 and IFNγ concentrations in culture supernatants of PBMCs (2.5x106/mL) (n=6 donors) that 
were stimulated with 107/mL HI A. fumigatus conidia or hyphae in the presence of 10% human serum. (B) 
Intracellular IL-17A, IL-22 and IFNγ in CD4 T-cells in the PBMCs of the experiments shown in panel A. (C) 
The percentage of CD4- and CD4+ cells within the IL-17, IL-22 and IFNγ positive populations in Aspergillus-
stimulated PBMCs of the experiments shown in panel a. (D) Assessment of surface markers CD56 and CD8 
to elucidate the contribution of different cell types to the population of IL-17A+, IL-22+ and IFNγ+ cells. (E) The 
expansion of CD8+ IFNγ+ and CD56+ IFNγ+ was determined by comparing unstimulated PBMCs to A. fumiga-
tus stimulated PBMCs (n=4 for CD8 and n=5 for CD56). (F, G) IL-17A, IL-22 and IFNγ concentrations in culture 
supernatants of PBMCs, (F) PBMCs depleted of CD4+ cells (n=10 donors for IL-17, n=12 donors for IL-22 and 
n=11 for IFNγ), (G) PBMCs depleted of CD56+ cells (n=6 donors) that were stimulated with 107/mL HI A. fu-
migatus conidia or hyphae in the presence of 10% human serum. The Wilcoxon signed rank test was used to 
determine whether the means were significantly different.
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IL-22 is not restricted to a specific T-helper subset
Since CD4+ cells were the major population that were IL-17A+, IL-22+ and IFNγ+ we inves-
tigated the phenotypic diversity of these CD4+ T-cells by focusing on the expression 
of single or multiple cytokines. Stimulation with HI conidia resulted in the induction of 
IL-17/IL-22 and IL-22/IFNγ double positive CD4 cells (Figure 2A). Whereas we found 
a relatively small percentage of IL-17/IFNγ double positive CD4+ T-cells. Strikingly, the 
cytokine IL-22 was not specifically expressed in a certain subset, but could be found 
in both the IL-17 and IFNγ positive T-cell populations. Moreover, Aspergillus induces IL-
17/IL-22/IFNγ triple positive CD4+ T-cells (Figure 2A). To determine whether the IL-22+ 
cells in our experiments match the phenotype of previously-described Th22 cells we 
figure 2 Phenotypic diversity of IL-17A, IL-22 and IFNγ positive CD4 T-cells
Proportional Venn diagrams of IL-17A, IL-22, and IFNγ positive CD4 cell populations of (A) medium stimulated 
PBMCs and (B) Aspergillus conidia-stimulated PBMCs. Overlap between the ellipses represent double and 
triple positive CD4 cells. (C) Expression of TNFα within the IL-22+ cell population of Aspergillus-stimulated 
PBMCs. (D) IL-17+, IL-17/IL-22+ and IL-22+ CD4 cell populations of Aspergillus conidia- stimulated PBMCs (n=6 
donors) in the presence or absence of IL-1Ra or sTNFRII (Enbrel) (Data represented as fold change from 
stimulation in absence of inhibitor).
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assessed whether these cells co-expressed TNFα, a characteristic of Th22 cells (15, 19, 
27). Indeed, the majority of IL-22+ cells co-expressed TNFα (Figure 2B). Additionally, we 
investigated how IL-1 and TNFα signalling can influence the IL-17 and IL-22 populations. 
Blocking IL-1 resulted in significantly decreased IL-17+ and IL-22+ populations and a trend 
towards decreased IL-17/IL-22+ cells, whereas blocking TNFα with sTNFRII only signifi-
cantly decreased the number of IL-22+ cells (Figure 2C).
Differential roles for TLR2 and TLR4 in Aspergillus-induced T-cell responses
We investigated the role of the Toll-like receptors in the induction of the IL-17, IL-22, and 
IFNγ responses to A. fumigatus, as TLR2 and TLR4 have been associated with the recog-
nition of A. fumigatus (28-32). PBMCs were pre-incubated with B. quintana LPS to block 
TLR4, and afterwards stimulated with conidia or hyphae. Pre-incubation with B. quintana 
LPS alone did not result in any cytokine induction in PBMCs (Supplementary Figure 1C). 
Blockade of TLR4 resulted in a significantly reduced IL-22 production in conidia-stim-
ulated PBMCs and reduced IL-17 and IL-22 production in hyphae-stimulated PBMCs, 
figure 3 Differential roles for TLR4 and TLR2 in Aspergillus induced T-cell responses
(A) IL-17, IL-22 and IFNγ were measured in culture supernatants of PBMCs (2.5x106/mL) stimulated with 107/
mL A. fumigatus conidia (n=7 for IL-17, n=8 for IL-22, and N=9 for IFNγ) or hyphae (n=7 for IL-17, n=7 for IL-22, and 
n=11for IFNγ) for 7 days, that were pre-incubated with B. quintana LPS to block TLR4 and were compared to 
pre-incubation with culture medium. (B) Similarly, TLR2 was blocked by 1 hour pre-incubation using mouse 
anti-human TLR2 monoclonal antibody which was compared to the isotype control (n=6).
4Aspergillus-induced T helper responses   |  91 
whereas IFNγ production was not affected by TLR4 blockade (Figure 3A). Blocking TLR2 
resulted in an upregulation of IL-17 and IL-22 production by conidia stimulated PBMCs 
and a trend towards upregulation of IL-22 in hyphae-stimulated PBMCs (Figure 3B).
Redundant role for dectin-1-Syk signalling in Aspergillus-induced T-cell 
responses
Dectin-1 has been associated with the defence against Aspergillus in numerous reports 
(3, 4, 33-38). Gessner and co-workers described that dectin-1 deficient mice lack the 
ability to induce IL-22 early in infection, which causes a decreased ability to induce 
antimicrobial peptides, resulting in an increased fungal burden and mortality (11). To 
see whether the dectin-1-Syk signalling pathway is involved in the induction of IL-22 
production by human T-cells, PBMCs were stimulated with conidia or hyphae in the 
presence of laminarin, a dectin-1 inhibitor. Blocking dectin-1 with laminarin did not result 
in any significant effect on hyphae or conidia-induced IL-17A, IL-22, or IFNγ (Figure 4A). 
However, there was one donor with unusual high IL-17 production in response to hyphae, 
which we excluded from analysis. It should be noted that the IL-17 production in this 
donor was almost completely blocked with laminarin.
We investigated whether Aspergillus conidia and hyphae expressed β-1,3-glucan on 
the surface by immunofluorescence staining. We found that β-1,3-glucan was only mini-
mally present on a few conidia, which is in line with reports demonstrating that resting 
conidia do not express β-glucan (34). In contrast, hyphae abundantly exposed beta-
glucan (figure 4B). To confirm that dectin-1/Syk signalling does not play a significant role 
in the induction of IL-17A, IL-22 or IFNγ by Aspergillus, PBMCs of three patients with the 
homozygous mutation Y238X in dectin-1 (lacking dectin-1 expression on the membrane 
of the cell (20)) were stimulated with conidia and hyphae. PBMCs from these patients 
demonstrated either a similar or higher cytokine response to Aspergillus compared to 
PBMCs from a healthy control (Figure 4C).
Syk kinase is the downstream signalling kinase of dectin-1 and other C-type lectin 
receptors (CLRs) (34). Although, hyphae-induced IL-17 production tended to decrease 
upon blocking of dectin-1, inhibition of Syk kinase demonstrated no difference in IL-17A, 
IL-22, or IFNγ production by Aspergillus stimulated PBMCs (Figure 4D).
The role for complement receptor 3 (CR3) for Aspergillus-induced T-cell 
responses
Recently, CR3 was demonstrated to recognize β-glucan, which leads to downstream 
signalling and activation of granulocytes (39). Moreover, CR3 has also been associated 
with phagocytosis of pentraxin3 opsonised Aspergillus (40). We investigated whether 
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figure 4 Redundant role of dectin-1 and Syk signalling in Aspergillus-induced IL-17A, IL-22, and 
IFNγ
(A) IL-17A, IL-22 and IFNγ in culture supernatants of PBMCs (2.5x106/mL) with 107/mL A. fumigatus conidia 
or hyphae for 7 days, that were pre-incubated with laminarin to block dectin-1, (n=8 for conidia and n=5 for 
hyphae). (B) Bright field (BF) and Immunofluorescence images after staining with mouse anti-β-1,3-glucan 
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CR3 was involved in the induction of IL-17A, IL-22, and IFNγ by A. fumigatus. Blockade of 
CR3 resulted in a significant reduction of IL-17A, IL-22 and IFNγ responses induced by 
conidia. In response to hyphal stimulation, only IL-17A and IL-22 were significantly inhib-
ited by blocking of CR3 (Figure 4D). Since the primary role of CR3 is recognition of C3 
opsonised structures, we investigated whether active serum complement was required 
for Aspergillus-induced IL-17A, IL-22 and IFNγ. When human serum was heat-inactivated 
prior to stimulation, no differences in IL-17A, IL-22 and IFNγ induction were observed 
(Figure 4E).
The role of IL-1 and IL-23 in A. fumigatus-induced IL-17 and IL-22
The predominant cytokine produced by human PBMCs in response to Aspergillus was 
IL-22, while the IL-17A production was relatively low (Figure 1A). To elucidate the reason 
for the low IL-17A release by Aspergillus stimulated PBMCs we focused on the cytokines 
that regulate the Th17 response. Both IL-1β and IL-23 have been associated with the 
induction and maintenance of the Th17 response in humans (41). Additionally, a critical 
role for IL-23 in the induction of IL-22 was observed in the early response against A. 
fumigatus (11). Interestingly, IL-23 induction by PBMCs stimulated with conidia and hy-
phae was below the detection limit of the ELISA, while IL-1β production was detectable 
(Figure 5A). To investigate whether the absence of IL-23 production is responsible for the 
low production of IL-17 in response to Aspergillus, IL-23 was blocked with an anti-human 
IL-23p19 antibody. Compared to stimulation with the isotype control, IL-17A production 
was reduced to undetectable levels although this was not statistically significant, while 
IL-22 production was not affected (Figure 5B). Addition of IL-23 significantly increased 
IL-17A production but did not increase IL-22 production (Figure 5C). Blocking IL-1 signal-
ling with IL-1 receptor antagonist (IL-1Ra) reduced IL-17A and IL-22 induction significantly 
conjugated with goat anti-mouse IgG alexa488. HI Aspergillus conidia (left panels) and HI Aspergillus hyphae 
(right panels) at 400x magnification and an exposure time of 900ms for fluorescence pictures. (C) IL-17A, IL-
22 and IFNγ in culture supernatants of PBMCs (2.5x106/mL) from three patients with a homozygous dectin-1 
Y238X polymorphism and two healthy controls without the polymorphism were stimulated with A. fumigatus 
conidia or hyphae for 7 days and IL-17, IL-22, and IFNγ were measured in the culture supernatant. IL-17, IL-
22 and IFNγ in culture supernatants of PBMCs (2.5x106/mL) stimulated with 107/mL A. fumigatus conidia or 
hyphae in presence or absence of (D) Syk kinase inhibitor (n=11 for conidia and n=6 for hyphae), or (E) goat 
anti-CR3 monoclonal antibody or an isotype control (conidia n=11 or hyphae n=6 for IL-17 and IL-22, n=8 for 
IFNγ). (F) IL-17, IL-22 and IFNγ in culture supernatants of PBMCs (2.5x106/mL) (n=6 donors) with 107/mL A. 
fumigatus conidia for 7 days in the presence of 10% human serum or 10% human serum that was heat inac-
tivated for 30 minutes at 56°C. Differences of the means were analysed for significance using the Wilcoxon 
Signed Rank test.
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(Figure 5D). These results suggest that IL-17A production requires both IL-1β and IL-23, 
whereas IL-22 production requires only IL-1β.
figure 5 Role of IL-23 and IL-1 in A. fumigatus induced IL-17A and IL-22
IL-1β and IL-23 concentrations in PBMCs (2.5x106/mL) (n=7) that were stimulated with HI A. fumigatus conidia 
or hyphae 37°C and 5% CO2 for 24 hours (A). IL-17 and IL-22 were measured in the culture supernatants of 
PBMCs (2.5x106/mL) stimulated with HI A. fumigatus conidia in the presence or absence of 10 μg/mL IL-1Ra 
(C) (n=7 for IL-17 n=12 for IL-22), IL-23 (D) (n=12), or anti-IL-23p19 (E) (n=5 for IL-17 n=6 for IL-22). Differences of 
the means were analysed for significance using the Wilcoxon Signed Rank test.
figure 6 Role of TNFα in A. fumigatus induced IL-17A and IL-22
(A) IL-17A and IL-22 were measured in the culture supernatants of PBMCs (2.5x106/mL) (n=10 donors) stimu-
lated for 7 days with 107/mL HI A. fumigatus conidia with or without recombinant human TNFα. (B) TNFα was 
blocked by pre-incubation of PBMCs (n=11) for 1 hour with sTNFRII (Enbrel) or human anti-TNFα (Humira). 
Subsequently the capacity to induce IL-17A and IL-22 was investigated by 7 days stimulation with HI A. fu-
migatus conidia. Differences of the means were analysed for significance using the Wilcoxon Signed Rank 
test.
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Role of TNFα in A. fumigatus-induced IL-17 and IL-22
Although IL-1β and IL-23 play key roles in the induction of T-helper responses by A. 
fumigatus, it cannot be excluded that other cytokines also play a role in the induction 
of the cytokines IL-17 and IL-22. To investigate the role of TNFα in A. fumigatus induced 
IL-17 and IL-22 we stimulated PBMCs with HI conidia in the presence of 10 or 100 ng/mL 
TNFα. Both IL-17 and IL-22 production were dose dependently increased in the presence 
of TNFα when compared to stimulation with Aspergillus alone (Figure 6A). To further 
investigate the role of TNFα we stimulated PBMCs with HI conidia in the presence of 
sTNFRII (Enbrel) or human anti human TNFα (Humira), two drugs that are used to block 
TNFα signalling in IL-17 related diseases like rheumatoid arthritis (RA) (42). Both blockers 
significantly reduced the IL-17 and IL-22 response (Figure 6B).
DIsCussIon
In the present study we demonstrate that CD4+ T cells are the main producers of IL-
17, IL-22 and IFNγ in human PBMCs upon Aspergillus stimulation. Interestingly, CD4 
T-helper cells that are capable of producing IL-22 after Aspergillus stimulation are not 
a distinct characteristic subset, but can have a Th1, Th17, or Th22 signature. Similar to 
IL-17, the production of IL-22 induced by Aspergillus is dependent on TLR pathways. 
While the TLR4 pathway contributing to the production of these cytokines, the TLR2 
has an inhibitory effect on Aspergillus-induced IL-17 and IL-22 production. In contrast, 
the TLR2 and TLR4 pathway do not modulate IFNγ production by human PBMCs that 
are stimulated with conidia. Rather unanticipated, the blockade of the dectin-1/Syk 
pathway or absence of the dectin-1 receptor did not significantly affect IL-17, IL-22 or 
IFNγ production induced by Aspergillus. In the current study, CR3 is the only receptor 
that is important for induction of all three cytokines IL-17, IL-22 and IFNγ, and therefore 
the CR3 pathway could specifically play an important role in the host defence against 
Aspergillus. Furthermore, we provided evidence that IL-17 and IL-22 responses induced 
by Aspergillus are dependent on the IL–1 and TNF pathway.
Using flowcytometric analysis of PBMCs and depletion of CD4 or CD56 cell subsets, 
we determined that the cytokines IL-17, IL-22 and IFNγ are primarily produced by CD4+ 
T-cells. Within the CD4+ T-cell populations diverse intracellular cytokine expression was 
detected. We detected IL-17 single positive and IL-17/IL-22 double positive CD4 cells 
that match the classically described Th17 cells (13) and IFNγ positive CD4 cells that 
match the classical Th1 type. Half of the IFNγ+ cells were CD4+ cells, whereas the rest of 
the IFNγ+ cells were negative for this T-helper-cell marker. We were able to demonstrate 
that a significant number of natural killer (NK) cells express IFNγ, which is in line with a 
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previous report that demonstrated that NK cells play an important role in the antifungal 
response to A. fumigatus by releasing IFNγ (43). However, depletion of CD56+ cells did 
not alter IFNγ responses, suggesting that NK cells are not important for the produc-
tion of IL-22 upon stimulation with Aspergillus. Furthermore, the IFNγ+ CD56+ cells did 
not expand upon stimulation with Aspergillus. These data suggest that, in the setting of 
PBMCs, NK cells do not contribute to the IFNγ response to Aspergillus. We found that af-
ter stimulation with Aspergillus IL-17/IFNγ double positive CD4+ cells were present in low 
numbers. Therefore, our results demonstrate that the polarization of T-helper responses 
induced by Aspergillus in-vitro is different from that induced by the commensal fungus 
Candida albicans (44). It was demonstrated that C. albicans induces a T-cell polarization 
with high numbers of IL-17/IFNγ double positive T-helper cells. Here we demonstrate 
that Aspergillus stimulation leads to low numbers of this T cell subset. This is of interest, 
since these double positive cells have been linked to autoimmunity (44).
We also observed IL-22 single positive cells that might fit the description of Th22 cells 
(15), as these cells co-expressed TNFα. In addition, large numbers of IFNγ/IL-22 double 
positive CD4 cells and even IL-17/IL-22/IFNγ triple positive CD4 cells are present. This 
is to our knowledge the first study that demonstrates that Aspergillus can induce single 
IL-22+ and IFNγ/IL-22 double positive cells. It remains to be elucidated whether these 
specific subsets contribute to pathology or protection. A study in mice revealed an 
important role for IL-22 in the early defence against Aspergillus (11), while another study 
demonstrates contribution to pathology in an allergic aspergillosis model (12). In the 
current study, we observed that the proinflammatory adaptive cytokine response to A. 
fumigatus is dominated by IL-22, and the primary cellular sources were CD4+ cells. In 
contrast to the study performed by Gessner and co-workers, our model revealed that 
IL-22 production by Aspergillus-stimulated PBMCs was independent of IL-23. We found 
that the innate cytokines IL-1 and TNFα played a crucial role in the induction of IL-22, 
which is in agreement with earlier studies (45). Previously, it was demonstrated that 
the IL-22 response also dominated over the IL-17 response in patients with pulmonary 
tuberculosis (46). Moreover, IL-22 was shown to be important in the defence against 
multiple pulmonary pathogens including Mycobacterium tuberculosis (14, 46, 47), Klebsi-
ella pneumonia (48), and influenza A virus (16). Since the host defence against all these 
pulmonary pathogens strongly relies on IL-22, we hypothesize that IL-22 plays a pivotal 
role in the human anti-Aspergillus pulmonary host defence.
Although TLR2 and TLR4 play an important role in innate immune responses against 
A. fumigatus (28-32), the role of these receptors in the induction of the adaptive immune 
responses such as the IL-22 response against Aspergillus remains to be established. 
Here we demonstrate that TLR4 plays a role in the induction of IL-17 and IL-22 in re-
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sponse to Aspergillus. In contrast, blockade of TLR2 resulted in higher IL-17 and IL-22 
production. Therefore, this might indicate that TLR2 plays a role in an inhibitory pathway 
for the induction of IL-17 and IL-22. These findings are in line with several studies that 
report an anti-inflammatory role for TLR2 through Th2 skewing (49, 50), the induction of 
anti-inflammatory cytokines by TLR2, and the TLR2-dependent induction of regulatory 
T-cells (51). Interestingly, TLR2 is a negative regulator of the Th17 response in a murine 
pulmonary infection model with Paracoccidioides brasiliensis (52), supporting a general 
role of TLR2 as a negative regulator of Th17 polarization of fungal infections.
The fact that the β-glucan receptor dectin-1 and its downstream kinase Syk play a 
redundant role in the induction of IL-17, IL-22, and IFNγ by hyphae, which abundantly 
express β-1,3-glucan, is rather unanticipated, since the dectin-1 pathway plays an impor-
tant role in the host defence against invasive aspergillosis (35, 53). In line with our results, 
it has been demonstrated that IL-17 production by PBMCs with the dectin-1 Tyr238X 
polymorphism is not different from PBMCs that do not have this SNP (35). Notably, this 
SNP influences innate proinflammatory cytokines produced by PBMCs in response to 
A. fumigatus (35, 53). In mice, dectin-1 deficiency results in an increased susceptibility 
to A. fumigatus (3), that has been linked to disability to induce protective cytokines like 
IL-17 (3) and IL-22 (11). Although it is evident that dectin-1 plays a role in the induction of 
IL-17 and IL-22 in mice and that it plays a role in the innate host defence against invasive 
aspergillosis in humans, our studies suggest that IL-17, IL-22 and IFNγ production by CD4+ 
T cells in the human host response to Aspergillus conidia is not predominantly mediated 
by dectin-1.
CR3 is a β2-integrin (CD11b/CD18) that is expressed by monocytes and neutrophils 
(54, 55). This receptor can recognize self-molecules such as complement, but it can 
also recognize PAMPs from pathogens such as LPS from E. coli (56). CR3 plays a role 
in phagocytosis and induction of cytokine responses (57). Here we show that CR3 is in-
volved in modulating T-helper cytokine responses induced by A. fumigatus. To date, the 
modulation of Th17 and Th1 responses induced by fungi has not been linked to CR3 and 
future studies are required to further characterize its role in fungal infection. Interest-
ingly, CR3 has been shown to bind b-glucan, which can have modulatory effects on the 
immune response, suggesting that fungal components can modulate proinflammatory 
T-helper responses (Th1 and Th17) through CR3 (58). Immunofluorescent staining of b-
glucan revealed a very low expression on Aspergillus conidia, therefore b-glucan seems 
to be unlikely the main CR3 ligand in the recognition of Aspergillus.
In the present study we compared the IL-1β and IL-23 cytokine profiles produced by 
PBMCs stimulated with A. fumigatus and related this to the induction of IL-17 and IL-
22. Aspergillus induced relatively low IL-17 levels, which was rather surprising since A. 
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fumigatus induced a significant number of IL-17 positive CD4 cells. These observations 
are in line with a previous report, which demonstrates that A. fumigatus is a poor in-
ducer of IL-17 and is even capable of inhibiting the IL-17 response by interfering with the 
tryptophan metabolism (7). One possible explanation for the low IL-17 production could 
be that Aspergillus does not induce a significant IL-23 response, since IL-23 production 
was undetectable in A. fumigatus stimulations. Interestingly, supplementation of IL-23 
to the Aspergillus stimulated PBMCs boosted the IL-17 response, which is in line with 
an earlier report which showed that IL-23 can augment IL-17 responses in Aspergillus-
infected mice (3). Although, Aspergillus did not induce IL-23 in PBMCs, it was found 
earlier that DCs induce high levels of IL-23 upon stimulation with Aspergillus and that 
these DCs can polarize towards both Th1 and Th17 responses (37, 59). However, when 
we used monocyte-derived DCs instead of PBMCs in our experimental setup we were 
not able to detect any IL-23 or IL-1β in response to Aspergillus (data not shown). We 
further demonstrate that Aspergillus-induced IL-17 and IL-22 responses were dependent 
on IL–1. Notably, although IL-1β was present and the Th17 response was almost com-
pletely dependent on the IL–1 pathway, Aspergillus did not abundantly induce IL-17/
IFNγ+cells. This is in contrast with a previous study that suggests that IL-1β is responsible 
for the development of IL-17+IFNγ+ T-helper cells in response to the fungal pathogen C. 
albicans(44). These data provide evidence that next to IL–1, another pathway, such as the 
IL-23 pathway, must be triggered in order to induce IL-17+IFNγ+ cells.
Another striking observation is the role of TNF in modulating proinflammatory Th17 
responses induced by A. fumigatus. Blocking TNF lowered the IL-17 production in re-
sponse to A. fumigatus, moreover the effects were most prominent on IL-22 production. 
These observations are in line with previous reports, which demonstrated that IL-22 
production can be triggered by TNFα (15, 60, 61), and is in line with the observation that 
anti-TNFα treatment can reduce IL-17 levels in patients(42). So far, the role of TNFα in 
pathogen-induced IL-22 production has not been described. This observation could be 
highly relevant given the widespread use of anti-TNF therapy. Notably, the use of anti-
TNF (62-64) and polymorphisms in TNFR1 or decreased TNFR1 mRNA expression (64, 
65) have been linked to increased susceptibility to invasive aspergillosis, underlining the 
importance to identify the impact of TNF blockade on anti-Aspergillus host responses, 
such as lowering IL-22 production in response to A. fumigatus as described in the pres-
ent study.
In conclusion, we demonstrate that the T-helper cytokines IL-17, IL-22, and IFNγ in 
response to A. fumigatus are primarily produced by CD4 T-cells, and that these cyto-
kines are not limited to a specific subset but can be produced by a variety of polarized 
T-helper subsets. TLR4 and CR3 and the cytokines IL-1, IL-23, and TNFα are of specific 
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importance for Aspergillus-induced IL-17 and IL-22, whereas we observed that the dec-
tin-1/Syk pathway is redundant for this response. Collectively, these findings contribute 
to a better understanding of the human adaptive host defence against A. fumigatus, 
and provide new knowledge that contributes to the development of targeted adjunctive 
immunotherapeutic regiments in patients with invasive aspergillosis.
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AbsTRACT
background: Allergic bronchopulmonary aspergillosis (ABPA) is characterized by an 
exaggerated Th2 response to Aspergillusfumigatus, but the immunological pathways 
responsible for this effect are unknown.
objective: The aim of this study was to decipher the pattern recognition receptors 
(PRRs) and cytokines involved in the Aspergillus-specific Th2 response, and to study 
Aspergillus-induced responses in healthy controls and ABPA patients.
Methods: Peripheral blood mononuclear cells (PBMCs) were stimulated with heat-killed 
Aspergillus conidia, various other pathogens, or PRR-ligands. PRRs and cytokine path-
ways were blocked with PRR-blocking reagents, anti-TNF (Etanercept or Adalimumab), 
IL-1Ra (Anakinra), or IFNγ (IFN-gamma). ELISA and FACS were used to analyze cytokine 
responses.
Results: Aspergillus was the only pathogen that stimulated the Th2 cytokines IL-5 and 
IL-13, while Gram-negative bacteria, Gram-positive bacteria, Candida albicans, chitin, b-
glucan, or Toll like receptors (TLR) ligands did not. Depletion of CD4+ cells abolished IL-13 
production. Blocking complement receptor 3 (CR3) significantly reduced IL-5 and IL-13, 
while blocking TLR2, TLR4 or dectin-1 had no effect. ABPA patients displayed increased 
Aspergillus-induced IL-5 and IL-13, and decreased IFNγ production compared to healthy 
controls. All biological agents tested showed the capability to inhibit Th2 responses, but 
also decreased Aspergillus-induced IFNγ.
Conclusions: Aspergillus conidia are unique in triggering Th2 responses in human 
PBMCs, through a CR3-dependent pathway. ABPA patients display a significantly in-
creased Aspergillus-induced Th2/Th1-ratio that can be modulated by biologicals. These 
data provide a rationale to explore IFNγ therapy in ABPA as a corticosteroid-sparing 
treatment option, by dampening Th2 responses and supplementing the IFNγ-deficiency 
at the same time.
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InTRoDuCTIon
Allergic Bronchopulmonary Aspergillosis (ABPA) is a hypersensitivity reaction against 
the ubiquitous mould Aspergillus fumigatus (1). Innate immune cells, such as lung 
epithelia cells or alveolar macrophages initiate this inflammatory reaction (2). Fungi 
are sensed by innate immune cells through pattern recognition receptors (PRRs), like 
Toll-like receptors (TLRs), C-type-lectin receptors (CLRs) or nucleotide-binding oligo-
merization domain (NOD)-like-receptors (NLRs) (3). Activation of these receptors by 
Aspergillus leads to induction of cytokines, recruitment of other immune cells, and can 
eventually trigger adaptive immune responses such as T helper (Th) responses. A robust 
induction of the Th1 response during Aspergillus infection is associated with protection 
and successful clearance, while elevated Th2 responses impairs fungal clearance (4-6). 
Exaggerated Th2 responses are being held responsible for the detrimental inflamma-
tory reaction observed in ABPA, namely eosinophilia, increased mucus production and 
immunoglobulin class switching to IgE. This inflammatory reaction subsequently results 
in airway hyper-responsiveness with typical asthmatic symptoms like bronchial obstruc-
tion, coughing and wheezing (7, 8). The current treatment for ABPA is the administration 
of oral corticosteroids during exacerbations and control of the underlying asthma with 
β2-agonists. Furthermore, antifungal treatment with azoles in ABPA patients could spare 
the use of corticosteroids (1, 9). Due to the potential severe side effects of azoles and the 
long-term consequences of corticosteroid treatment, new approaches for ABPA therapy 
are needed.
While most Aspergillus-related PRRs have been studied in the context of invasive 
aspergillosis, limited data exists of the Aspergillus-associated molecular patterns and 
their PRRs responsible for triggering the Th2 response in ABPA. In mouse studies, TLR2 
and TLR9 have been described to skew the Aspergillus induced Th response towards a 
Th2 profile (10, 11), and chitin exposure has been associated with lung eosinophilia (12). 
The current study aims to identify the immunological pathways through which Aspergil-
lus induces a Th2 response in humans. Furthermore, the cytokine profile of a cohort 
of ABPA patients was investigated for assessing the Th1/Th2 balance. The capacity of 
treatment with biological therapy to modulate Aspergillus-induced Th-responses was 
tested in vitro, with the goal to find innovative corticosteroid-sparing treatment options 
for ABPA patients.
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MeTHoDs:
Volunteers and patients
Blood was collected from healthy volunteers or patients by venous blood puncture after 
informed consent. Three Dectin-1 deficient patients with a homozygous Y238X mutation 
in exon 6 of CLEC7A gene (the gene encoding Dectin-1) donated blood, two of them 
twice at two different time points. In these patients diminished expression of dectin-1 
and failure to induce a cytokine response to β-glucan was demonstrated previously (13). 
Seven asthma patients and nine patients diagnosed with ABPA according to the ABPA 
diagnostic criteria as described elsewhere were asked for blood donations, two of whom 
had cystic fibrosis with a homozygous mutation in the CFTR gene (Table 1).
PRR ligands, blockers and other stimuli
E.coli LPS (10 ng/ml) (TLR4 ligand, E. coli serotype O55:B5, Sigma-Aldrich St. Louis, MO 
USA), Pam3Cys (10 μg/ml) (TLR2 ligand, EMC microcollections, Tübingen, Germany), 
Poly I:C (10 μg/ml) (TLR3 ligand, Cayla-Invivogen, Toulouse, France), flagellin (10 μg/ml) 
(TLR5 ligand, Cayla-Invivogen, Toulouse, France), N-acetylmuramyl-ananyl-D-isogluta-
mine (MDP) (10 μg/ml) (NOD-2 ligand, Sigma-Aldrich), phytohemagglutinin (PHA) (10 
μg/ml) (Sigma-Aldrich). Escherichia coli ATCC 35218 (E. coli) (1x107 /ml); Staphylococcus 
aureus clinical isolate (S. aureus) (1x107 /ml); Mycobacterium tuberculosis sonicate H37Rv 
bub DL 6122005 (M. tuberculosis) (10 μg/ml); Borrelia burgdorferi ATCC 35210 (B. burg-
dorferi) (1x106 /ml); Candida albicans ATCC MYA-3573 (UC820) (C. albicans) (1x106 /ml); 
Aspergillus fumigatus clinical isolate V05-27 (A. fumigatus), resting conidia and hyphae 
(1x107 /ml,) were cultured and isolated as described in a previous study (14).
Fungal cell wall components: β1,3-(D)-glucan (β-glucan) (10 μg/ml) was kindly provided 
by Prof. David Williams (Tennessee University), and α1,3-glucan, α1,3-1,4-glucan (either 
dissolved in PBS or DMSO), chitin (Aspergillus niger) (all 10 μg/ml) and galactosaminoga-
lactan (GAG) (7,5 μg/ml) were a gift from Prof. Jean-Paul Latgé (Pasteur Institute, Paris).
Bartonella quintana LPS was prepared and purified as described elsewhere (15) and 
used as a TLR4 inhibitor (20 ng/ml) (16); isotype control mouse IgG1 (10 μg/ml) (eBiosci-
ence, Halle-Zoersel, Belgium); anti-TLR2 (10 μg/ml) (eBioscience); laminarin (50 ng/ml) 
(17); a Syk-kinase inhibitor (50 nM, Merck, Darmstadt, Germany); isotype control goat 
IgG (10 μg/ml) (R&D Systems Minneapolis, MN, USA); anti-human β2-integrin (anti-CR3) 
(10 μg/ml) (R&D Systems); anti-human OX40ligand (anti-OX40L) (10 μg/ml) (R&D Sys-
tems); cytochalasine D (1 μg/ml, dissolved in DMSO) (Enzo life sciences, Antwerpen, 
Belgium); IL-1 receptor antagonist (IL-1Ra) (10 μg/ml) (Amgen, Inc., Thousand Oaks, CA, 
USA); soluble TNFR2 (Etanercept) (100 μg/ml), human anti-human TNFα (Adalimumab), 
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(100 μg/ml), both kindly provided by Dr. Marije Koenders (Department of Rheumatology 
Radboud University Nijmegen Medical Centre the Netherlands); Interferon-gamma 1b 
(Immukine®) (50 ng/ml) (Boehringer-Ingelheim, Almaar, The Netherlands).
PBMCs isolation
Venous blood was drawn in 10 ml EDTA tubes. The blood was diluted 1:1 with Phos-
phate Buffered Saline (PBS). Subsequently PBMCs were isolated using Ficoll-paque (GE 
healthcare, Zeist, The Netherlands) density gradient centrifugation. The PBMCs layer was 
collected and washed twice in cold PBS. Cells were reconstituted in RPMI-1640 culture 
medium (Dutch modification, Gibco, Invitrogen, Breda, The Netherlands) supplemented 
with 10 µg/ml gentamicin, 10 mM L-glutamine and 10 mM pyruvate (Gibco). The cells 
were counted with a particle counter (Beckmann Coulter, Woerden, The Netherlands) 
and the concentration was adjusted to 1x107 cells/ml.
Cell depletion
PBMCs were incubated with magnetic anti-CD4+, anti-CD56+ and anti-CD19+ beads and 
purified using MACS depletion columns (LD, Miltenyi Biotec, Bergisch Gladbach, Ger-
many) according to the instructions supplied by the manufacturer to generate CD4- (T-
cells depleted), CD56- (NK-cells depleted) or CD19- (B-cells depleted) PBMC fractions. 
Next to the labeled cells, also an unlabeled PBMC fraction was run over the depletion 
column and used as a mock treatment control.
PBMCs stimulation
PBMCs were plated in a 96-well plate (Corning, NY, USA) at a final concentration of 
2.5x106 /ml in an endvolume of 200 μl per well. All stimulations were performed in the 
presence of 10% human serum. Serum was either complement active if not otherwise 
indicated or heat-inactivated by incubation for 30 minutes at 56°C in a water bath ac-
cording to a commonly used protocol (18). Mannose-binding lectin (MBL) deficient serum 
was obtained from a patient with MBL level of 0.09 μg/ml. After 1h pre-incubation with 
inhibitor or medium, stimuli or medium were added. Cells were incubated at 37°C with 
5% CO2, after 7 days supernatants were collected and stored at -20°C.
Cytokines measurements
IL-5, IL-13, IFNγ and IL-10 were measured in the cell culture supernatants using a com-
mercial ELISA kit (IL-5 and IL-13: R&D Systems; IFNγ and IL-10: Sanquin) according to the 
instructions supplied by the manufacturer.
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Intracellular staining and flowcytometric analysis
After 7 days incubation, cells were re-stimulated for 4-6 hours with 200 μl of RPMI 
supplemented with gentamicin, L-glutamine and pyruvate and PMA (50 ng/ml) 
(Sigma-Aldrich), ionomycin (1 μg/ml) (Sigma-Aldrich), Golgiplug (BD Biosciences, Breda, 
the Netherlands) and 10% human serum. Cells were stained extracellular using PE-
Cy7–conjugated anti-CD4 (BD Biosciences), PE-Cy7–conjugated anti-CD8 (BioLegend, 
San Diego), or PE-Cy7–conjugated anti-CD56 (Beckman Coulter) and ECD-conjugated 
monoclonal anti-CD3 antibody (Beckman Coulter, Krefeld, Germany). Fixation and per-
meabilization was performed with Cytofix/Cytoperm solution (eBioscience) according 
to the instructions supplied by the manufacturer. Cells were stained intracellular with 
anti-IL-4 (FITC conjugated), anti-IL-5 (PE conjugated) and anti-IL-13 (APC conjugated) 
(all BD Bioscience). Fixated cells were measured with a FC500 flowcytometer (Beckman 
Coulter) and the data were analyzed using CXP analysis software v2.2 (Beckman Coulter).
OX40L expression
RNA was isolated from 1x106 PBMCs after stimulation for 48h with Aspergillus conidia 
either in the presence of medium or Adalimumab or IL-1Ra using Trizol Reagent (Invitro-
gen) according to a protocol supplied by the manufacturer. RNA (500 ng) was reverse 
transcribed into cDNA using the iScript cDNA synthesis kit (Hercules, Bio-Rad Labora-
tories, CA). Quantitative PCR (qPCR) analysis was performed using SYBR Green Master 
Mix (Applied Biosystems, Carlsbad, CA) and the Applied Biosystems 7300 real-time PCR 
system. As PCR protocol the following conditions were used: 2 min 50°C, 10 min 95°C fol-
lowed by 40 cycles at 95°C for 15 s and 60°C for 1 min. For the amplification of hOX40L the 
primers 5’-TCCCCTCTCTTAGGTGCTCA-3’ and 5’-GGCTGGTGCATAGCAGAAAT-3’ were 
used. To correct for differences in loading concentrations of RNA between the different 
conditions, qPCR results were corrected with the housekeeping gene β2 microglobulin 
(β2m) amplified using the primers 5’- ATGAGTATGCCTGCCGTGTG-3’ and 5’-CCAAATGC-
GGCATCTTCAAAC-3’. Primer efficacy was evaluated using a standard curve. OX40L Ct 
values were compared with the β2m Ct using the formula 2-ΔCt and the foldchange was 
calculated by setting the Aspergillus-stimulated samples as 1 to determine the effect of 
anti-TNF (Adalimumab) and IL-1Ra on OX40L expression.
Genotyping 
Genomic DNA from healthy caucasian controls was isolated using the Gentra Pure Gene 
blood kit (Qiagen, Hilden, Germany) according to the instructions supplied by the manu-
facturer. The specific SNP identifiers (rs numbers) were extracted from a recent publica-
tion describing SNPs associated with ABPA (19). Genotypes of the different SNPs were 
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obtained from the Illumina immunochip which has previously been run according to the 
manufactures protocol (20). Beforehand, a quality filter was applied which automatically 
excluded SNPs with either a low call rate (<99%), SNPs that were not in Hardy-Weinberg 
equilibrium (p<0.01) or that had a reported minor allele frequency of less than 0.01.
Statistical analysis
The Mann-Whitney-U test was used to detect differences between healthy controls and 
patients or between different genotypes. The Wilcoxon signed rank test was used to 
determine differences between stimulation with and without inhibitors of PRRs, cyto-
kines or cytokine inhibitors. A p-value of < 0.05 was considered statistically significant 
(*=p < 0.05, ** = p < 0.01 and *** = p < 0.001). Graphs represent cumulative results of all 
performed experiments and are presented as mean ± standard error of the mean. Data 
were analyzed with GraphPad Prism v 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).
ResulTs:
Aspergillus conidia induce a Th2 response in human PBMCs, in contrast to 
other pathogens or PRR ligands
We investigated which PRRs are involved in the initiation of a Th2 response by stimulat-
ing PBMCs with different specific ligands for TLR4, TLR2, TLR5, NOD2 or Dectin-1, and 
measuring IL-5 and IL-13 (Figure 1A). None of these ligands or combinations of TLR2 with 
ligands for Dectin-1 or NOD2 was able to induce IL-5 or IL-13. We thereafter screened a 
panel of pathogens consisting of extra- and intracellular bacteria, as well as two types 
of fungi for their capacity to induce Th2 cytokines (Figure 1B). The whole bacteria E. coli, 
S. aureus or B. burgdorferi, as well as sonicated M. tuberculosis were unable to induce 
IL-5 and IL-13, while these pathogens induce other immune responses such as IL-17 
and IFNγ in these conditions (data not shown). Among the fungal pathogens, the Th2 
response was restricted to the stimulation with A. fumigatus conidia, while C. albicans 
yeast did not induce IL-5 and IL-13. Moreover, Aspergillus hyphae induced relatively low 
IL-5 production (76.4 pg/ml hyphae vs. 296 pg/ml conidia) and IL-13 (310 pg/ml hyphae 
vs. 568 pg/ml conidia). Stimulation with the fungal cell wall components α1,3-glucan 
and α1,3-1,6-glucan, β1,3-glucan, galactosaminagalactan (GAG) or chitin did not induce 
IL-5, while IL-13 production was slightly induced by α1,3-1,6-glucan or chitin (Figure 1C). 
PHA was used as a mitogenic stimulus to detect T cell memory activation, and induced 
low levels of Th2 cytokines.
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Aspergillus-induced IL-5 and IL-13 are dose and time dependent and 
predominantly produced by CD4+ T cells
To study the kinetics and dose dependency of IL-5 and IL-13 induced by Aspergillus 
conidia, we performed a time course of 7 days with 3 different concentrations rang-
ing from 1x105 to 1x107 conidia/ml (Figure 2A). IL-4 was undetectable in all stimulations 
(data not shown). In contrast, IL-5 and IL-13 were detectable from day 4 onwards and 
increased steadily. Only the highest dosage of 1x107 conidia/ml induced IL-5 and IL-13, 
while dosages below this threshold induced cytokine values barely detectable above 
the detection limit.
To investigate which cells are responsible for the production of IL-4, IL-5 and IL-13 
induced by Aspergillus, flowcytometric analyses with intracellular staining for IL-4, IL-5 
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figure 1: Aspergillus conidia induce a Th2 response in human PBMCs in contrast to other pathogens or 
PRR ligands
IL-5 and IL-13 concentrations were measured in cell culture supernatants of PBMCs of healthy controls (2.5 
x 106 /ml, n=6 donors) by ELISA (IL-5 detection level 24 pg/ml, IL-13 detection level 71 pg/ml) after stimula-
tion with (A) TLR4 ligand (LPS), TLR2 ligand (Pam3Cys), TLR3 ligand (Poly I:C), TLR 5 ligand (flaggelin), NOD3 
ligand (MDP) or Dectin-1 ligand (β-glucan) (B) Various pathogens like E.coli, S.aureus, M. tuberculosis sonicate 
(H37Rv), B. burgdorferi, C. albicans yeast and A. fumigatus conidia (C) A. fumigatus conidia and hyphae as 
well as different cell wall components like α1,3 glucan, α1,3-1,4 glucan, β1,3 glucan, galactosaminogalactan, 
chitin PHA.
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figure 2: Aspergillus-induced Th2 cytokines are dose and time dependent and predominantly 
produced by CD4+ cells
(A) PBMCs (2.5 x 106 /ml, n=4 donors) were stimulated with increasing concentrations of Aspergillus conidia 
(1x105 /ml, 1x106 /ml, 1x107 /ml) for 1-7 days and IL-5 and IL-13 was measured in the cell culture supernatant 
by ELISA. (B-C) Cells were stained extracellular for CD4+-, CD8+-, CD56+ and CD19+ and intracellular for IL-4, 
IL-5 and IL-13. (B) CD4+ and CD4− cells (n=10) within the IL-4, IL-5 or IL-13 positive cells. (C) CD4+-, CD8+-, CD56+ 
and CD19+-cells within the Aspergillus-specific IL-4+-, IL-5+- and IL-13+-populations (normalized to 100%, one 
representative donor) (D) PMBCs were depleted either for CD4+, CD56+ or CD19+ cells (white bars) or run over 
the depletion columns unlabeled (black bars) and stimulated with Aspergillus conidia. IL-13 was measured in 
the cell culture supernatant by ELISA (n=6 donors). The Wilcoxon Signed Rank test was used to determine, 
whether the means were significantly different (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001).
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and IL-13 were performed on PBMCs that were cultured for 7 days in the presence of 
Aspergillus conidia. Within the Th2 cytokine positive population, CD4+ cells were the 
main representatives (72.9% of IL-4+, 61.7% of IL-5+ and 68.5% of IL-13+ cells) (Figure 2B). 
Surface staining for CD8, CD56 and CD19 revealed the CD8+ cells as the second biggest 
subpopulation contributing to the IL-5 and IL-13 production (Figure 2C). To determine 
which cell populations within PBMCs contribute to the IL-5 and IL-13 secretion induced 
by Aspergillus stimulation, PBMCs were depleted of CD4+, CD56+ or CD19+ cells (Figure 
2D). Mock-treated PBMCs lost their capacity to produce IL-5, which made it impossible 
to evaluate the effect of depleting a special subpopulation on IL-5 production (Supple-
mental Figure 1). Depletion of the CD4+ cells led to a reduction of Aspergillus-induced IL-
13 production to undetectable levels, while depleting CD56+ or CD19+ cells did not affect 
IL-13 production. These data suggest that CD4+ T-lymphocytes are the main producers 
of Th2 cytokines induced by Aspergillus conidia.
Aspergillus-induced IL-5 and IL-13 response is dependent on Complement 
Receptor 3 and phagocytosis
Since most PRRs have been studied in the context of invasive aspergillosis (3) only 
little is known about the PRRs and pathways involved in the pathogenesis of ABPA. We 
investigated the role of TLR2, TLR4, Dectin-1 and CR3 pathways in Aspergillus-induced 
Th2 responses in human PBMCs. PBMCs were stimulated with Aspergillus conidia in the 
absence or presence of specific inhibitors for the PRR pathways. Inhibition of TLR4 did 
not alter IL-5 production, while IL-13 was slightly reduced (mean 15.7% reduction, Figure 
3A). Although TLR2 has been described to polarize Aspergillus-specific T cell responses 
towards Th2 (21), neither IL-5 nor IL-13 was affected when TLR2 was blocked (Figure 3B).
Dectin-1 is known to recognize the fungal cell wall component β-glucan (22) and is 
known to promote immunopathology in the lung during fungal allergy (23). However, 
blocking dectin-1 with laminarin (Figure 3C), or inhibition of Syk kinase, the downstream 
signaling kinase of the dectin-1 receptor, did not alter the Th2 response induced by As-
pergillus (Figure 3D). Additionally, PBMCs isolated from three dectin-1 deficient patients 
produced IL-5 and IL-13 levels comparable to healthy controls (Figure 3E). Subsequently, 
we investigated CR3 (CD11b/CD18), a β2-integrin expressed on neutrophils and mono-
cytes, since it has been described that CR3 is also able to recognize β-glucan (24). Block-
ade of CR3 inhibited the Aspergillus-induced Th2 response completely (Figure 3F). We 
did not observe different cytokine production when the serum was de-complemented 
by heat-inactivation (Figure 3G).
Since CR3 is involved in phagocytosis (25), we blocked phagocytosis by inhibiting actin 
polymerisation by cytochalasine D, which significantly reduced IL-5 and IL-13 produc-
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tion (Figure 3H). High plasma levels of MBL are associated with bronchial asthma with 
allergic rhinitis and ABPA (26), therefore we wanted to investigate whether the recogni-
tion of Aspergillus conidia with subsequent Th2 induction via CR3 is MBL dependent. 
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figure 3: Aspergillus-induced IL-5 and IL-13 response is dependent on Complement Receptor 3 and 
phagocytosis
PBMCs were pre-incubated for 1h with different blockers and stimulated with Aspergillus conidia. IL-5 and 
IL-13 were measured in the cell culture supernatant (black bars: Aspergillus conidia stimulation with medium 
or control, grey bar: Aspergillus conidia stimulation after blocking). (A) TLR4 blocking with B. quintana LPS 
(IL-5 n=9 donors, IL-13 n=8 donors). (B) TLR2 blocking with αTLR2 antibody (IL-5 n=6 donors, IL-13 n=7 donors). 
(C) PBMCs of three Dectin-1 deficient patients compared with four healthy controls. (D) Dectin-1 blocking 
with laminarin (n=10 donors). (E) syk inhibition (IL-5 n=9 donors, IL-13 n=7 donors). (F) CR3 blocking with αCR3 
antibody (IL-5 n=7 donors, IL-13 n=9 donors). (G) PBMC stimulation with 10% active human serum compared 
with 10% heat-inactivated human serum (IL-5 n=5 donors, IL-13 n=6 donors). (H) Blocking phagocytosis with 
cytochalasine D (n=6 donors). (I) CR3 blocking with αCR3 antibody (IL-5 and IL-13 n=4 donors) in the presence 
of MBL deficient serum. The Wilcoxon Signed Rank test was used to determine, whether the means were 
significantly different (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001).
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Aspergillus-specific Th2 cytokines in the presence of MBL deficient serum were sig-
nificantly decreased after blocking CR3, suggesting that signaling via CR3 leading to 
Th2 responses is independent of MBL (Figure 3I). These data demonstrate that the IL-13 
response induced by Aspergillus in human PBMCs is partially dependent on TLR4, while 
both IL-5 and IL-13 are dependent on CR3 and phagocytosis.
ABPA patients have an Aspergillus-specific increased Th2/Th1 ratio
PBMCs isolated from nine ABPA patients and healthy controls were stimulated with 
Aspergillus conidia and IL-5, IL-13 and IFNγ production was measured. Compared to non-
allergic healthy controls, ex vivo induction of Th2 cytokines by Aspergillus stimulation 
was stronger in ABPA patients, which was statistically significant for IL-5 but not for IL-13 
(Figure 4A). In contrast, Aspergillus-induced IFNγ production by PBMCs was significantly 
lower in ABPA patients when compared to healthy controls (Figure 4A). Interestingly, 
IFNγ was significantly decreased after stimulation with both Aspergillus conidia and 
hyphae (data only shown for conidia). When we compared the IL-5/IFNγ and IL-13/IFNγ 
ratios in ABPA patients and controls, we observed that they were significantly different 
and discriminated ABPA patients from healthy controls (Figure 4B, C).
To determine whether the elevated Th2/Th1 ratio in ABPA is due to the underlying 
asthma itself or due to Aspergillus sensitization, we investigated Aspergillus-specific ratios 
in asthma patients with and without an elevated Aspergillus-specific IgE (supplemental 
table 1). PBMCs isolated from asthma patients with Aspergillus-sensitization that were 
stimulated with Aspergillus conidia showed a higher Aspergillus-specific Th2 response 
than the asthma group without Aspergillus-sensitization and the control group (Figure 
4D). This resulted in an elevated Th2/Th1 ratio comparable to ABPA patients (Figure E). 
In addition, we investigated whether the anti-inflammatory cytokine IL-10 is involved in 
the elevated ratios observed in ABPA. Neither in the control, nor in the patient group did 
we detect IL-10 concentrations (supplemental Figure 2).
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Etanercept, Adalimumab, Anakinra and IFN-gamma have the capability to 
modulate the Aspergillus-induced Th2/Th1 ratio in human PBMCs
Since we observed significantly different Th2/Th1 ratios in ABPA patients we wanted to 
investigate whether available biologicals for treatment of inflammatory disease are ca-
pable of modulating the Aspergillus-specific Th2/Th1 ratio. We used Etanercept (soluble 
TNFα receptor II-Fc), Adalimumab (human anti-human TNFα), Anakinra (IL-1 receptor 
antagonist) and Immukine (recombinant human IFNγ) and stimulated PBMCs either with 
Aspergillus conidia in the presence of medium or one of the biologicals. All biologicals 
significantly suppressed Aspergillus-induced IL-5 and IL-13 production in human PBMCs. 
However, Etanercept, Adalimumab and Anakinra also suppressed IFNγ production in 
response to Aspergillus and hence did not correct the IL-5/IFNγ-ratios (Medium: 0.65, 
figure 4: The Th2/Th1 balance in ABPA patients is shifted towards Th2
(A) PBMCs of 9 ABPA patients were stimulated with Aspergillus conidia and compared with PBMCs of healthy 
controls. IL-5, IL-13 and IFNγ levels were measured in the cell culture supernatant (black bars controls, white 
bars patients). (B) The Th2/Th1-ratio between IL-5 vs. IFNγ and IL-13 vs. IFNγ was generated by dividing the 
individual IL-5 or IL-13 level by the individual IFNγ level. (C) The triangle diagram shows the mean of IL-5, IL-13 
or IFNγ of every group on the corresponding cytokine axis (continuous line: controls, dotted line: patients). 
(C) PBMCs isolated from 3 asthma patients with an elevated Aspergillus-specific IgE (Asp asthma) and 4 
without elevated Aspergillus-specific IgE (asthma) were stimulated with Aspergillus conidia and compared 
with healthy controls. IL-5, IL-13 and IFNγ levels were measured in the cell culture supernatant. (D) The Th2/
Th1-ratio between IL-5 vs. IFNγ and IL-13 vs. IFNγ was generated by dividing the individual IL-5 or IL-13 level 
by the individual IFNγ level. The Mann-Whitney-U test was used to determine, whether the means were 
significantly different (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001).
5Aspergillus-induced Th2 responses  |  121 
Etanercept l: 0.61, Adalimumab: 0.92, Anakinra: 1.82) and IL-13/IFNγ-ratios (Medium: 1.49, 
Etanercept: 1.41, Adalimumab: 1.89, Anakinra: 2.77). Therefore, it was only recombinant 
IFNγ that was able to restore the increased Th1/Th2 ratio by down-regulating IL-5 and 
IL-13, but not IFNγ.
The co-stimulatory molecule OX40L is known to be involved in inflammatory Th2 
responses triggered by thymic stromal lymphopoetin (TSLP)-activated dendritic cells 
in ABPA patients (27). We therefore investigated whether OX40L is also involved in the 
Th2 responses induced by Aspergillus in human PBMCs. Blocking OX40L resulted in 
significantly decreased Aspergillus-induced IL-13 production (FIG 5D). Since TNF and IL-1 
can modulate the expression of OX40L (28, 29), we analyzed whether blocking TNF or 
IL-1 would result in a different expression of OX40L in PBMCs. We observed no significant 
modulation of the Aspergillus-induced OX40L expression in the presence of adalimumab 
or anakinra (Figure 5E).
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figure 5: Etanercept, Adalimumab, Anakinra and IFNγ have the capability to modulate the Aspergillus-
induced Th2/Th1 ratio in human PBMCs
PBMCs of healthy controls were stimulated with Aspergillus conidia either the presence of medium (black 
bars) or one of the biological drugs (grey bars) like Etanercept (soluble TNFα receptor), Adalimumab (human 
TNFα antibody), Anakinra (IL-1Ra) or recombinant IFNγ. (A) IL-5, (B) IL-13 and (C) IFNγ were measured with 
ELISA in the cell culture supernatant. (D) IL-5 and IL-13 measurement after blocking OX40L with αOX40L 
antibody (IL-5 and IL-13, n=9 donors). (E) OX40L expression in PBMCs of healthy controls stimulated with 
Aspergillus conidia either in the presence of Adalimumab or Anakinra (n=6). The Wilcoxon Signed Rank test 
was used to determine, whether the means were significantly different (*=p < 0.05, ** = p < 0.01 and *** = p < 
0.001).
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figure 6: The role of polymorphisms associated with ABPA on Aspergillus-specific Th2/Th1 ratios.
PBMCs isolated from healthy volunteers (n=35) were stimulated with Aspergillus conidia and IL-5 and IFNγ 
were measured in the cell culture supernatant. SNPs were analyzed for association with cytokine production. 
The Mann-Whitney-U test was used to determine, whether the means were significantly different (*=p < 0.05, 
** = p < 0.01 and *** = p < 0.001).
5Aspergillus-induced Th2 responses  |  123 
Polymorphisms influencing Aspergillus-specific Th2/Th1 ratios
Single nucleotide polymorphisms (SNPs) in the IL10, IL4Rα, MBL, and SFTPA2, gene have 
been associated with an increased susceptibility to ABPA (19). We took a systematic ap-
proach to investigate whether reported polymorphisms that are associated with ABPA 
could influence Aspergillus-specific Th2/Th1 ratios (table 2). PBMCs isolated from 35 
healthy controls were stimulated with Aspergillus conidia and IL-5 and IFNγ was mea-
sured. The homozygote GG genotype of IL-4Rα (rs1805010) showed a trend towards 
higher IL-5 production and an increased IL-5/ IFNγ ratio (Figure 6A). The GG genotype 
in the IL-10 SNP (rs1800896) showed a trend towards higher IFNγ production, however 
no association was observed with Aspergillus-specific IL-5 or IL-5/ IFNγ ratio (Figure 6E). 
The other polymorphisms in SFTPA2 (rs17886395 and rs17880349) and MBL (rs5030737) 
did not show an association with IL-5 or IFNγ production (Figure 6B, C and D).
DIsCussIon
In the present study, we investigated the general and Aspergillus-specific features of 
the Th2 response in primary human PBMCs of healthy controls and ABPA patients. Th2 
cytokine responses in vitro could only be detected when PBMCs were stimulated with 
A. fumigatus, while Candida, specific PRR ligands, Gram-positive and Gram-negative 
bacteria did not induce IL-5 or IL-13 production. Furthermore, no single fungal compo-
nent induced IL-5 or IL-13 in the same amount as Aspergillus conidia, suggesting that 
a complex of fungal PAMPs present on the cell wall of Aspergillus conidia is needed to 
induce a Th2 response in human PBMCs. The Aspergillus-specific IL-5 and IL-13 produc-
tion was dependent on CD4+ cells, the pattern recognition receptor CR3, and phagocy-
tosis. Moreover, we identified that ABPA patients, in contrast to non-allergic controls, 
had a significantly elevated Th2/Th1 ratio induced by Aspergillus. Interestingly, not the 
asthma itself but the Aspergillus sensitization in asthma patients appears to be respon-
Table 2: SNPs associated with ABPA
Gene rs number SNP position MAF function
IL-4Rα (16p12.1- p11.2)  rs1805010 4679 A/G 0.466 missence
SFTPA2 (10q22.3) rs17886395 1649 C/G 0.206 missence
SFTPA2  rs17880349  1492 C/T 0.461 Intronvariant
IL-10 (1q31-q32) rs1800896  min 1082 A/G 0.303 near-Gene5
MBL (10q11.2-q21) rs5030737 868 C/T 0.028 missence
Gene, rs number, SNP position, minor allele frequency (MAF) and resulting defect of gene function of SNPs 
associated with ABPA are listed.
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sible for the increased Th2/Th1 ratios observed in ABPA. We suggest that treatment 
strategies restoring this Th2/Th1 imbalance triggered by Aspergillus might be beneficial 
in the treatment of ABPA. Although anti-TNF and IL-1Ra had the capacity to decrease 
Aspergillus-induced IL-5 and IL-13 production they also lowered IFNγ production. There-
fore, the capacity of recombinant IFNγ to lower IL-5 and IL-13 and to supplement the 
IFNγ deficiency in ABPA, provides a rationale to use IFNγ as a corticosteroid-sparing 
treatment option in ABPA.
The observation that the induction of Th2 cytokines in human PBMCs was restricted to 
Aspergillus was striking. In the context of diseases caused by bacteria such as E. coli, S. 
aureus, M. tuberculosis, B. burgdorferi it can be anticipated that they do not induce strong 
Th2 responses in human PBMCs. However, the observation that no single TLR ligand, 
NOD2 ligand, or fungal cell wall component, specifically chitin, did not induce IL-5 and 
IL-13 was unexpected. Chitin has been associated with allergic inflammation in the lung 
(30, 31). Therefore, it is most likely that chitin in the setting of an inflammatory milieu is 
able to polarize towards Th2 responses, while as a single ligand it is not able to induce 
a Th2 response.
This study revealed a non-predominant role of TLRs in the induction of Aspergillus-
specific Th2 cytokines. Blocking of TLR2 did not have a significant impact on IL-5 and 
IL-13 production induced by Aspergillus. In contrast, it has been shown that there is an 
association between increased TLR2 expression in fatal asthma (32), and polymorphisms 
in TLR2 are associated with a higher prevalence of asthma (33). Furthermore, TLR2-/- 
mice show a deficient Th2 production in a chronic fungal asthma model (11). The minor 
but significant contribution of TLR4 in the Aspergillus-induced IL-13 induction found in 
the present study is in line with former studies describing TLR4 in allergic responses 
against house dust mite in which an endotoxin containing extract signaling via TLR4 
(34). In addition, we identified a redundant role of dectin-1 in the Aspergillus-induced Th2 
response. Blocking dectin-1 or Syk did not alter IL-5 and IL-13 production, and dectin-1 
deficient patients produced Th2 cytokine responses comparable to healthy controls. The 
dectin-1 ligand β-glucan (17), however has recently been described to play an important 
role in Aspergillus-triggered asthma immunopathology in mice (23). The role of dectin-1 
in the immunopathology of asthma is not clear. It has been suggested that dectin-1 pro-
motes the immunopathology in fungal asthma (23), while another study demonstrated 
that dectin-1 plays a role in suppressing asthmatic inflammation (35). Our findings sug-
gest that TLR2 and dectin-1 are not the main pathways driving the Aspergillus-specific 
Th2 response in human mononuclear cells. Whether TLR2 and dectin-1 play a role in 
Aspergillus-induced Th2 responses that are dependent on epithelial cells remains to be 
elucidated.
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Th2 induction by Aspergillus was dependent on CR3 (CD11b/CD18). CR3 is a β2-integrin 
that contains a lectin-like domain and is expressed on neutrophils and monocytes (25). 
CR3 contributes to antifungal host defense by interacting with pentraxin-3 opsonized 
particles, and by recognizing β-glucan(24). Furthermore, CR3 is involved in complement 
driven host responses (36), however the induction of IL-5 and IL-13 was still present in 
de-complemented serum, suggesting a complement independent contribution of CR3 
to the Th2 response. Activation of the complement via the MBL pathway is an alternative 
route of the complement pathway, and increased MBL serum concentrations have been 
associated with ABPA (26). However, Th2 induction by Aspergillus via CR3 signaling was 
independent of serum MBL, suggesting that MBL is not crucial for CR3-mediated Th2 
responses induced by Aspergillus. Phagocytosis of non-opsonized particles via signaling 
together with FcγR is also dependent on CR3 (25). In line with blocking CR3, blocking 
phagocytosis led to a complete abolishment of Th2 production induced by Aspergil-
lus. These data collectively suggest that CR3 is involved in phagocytosis of Aspergillus 
conidia, and that this process is essential for Th2 cytokine production by human PBMCs. 
Recently, CR3 was described in the induction of the Aspergillus specific pro-inflammatory 
T helper cytokines (16), suggesting a more general role for CR3 in modulating T helper 
responses.
An important issue to address was the cellular source of the Th2 cytokine in human 
mononuclear cells induced by Aspergillus. We could demonstrate that CD4+, but not 
CD19+ and CD56+ cells were the predominant source for the Aspergillus-induced IL-13 in 
human PBMCs. This is in line with previous studies showing that CD4+ cells are respon-
sible effector cells in allergic reactions, and that CD19+ and CD56+ play a redundant role 
in an asthmatic mouse model (37). Although increased levels of CD8+ and IL-13+ cells 
have been associated with asthma and bronchial obstruction (38), IL-13 production in hu-
man PBMCs was completely dependent on CD4+ cells, suggesting that CD8+ T cells are 
not involved in the production of Aspergillus-induced IL-13 in human mononuclear cells. 
We could not demonstrate the cellular source of IL-5 in our setting since IL-5 was not 
measurable in depletion experiments. Since FACS analysis demonstrated a significant 
CD8+ population that stained positive for IL-5, we cannot exclude that CD8+ T cells play a 
role in Aspergillus-induced IL-5 production in human PBMCs.
Several studies have shown an exaggerated Th2 response in ABPA (39-41)_ENREF_40. 
We investigated the Aspergillus-specific Th2 response in the context of Aspergillus-
induced T helper responses in human PBMCs isolated from ABPA patients. Interestingly, 
ABPA patients not only show an increased IL-5 and IL-13 production after stimulation 
with Aspergillus conidia, which is in line with previous studies (42), they also have an 
Aspergillus-specific decreased IFNγ production. Since we also observed an increased 
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Th2/Th1 ratio in asthma patients with Aspergillus-sensitization, but not in patients with 
asthma that did not have Aspergillus-sensitization, it is most likely that the increased Th2/
Th1 ratios in ABPA are due to an Aspergillus-specific host response and not due to the 
underlying host response associated with asthma itself. These observations strengthen 
the hypothesis that ABPA and asthma with Aspergillus sensitization share underlying 
pathophysiological mechanisms that are distinct from asthma itself, and support the 
concept that similar treatment approaches could be beneficial in both asthma-sensitized 
patients and ABPA, such as the treatment with azoles (9).
Aspergillus hyphae have been found in tissue biopsies in ABPA and have been sug-
gested to play a significant role in inflammation in ABPA (43, 44). Furthermore, IgE 
antibodies directed against Aspf4 and Aspf6 can be observed in ABPA in patients with 
CF (45, 46). Aspf6 has been shown to be a hyphae-specific protein. Therefore, ABPA 
patients are exposed to Aspergillus hyphae, which contributes to a Th2 response in vivo. 
We observed however that Aspergillus hyphae induced much lower amounts of Th2 
cytokines in ABPA patients compared to Aspergillus conidia, suggesting that fungal 
cell wall structures specific for Aspergillus conidia, or phagocytosis might play a more 
prominent role in the induction of Th2 responses in ABPA than previously thought.
Regulatory T cells (Tregs) are important for controlling allergic immune responses (47). 
A recent study has shown, that Aspergillus-sensitized asthma patients with high Aspergil-
lus-specific Th2 induction had significant decreased levels of Aspergillus-specific Tregs, 
while they were strongly induced in the healthy control group (48). Also in CF patients 
with ABPA, Tregs were less frequent than in non-ABPA CF patients (27) suggesting that 
a deficient Treg response could contribute to the excessive and unbalanced inflamma-
tory response observed in ABPA patients. It is tempting to speculate that the increased 
Aspergillus-specific Th2/Th1 response that we observed in the ABPA patients is due to a 
deficient Treg response, and that a deficient Tregs response, accompanied by a high Th2 
and low Th1 response plays a significant role in the pathophysiology of ABPA.
The characterization of this immunological profile of ABPA patients with an elevated 
Th2/Th1 ratio provides a read-out for testing potential immunomodulatory treatment 
options in ABPA. TNF and IL-1 are interesting targets. TNF has been shown to be the key 
cytokine inducing increased IL-17 levels and neutrophilia in the lung in a murine ABPA 
model (49). The involvement of the inflammasome and epithelial derived IL-1 cytokines 
are also described in bronchial asthma in several studies (50, 51). Therefore we tested the 
TNF neutralizing biologicals, Etanercept and Adalimumab, and the IL–1 pathway block-
ing biological IL-1Ra (Anakinra). All biologicals decreased IL-5 and IL-13 production, but 
also IFNγ production, therefore resulting in unaltered IL-13/IFNγ and IL-5/IFNγ ratios. In 
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addition we investigated recombinant IFNγ, which decreased Aspergillus-specific IL-5 
and IL-13 production.
The co-stimulatory molecule OX40L is involved in the initiation and maintenance of 
allergic responses, mainly driven by TSLP activated dendritic cells (52). Clinical stud-
ies that have been performed to elucidate the role of OX40L as a possible therapeutic 
target in asthma and have shown that blocking OX40L results in a decrease of serum 
IgE and eosinophils in asthma (53). OX40L was also involved in the Aspergillus-induced 
Th2 response, which is in line with former studies showing OX40L expressed on a va-
riety of cells like activated T cells, NK cells, B cells and monocytes (54). We observed 
a low expression of OX40L in PBMCs that was not significantly modulated by TNF or 
IL-1. Although it is reported that TNF can increase OX40L expression in smooth muscle 
cells, significantly higher in asthmatic than non-asthmatic patients (28) and TNF can up-
regulate OX40L promoter-activity (29), this mechanism appears to play a more prominent 
role in DC-driven Th2 responses (55).
Taking the shifted Aspergillus-induced Th1/Th2 ratio into account, restoring the 
increased Th1/Th2-ratio might be an interesting alternative for target-specific immu-
nomodulatory therapy in ABPA. Previous studies have shown that neutralizing IL-13 
has beneficial effects in an asthmatic mouse model (56) by dampening the IL-13 driven 
allergic airway inflammation. Similarly, blocking IL-4 has been tried to attenuate aller-
gic airway responsiveness, however the effect was not as strong and long-lasting as 
blocking IL-13(56). Biologicals targeting IL-4, IL-5 and IL-13 have been shown to have 
some efficacy in patients with high Th2 cytokine levels, however optimal biomarkers to 
identify responders and non-responders are still lacking (57). There is only little clini-
cal evidence for immunomodulatory treatment with biologicals in ABPA. Omalizumab 
has been successfully used in a few cases of ABPA with and without CF resulting in 
a corticosteroid-sparing treatment (58-60). The data of this study suggests that IFNγ 
might be an adequate immunomodulatory therapeutic option for ABPA, since it has the 
capacity to restore the increased Th1/Th2-ratio. Next to lowering the Th2 response it 
also supplements the relative Aspergillus-specific IFNγ deficiency. Recombinant IFNγ 
has been used with success in patients with chronic granulomatous disease to prevent 
Aspergillus infection (61) and there are several case reports that describe the beneficial 
effect of IFNγ treatment in Aspergillus infection (62). Thus, IFNγ might contribute to 
disease control in ABPA by having a beneficial effect on clearing the fungal burden 
thereby decreasing the trigger of the allergic inflammatory reaction, and by restoring 
the increased Th2/Th1 ratio.
Single nucleotide polymorphisms (SNPs) in the IL10, IL4Rα, MBL, and SFTPA2 genes 
have been associated with an increased susceptibility to ABPA (19). We therefore in-
128  |  Chapter  5
vestigated whether these genetic variants could modulate the Aspergillus-induced Th1 
or Th2 response. Variants in the MBL (63) and SFTPA2 (64) genes did not lead to differ-
ent Aspergillus-specific Th2 and Th1 responses. In contrast, we could identify a trend 
between the IL-4Rα (65) GG genotype with higher Aspergillus-specific IL-5 production 
and Aspergillus-specific Th2/Th1 ratio. We observed a trend in the IL-10 (rs1800896) GG 
genotype towards higher IFNγ production. Previous studies have identified this genotype 
to be associated with Aspergillus colonization and ABPA in CF patients (66).
In conclusion, Aspergillus conidia are unique in triggering Th2 responses in human 
PBMCs, and we provide evidence that CR3 and phagocytosis play a predominant role 
in Aspergillus-induced Th2 responses. Moreover, we identified that patients with ABPA 
have an increased Aspergillus-specific Th2/Th1 ratio, and the data in this study together 
with the clinical experience and safety of IFNγ treatment provide a rationale for exploring 
IFNγ in a clinical trail in patients with ABPA.
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supplemental figure 1: The Th2 response against Aspergillus conidia of PBMCs before and after 
running over a cell depletion column.
PBMCs were either directly stimulated or mock treated by running unlabeled cells of a cell depletion col-
umn. PBMCs (2.5 x 106 /ml, n=4 donors) were stimulated with Aspergillus conidia and IL-5 and IL-13 were 
measured in the cell culture supernatant by ELISA.
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supplemental figure 2: IL-10 induction by Aspergillus conidia of PBMCs in ABPA patients and healthy 
controls.
PBMCs (n=9 ABPA patients or healthy controls) were stimulated with Aspergillus conidia for 7 days and IL-10 
was measured in the cell culture supernatant by ELISA.
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supplemental table 1: Demographic table of asthma patients
age gender Asp. Spec. IgE (U/ml) Asp. Spec. IgG (mg/ml) total IgE (U/ml)
Asp-asthma #1 61 m >5 neg 1913
Asp-asthma #2 76 m 11,2 62,1 570
Asp-asthma #3 44 m >5 3,76 52
asthma #1 44 f <0,35  n.a. 79
asthma #2 23 f <0,35 36,2 212
asthma #3 47 f <0,35 4,11 182
asthma #4 47 f <0,35 43,1 95
Age, gender, total IgE (U/ml), Asp-specific IgE (U/ml) and Asp-specific IgG (mg/ml) of the asthmatic control 
groups enrolled in this study are listed.
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leTTeR To THe eDIToR
Allergic Bronchopulmonary Aspergillosis (ABPA) is a hypersensitivity reaction to the 
common mould Aspergillus fumigatus in the lung (1, 2). It occurs predominantly in 
patients with asthma and cystic fibrosis. Interestingly, it has a high prevalence in India. 
While Non-Indian asthma patients suffer in 3.3% of the cases from ABPA, these are 16% 
of all asthma patients in India (3). Because a recent study did not find environmental 
factors to have a strong influence on the prevalence of ABPA, it has been suggested that 
the genetic background is the main cause driving pathophysiology in ABPA (4). Clinically, 
ABPA patients present with typical asthmatic symptoms such as coughing, wheezing 
and shortness of breath, but the exact immunopathological processes causing these 
clinical symptoms are not yet fully understood.
After inhalation of the Aspergillus conidia an innate immune response gets initiated: 
bronchial epithelial cells, alveolar macrophages, as well as neutrophilic and eosinophilic 
granulocytes contribute to the innate host defence against Aspergillus conidia. Epithelial 
cells internalize Aspergillus conidia into acid organelles, through which the conidia suc-
ceed entering the body (5, 6). Additionally, Aspergillus proteases and proteins lead to 
damage of the epithelial barrier and activate macrophages resulting in secretion of a 
broad panel of pro-inflammatory cytokines such as IRF8, IL-1β and IL-6 and chemo-
kines (7). Neutrophil recruitment was shown to be essential for effective control of the 
Aspergillus conidia (8), but pathologically characteristic for allergic reactions in ABPA is 
an overwhelming eosinophilic influx (9). This promotes further damage of the bronchial 
epithelium (10) leading to decreased barrier function maintaining the hypersensitivity 
reaction.
After recognition by the innate immune system, adaptive T helper responses are initi-
ated. The balance between the different T helper subsets is crucial for the Aspergillus-
specific immune response. TNFα derived from dendritic cells was shown to play a regu-
latory role in the activation of Th17 cells during an experimental ABPA model, promoting 
neutrophilic airway inflammation rather than Th2 cells activation, which leads to reduced 
eosinophil recruitment (11). While a robust Th1 response, reflected by a high IFNγ pro-
duction, was associated with the successful clearance of the fungus, ABPA patients are 
described to have an exaggerated Th2 response and decreased Th1 response (12). As 
a result, they fail to eliminate the fungus efficiently, predisposing the host to allergic 
reactions (13). Whether Th17 cells play a protective or detrimental role in the allergic 
pathology is still unclear.
Treatment can be targeted at the host immune response level by dampening the 
hyper-reactive immune system with systemic corticosteroids, or targeted at the patho-
gen level with antifungal drugs (14). However, long-term treatment with corticosteroids 
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and itraconazole was associated with severe side-eff ects (15). Therefore, a fundamental 
understanding of the immunopathological processes underlying ABPA is needed to fi nd 
more target-specifi c and eff ective treatment options in APBA. In this study we used a 
systems biology approach by comparing more than 120,000 genetic polymorphisms 
in ABPA patients, asthma patients and healthy controls, and we integrated genetic and 
functional data to defi ne the pathways important for ABPA.
I. GeneTIC AssoCIATIons CoMPARInG AbPA PATIenTs AnD HeAlTHy 
ConTRols
We collected blood from 98 Indian ABPA patients and 95 Indian asthma patients for 
genetic association. Blood from 852 Indian healthy controls was used from a previous 
study. After DNA isolation 124,784 genetic markers were measured by genotyping using 
a custom-made Immunochip according to Illumina’s protocols (16), and subsequently 
analysed using logistic regression including gender and three principal components as 
covariants. We applied SNP quality-control fi lters to exclude single nucleotide polymor-
phisms (SNPs) with (a) a low call rate (<99%), (b) a Hardy–Weinberg equilibrium of P<0.01 
in control samples only and (c) a minor allele frequency (MAF) of < 0.01. We excluded 
18 samples in the ABPA cohort, 97 samples in the control cohort and 9 asthma patients 
figure 1: Manhattan plot with 10 suggestive associations with a p value of < 9.9 x 10-4
Manhattan plot showing the P values of the genes associated with ABPA resulting from the Immunochip-
assay. The y-axis represents the -log10 P values of 118,989 SNPs and their chromosomal positions are shown 
on the x-axis. The horizontal line shows the genome-wide signifi cant threshold of P<9x10-4. The P-values 
were obtained by logistic regression test after adjusting for the fi rst three components from the multidimen-
sional scaling analysis.
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because of duplicates (n=21), relationship (n=43) or a low genotyping rate (<98%) (n=45). 
Genetic matching between cases and controls was tested based on multidimensional 
scaling (MDS) analysis.
We tested association at 118,989 SNPs between ABPA and healthy controls using lo-
gistic regression test by including age, sex and four MDS components as covariates. The 
results of this analysis did not identify genome-wide significant (P < 5 x 10-8) associations. 
However, we considered a threshold of P<9.9x10-4 as significant association to identify 
underlying susceptibility genes and discovered 10 independent loci that showed sug-
gestive association with ABPA (Figure 1, Table 1). The comparison of ABPA patients with 
the asthmatic controls was not significant. We subsequently performed cis-eQTL map-
ping at the ten suggestive loci and revealed five SNPs (rs3130559, rs6898137, rs1745836, 
rs6573859, rs62051232) that significantly correlated with the expression of several genes 
that could be categorized into three relevant pathways for ABPA, namely the IRF8, the 
STAT3 and the vitamin D receptor pathways.
II. funCTIonAl vAlIDATIon of THe GeneTIC HITs
a. IRF8
The polymorphism rs62051232 was significantly associated with the regulation of the 
gene IRF8 resulting from eQTL mapping. IRF family proteins bind to the IFN-stimulated 
response element (ISRE) and regulate expression of genes stimulated by type I IFNs. Also 
Aspergillus has been described to induce type I interferons in respiratory epithelial cells 
in vitro (17), and IFNβ led to expression of IFNβ inducible genes, such as the IFNγ induc-
ible protein IP10. For the functional validation, serum samples of 62 ABPA patients were 
Table 1: Ten Suggestive genetic associations
CHR SNP OR STAT P
3 rs34622981 2.428 4.117 3.84E-05
3 rs7630157 2.796 4.364 1.28E-05
4 rs10015016 7.587 3.955 7.64E-05
5 rs6898137 2.759 4.78 1.76E-06
6 rs9405643 2.385 3.905 9.41E-05
6 rs3130559 2.251 4.263 2.02E-05
13 rs1745836 2.719 4.45 8.58E-06
14 rs6573859 2.174 4.332 1.48E-05
16 rs62051232 2.1 4.03 5.58E-05
18 rs17663691 5.928 4.504 6.67E-06
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collected and cytokines derived from various cell populations were analysed. Compar-
ing the serum IP-10 level of ABPA patients and healthy controls from the same endemic 
area revealed no significant differences between both groups, while IL-12 and IFNγ were 
significantly higher in the ABPA patients (Figure 2). Interestingly, IFNγ enhances the IRF8 
expression in macrophages (18). The predominant Th1 response was an unexpected 
finding in ABPA, since a predominant Th2 helper with low Th1 responses has been dem-
onstrated in other studies (12, 19, 20). In addition to IFNγ, IL-4 was significantly higher in 
ABPA patients’ sera (Figure 2). To better understand the functional role of the cytokine 
profile of ABPA serum, a bioactivity assay was performed. PBMCs isolated from healthy 
volunteers were stimulated with Aspergillus conidia in the presence of ABPA serum or 
healthy control serum. Interestingly, ABPA serum skewed the immune response towards 
a pro-inflammatory profile. IL-6 was significantly higher, while IL-5 was significantly lower 
in the presence of ABPA serum (data not shown). Other studies have also investigated 
pro-inflammatory cytokines in ABPA, with Walker et al. describing elevated IL-6, TNFα 
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figure 2: ABPA patients have elevated T helper responses compared to healthy controls,
Cytokines derived from different cell types were measured in treatment naïve ABPA serum (n=14) or control 
serum (n=12). IP-10, IL-12 and IFNγ were measured representative for the Th1 response. IL-6 and IL-17 for the 
Th17 response and IL-4 for the Th2 response in the serum using Luminex magnetic beads ELISA. Statistical 
analysis was performed with the Mann-Whitney test.
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and IL-1β levels in BAL fluid of ABPA patients compared to healthy controls that is in line 
with the elevated circulating pro-inflammatory cytokine levels in the present study (21).
b. STAT3 pathway
The second striking result from eQTL mapping for ABPA associated SNPs was predomi-
nance of genes involved in STAT3 regulation. rs3130559 was significantly associated 
with the regulation of seven different genes, namely TCF19, CCHCR1, HCG27, POU5F1, 
HCG22, HLA-C and rs1745836 with the regulation of LRCH1 and ESD. Interestingly, œ 
genes had a transcription factor-binding site for STAT3. STAT3 is induced by IL-6, IL-1β 
or IL-23 and drives the differentiation of a naïve T helper cell towards a Th17 cells (22). 
To functionally validate the role of STAT3 in Aspergillus induced cytokine responses, we 
stimulated PBMCs of STAT3 deficient patients with Aspergillus conidia and measured 
IL-17 and IL-22. All patients showed deficient production of Th17 derived cytokines 
after stimulation with the fungus (Figure 3A). This suggests that STAT3 is involved in 
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figure 3: STAT3 activation by Aspergillus is dependent on IL-6 pathway
(A) PBMCs of healthy controls and HIES patients with a STAT3 loss of function mutation were stimulated with 
Aspergillus and Candida. IL-17 and IL-22 were measured in the cell culture supernatant by ELISA. (B) PBMCs 
of healthy volunteers were stimulated with Aspergillus and STAT3 activation on CD4+ cells was measured in 
the presence of an isotype control and anti-IL-6 receptor antibody.
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the Aspergillus-specific Th17-response. As mentioned above we observed that the net 
cytokine profile in the serum skews Aspergillus-induced responses towards increased 
IL-6 production. To confirm the role of IL-6 in the Aspergillus-specific STAT3 induction, 
we stimulated PBMCs with Aspergillus and measured the frequency of STAT3 positive 
CD4+ cells after blocking the IL-6 receptor: in this experimental setting STAT3 activation 
was reduced (Figure 3B). This underscores the role of IL-6 in the Aspergillus-induced 
STAT3 activation. Subsequently, we analyzed IL-6 and IL-17 serum concentrations of 
ABPA patients. Both cytokines were significantly higher compared to healthy controls 
(Figure 2). Therefore, next to the elevated Th1 and Th2 response, ABPA seems to be 
characterized by an elevated Th17 response that might be dependent on IL-6 and a 
genetic predisposition for increased STAT3 function.
The STAT3 activation by Aspergillus has been suggested by former studies as well. 
Chen et al. showed by analysis of the transcriptome of Aspergillus-stimulated A549 cells 
that the STAT3 pathway is significantly upregulated (23). Also the functional role of STAT3 
has been investigated in a mouse model of multi-allergen induced asthma. STAT3 inhibi-
tion had the same effect as the administration of corticosteroids on to the inflammatory 
cell influx seen by the histological analysis as well as by the dampening effect on the 
IL-17 response (24). These data are suggestive of an increased STAT3 pathway in ABPA 
and might be promising for a more target-specific treatment option in ABPA.
c. Vitamin D receptor
The SNP rs4334089 was significantly associated with the expression of the vitamin D 
receptor in a cis-eQTL analysis of peripheral blood RNA–sequencing data from 2,116 
unrelated individuals as described by Zhernakova et al. (25). To elucidate the functional 
relevance of the influence of vitamin D on the T helper cytokine production induced 
by Aspergillus, we performed experiments in the presence or absence of vitamin D in 
vitro. Vitamin D had an inhibitory effect on all T helper subsets induced by Aspergillus 
(Figure 4). Recently, the role of vitamin D as a treatment option has been explored in 
patients with ABPA. Kreindler et al. observed the attenuation of the Aspergillus-specific 
Th2 response of CF patients with ABPA by vitamin D in vitro (26). Additionally, a recent 
clinical trial confirmed this data: Aspergillus-specific Th2 responses of ABPA patients 
were decreased after supplementation of vitamin D (27).
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Collectively, these fi ndings reveal novel insights into the pathophysiology of ABPA. By 
using a systems biology approach we identifi ed three interesting pathways that might 
prove to be important in the pathophysiology of ABPA and could help to design novel 
treatment strategies. Supplementation with vitamin D resulted in a better clinical out-
come of ABPA patients with CF as recently published in a clinical trial. The polymorphism 
in the vitamin D receptor gene described in this study supports this data and proposes 
a benefi cial eff ect of vitamin D on the clinical presentation of Indian ABPA patients as 
well. ABPA patients had polymorphisms in genes associated with the Th1 and Th17 
pathway, suggesting that the pathophysiology of ABPA might be dependent on a 
dysregulated Th1 and Th17 response, in addition to the well-known exaggerated Th2 
response. We found pro-infl ammatory and Th17 derived cytokines in the ABPA serum 
as well as polymorphisms in genes that were predominantly regulated by STAT3. This 
might open strategies to block these infl ammatory pathways in ABPA: such as  treatment 
with anakinra, (interleukin-1 receptor antagonist) that has the capacity to block STAT3-
induced Th17 responses (28) or anti-IL-6 therapy (tocilizumab) that targets IL-6 that 
drives STAT3-dependent Th17 responses. Novel treatment options are urgently needed 
for ABPA and research validating the pathways identifi ed by genetic studies is the next 
step to identify to provide the rationale to explore experimental options in ABPA.
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figure 4: T helper responses are dampened in the presence of Vitamin D
PBMC of healthy volunteers were stimulated with Aspergillus conidia in the presence of RPMI or vitamin D. 
The cytokines IFNγ, IL-5 and IL-17 were measured in the cell culture supernatant by ELISA.
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suMMARy:
Invasive aspergillosis mainly occurs in severely immunocompromised patients and is 
commonly caused by Aspergillus fumigatus, while Aspergillus nidulans is rarely found. 
By contrast, in chronic granulomatous disease (CGD) patients, A. nidulans is a frequent 
cause of aspergillosis and is associated with higher mortality. Immune recognition of 
A. nidulans was compared to A. fumigatus to understand why A. nidulans infections are 
rarely observed and only seen in CGD.
Live-cell imaging was used to define the dynamics of recognition and phagocytosis 
by macrophages. Recognition and phagocytosis of A. nidulans compared to A. fumigatus 
was slower, which could be attributed to slower macrophage migration. Moreover, slower 
phagosome acidification was observed upon phagocytosis of A. nidulans. Similarly, a 
lower oxidative burst was observed following exposure to A. nidulans. In contrast, A. ni-
dulans induced significantly higher concentrations of cytokines. Collectively, A. nidulans 
has a higher immunostimulatory and lower ROS-inducing capacity, yet is engulfed at a 
slower rate compared to A. fumigatus. Therefore, the slower phagocytosis caused by A. 
nidulans itself in addition to the specific defective phagocytic machinery that already 
makes CGD patients extremely susceptible to aspergillosis might explain why A. nidu-
lans is specifically seen in this disease and not in other disease settings.
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InTRoDuCTIon
Aspergillus species are environmental molds that play essential roles in carbon recycling 
of decaying organic debris. On a daily basis, humans are estimated to inhale hundreds of 
spores, yet these spores are efficiently removed from the lung resulting in the fact that 
healthy individuals only in very rare cases develop an Aspergillus infection.
However, certain patient groups have an elevated risk of developing aspergillosis; this 
susceptibility strongly depends on the status of the host immune system. Patients who 
are immunocompromised as a result of immunosuppressive therapy are highly suscep-
tible to develop invasive aspergillosis (1). This mainly concerns patients with a secondary 
immunodeficiency due to chemotherapy or treatment with immunosuppressive drugs in 
the context of malignancies, organ or hematological stem cell transplantation (1-6). Such 
treatments are a major risk factor due to their suppression of the first line of antifungal 
host defence in the lungs (3-6). Although patients with primary immunodeficiency are not 
usually susceptible to aspergillosis, individuals with genetic dysfunction of the NADPH-
oxidase complex, called chronic granulomatous disease (CGD), are highly susceptible to 
Aspergillus infections (7-10). Five genes are known, in which mutations can lead to the 
reduced activity of the NADPH-oxidase with a subsequent loss of the respiratory burst, 
mainly in neutrophils and macrophages resulting in a reduced killing capacity due to 
defective LC3 associated phagocytosis (11-13).
Interestingly, aspergillosis in CGD patients presents as less severe and is associated 
with a lower mortality of 25-27 % compared to 50-60% in hemato-oncological patients (7). 
The epidemiological distribution of the different Aspergillus species is also significantly 
different (14). A. fumigatus is the most commonly isolated species (62% SD±16.1) in inva-
sive aspergillosis of hemato-oncological patients, followed by A. flavus, (17%, SD±17.5), 
A. terreus (10%, SD±10.1) and A. niger (2%, SD±2.5); infections with A. nidulans are much 
less common and account for 1% (SD±0.9) (14-20). Interestingly, no higher mortality has 
been attributed to the different species (16). In contrast, within the group of CGD patients 
that develop aspergillosis, infections caused by A. fumigatus are lower in number (48% 
SD±20), and a significantly higher number of infections are caused by A. nidulans (33% 
SD±12.7) (8, 9, 21, 22) (Supplemental figure 1A). Although A. nidulans is still less prevalent 
than A. fumigatus in CGD, its disease severity and mortality is significantly higher (9, 21, 
22). Taken together, these studies point towards elevated mortality associated with A. 
nidulans infections (41% SD±15 vs 12% SD±13) (Supplemental figure 1B).
There is an interesting epidemiological difference when comparing the environmen-
tal prevalence of the different Aspergillus species. A. fumigatus is the most common 
airborne environmental fungus (1) and more prevalent compared to A. nidulans, 54% vs. 
4% in a Spanish study (23). In contrast, in an Indian study A. fumigatus was as common 
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in the environment as A. nidulans (24). Although there are strong seasonal and regional 
differences, these studies suggest an overall higher prevalence of A. fumigatus in the 
environment compared to A. nidulans (25). Apart from the better air dispersibility of A. 
fumigatus conidia due to its higher hydrophobicity (26), the differences in prevalence of 
cases associated with both species suggest that factors such as differences in activation 
of the host response may determine the pathogenicity of A. fumigatus and A. nidulans. 
The high prevalence of A. nidulans in CGD patients cannot simply be attributed to the 
loss of ROS, since the A. nidulans-specific immune response has been shown to be 
independent of the NADPH-oxidase complex (27). To date, no studies have investigated 
and compared the initial immune recognition and phagocytosis of A. nidulans versus A. 
fumigatus.
By deciphering different aspects of the innate immune responses induced by A. 
fumigatus and A. nidulans under intact NADPH-oxidase conditions, we compared the 
immunostimulatory capacity of A. nidulans versus. A. fumigatus. Differences in the level 
of phagocytosis, cytokine induction and oxidative burst of phagocytes might help to 
explain why A. nidulans infection is only observed in CGD When a certain threshold 
of phagocytic clearing is reached Aspergillus will have the chance to keep growing 
and cause infection. Therefore, we focus on investigating phagocytosis dynamics of 
A.fumigatus and A. nidulans using live cell imaging to find a potential explanation for the 
higher incidence and mortality associated with A. nidulans in CGD patients.
exPeRIMenTAl PRoCeDuRes
Aspergillus species
Aspergillus conidia were cultured and harvested as described in a previous study (56). 
Resting conidia of A. fumigatus (CBS 101355/ATCC MYA-4609) and A. nidulans (CBS 
114.63) were used at a final concentration of 1x107/ml either live or heat-killed (30 minutes 
at 95°C in a water-bath) for the PBMC stimulation assays. Live conidia were germinated 
and opsonized by incubation for 4 hours at 37°C in 10% human serum and used for the 
ROS assay.
Live cell imaging
Murine J774.A1 macrophages were seeded in 8 well ibidi imaging dishes at a density of 
1x105/well and were allowed to adhere overnight. Live-cell video microscopy phagocy-
tosis assays were carried out at 37°C using an Ultra-VIEW VoX spinning disk microscope 
(Nikon, Surrey, United Kingdom). Volocity software was used for data analysis (version 
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6.3.1, Improvision, PerkinElmer, Coventry, United Kingdom). Immediately prior to live-cell 
imaging, DMEM was replaced with 200 mL prewarmed supplemented CO2-independent 
medium (Gibco, Invitrogen, Paisley, United Kingdom). Live A. fumigatus or A. nidulans cell 
suspensions of resting conidia or 4 h swollen conidia were added to macrophages at 
a multiplicity of infection (MOI) of 1:1. In experiments with J774.A1 macrophages, acidic 
compartments were stained with 1 mM LysoTracker Red DND-99 (LTR) (Invitrogen). 
Volocity software (Improvision) was set to capture images every minute for a 6 h period 
using an electron-multiplying charge-coupled device (EMCCD) camera. For all condi-
tions, at least two independent experiments were carried out, with a minimum of three 
movies per experiment.
Volunteers
Blood was collected from healthy volunteers by venous blood puncture after informed 
consent was obtained. All experiments were performed and conducted in accordance 
to Good Clinical practice, the Declaration of Helsinki, and the approval of the Arnhem-
Nijmegen Ethical Committee (nr.2010/104).
PBMC isolation
Venous blood was drawn in 10 mL EDTA tubes. The blood was diluted 1:1 with Phos-
phate Buffered Saline (PBS). Subsequently PBMCs were isolated using Ficoll-paque (GE 
healthcare, Zeist, The Netherlands) density gradient centrifugation. The PBMCs layer 
was collected and washed twice in cold PBS. Cells were reconstituted in RPMI+, con-
sisting of RPMI-1640 culture medium (Dutch modification, Gibco, Invitrogen, Breda, The 
Netherlands) supplemented with 10 µg/mL gentamicin, 10 mM L-glutamine and 10 mM 
pyruvate (Gibco). The cells were counted with a particle counter (Beckmann Coulter, 
Woerden, The Netherlands) and the concentration was adjusted to 1x107 cells/mL.
PBMCs stimulation
PBMCs were plated in a 96-well plate (Corning, NY, USA) at a final concentration of 
2.5x106 /mL in an end volume of 200 μL per well. Stimulations were performed in the 
presence of 10% human serum. Cells were incubated at 37°C with 5% CO2, after stimula-
tion either for 24 hours or 7 days supernatants were collected and stored at -20°C.
Cytokine measurements
The innate cytokines IL-1β, IL-6, TNFα and IL-1Ra and the adaptive cytokines IFNγ, IL-5 
and IL-17 were measured in the cell culture supernatants using commercial ELISA kits 
(IL-1β, TNFα, IL-1Ra, IL-5, IL-17: R&D Systems, Minneapolis, MN, USA; IL-6, IFNγ: Sanquin, 
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Amsterdam, The Netherlands) according to the instructions supplied by the manufac-
turer.
Killing of Aspergillus by human macrophages or PBMCs
Following differentiation human macrophages (1x105) or freshly isolated PBMCs (5x105) 
were exposed to Aspergillus conidia (2x106) in 96 well plates a final volume of 200μl. 
After 24 hours at 37ºC the cells were washed in water and plated in serial dilution on 
sabouroud agar plates. CFUs were counted after 24 hours at 37ºC.
ROS induction
The induction of reactive oxygen species were measured by oxidation luminol (5-amino-
2,3,dihydro-1,4-phtalazinedione). PBMCs (5x105) were resuspended in HBSS and put in 
dark 96 well plates. Cells were exposed to HBSS, A. fumigatus heat inactivated resting 
conidia, live resting conidia, live germinated conidia (all at 1x107/mL), A. nidulans heat 
inactivated resting conidia, live resting conidia, live germinated conidia (all at1x107/mL) 
or Zymosan (150 µg/mL) and immediately 20 µL of 1 mM luminol was added. Chemilu-
minescence was measured in BioTek Synergy HTreader at 37°C for every minute during 
one hour.
Statistical analysis
Experimental data was plotted and analyzed using the GraphPad Prism V6.0 (GraphPad 
Software, Inc., USA). Results are shown as mean ± standard errors of the mean (SEM). The 
Mann-Whitney U-test and two-way analysis of variance (ANOVA), followed by Bonfer-
roni post hoc tests, were used to test statistical significance (* = p<0.05; ** = p<0.01;*** = 
p<0.001; and **** = p<0.0001).
ResulTs
Phagocytosis of A. nidulans and A. fumigatus
Live cell imaging was performed to investigate whether there are differences in recogni-
tion and subsequent phagocytosis of A. nidulans and A. fumigatus. Cells of the murine 
macrophage cell line J774.A1 were allowed to engulf freshly isolated A. fumigatus or 
A. nidulans spores for six hours. First, phagocytosis efficiency was assessed at the end 
of the 6 hours exposure to investigate whether there are major differences in overall 
phagocytosis of A. fumigatus and A. nidulans. Over the 6h time period J774.A1 macro-
phages were able to engulf freshly isolated A. fumigatus and A. nidulans spores with 
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equal efficiency. No significant difference was observed in the percentage of engulfed 
spores (figure 1A), or the number of spores that germinate at the end of the experiment 
(figure 1B). When looking at the macrophages that were exposed to A. fumigatus or A. 
nidulans at a MOI of 1:1, half of the macrophages engulfed spores and no significant 
differences were observed in the number of spores engulfed per macrophage (figure 1C) 
or the number of macrophages that undergo apoptosis (figure 1D).
Macrophages engulf A. nidulans at a slower rate compared to A. fumigatus
To dissect the dynamics of recognition and phagocytosis of A. fumigatus and A. nidulans 
in more detail, live cell imaging videos were analyzed to assess differences in recogni-
tion of fungal spores by macrophages (see video 1 for representative live cell imaging 
video). The moment of contact, defined as the moment of cell-cell contact between the 
macrophage and the spores, was assessed. A significant difference was observed in the 
moment of contact between cells and spores of A. fumigatus versus A. nidulans (figure 
2A), which indicated slower recognition. Fifty percent of all A. fumigatus spores are 
recognized within 30 minutes, while this took over 1 hour for A. nidulans (figure 2A). Sub-
sequently, the time of engulfment was assessed that was defined as the time between 
contact and full enclosure (figure 2B,C). However, no significant difference in the mean 
time of engulfment was observed (figure 3D) or the dynamics of engulfment (figure 2D). 
Therefore, we observed that dynamics of phagocytosis of A. fumigatus was different 
from A. nidulans, with A. fumigatus having significantly faster contact with phagocytic 
cells compared to A. nidulans spores (figure 2D).
figure 1: Comparison of phagocytosis of A. fumigatus and A. nidulans by J774.A1 murine macrophages
(A) Percentage of engulfed live resting and 4h swollen A. fumigatus (Af) and A. nidulans (An) spores after 
6h of exposure to J774.A1 murine macrophages at a MOI of 1:1. (B) Percentage of germinating spores within 
the population of non-phagocytosed spores. (C) Macrophage activity assessed by the percentage of mac-
rophages that engulfed spores (left panels) and within all macrophages an assessment of the number of 
spores engulfed per macrophage (right panels). (D) Percentage of macrophages that undergo apoptosis 
within the 6h experiment. Data is presented as the mean ±SEM and * = p<0.05.
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Macrophages migrate faster to engulf A. fumigatus spores than A. nidulans 
spores
To explain the decreased time to the engulfment of A. nidulans spores macrophage 
migration was analyzed during incubation of phagocytes with each fungal species. For 
individual engulfed spores we investigated whether macrophages actively migrated 
to engulf the spore. No significance difference was observed in the number of macro-
phages migrating towards resting spores. Although macrophages migrated significantly 
more towards swollen spores, no significant differences in the percentage of macro-
phages that migrated were observed between A. fumigatus and A. nidulans (figure 3A). 
In addition, no significant differences were observed in the distance that macrophages 
migrated to engulf spores. (figure 3C). However, macrophages migrated significantly 
faster towards A. fumigatus resting and swollen conidia than to A. nidulans (figure 3D).
figure 2: Macrophages engulf A. nidulans at a slower rate compared to A. fumigatus
(A) Cumulative percentage of A. fumigatus and A. nidulans spores in contact with J774.A1 macrophages. 
Contact is defined as the time-point where the macrophage makes visible physical contact with the spore. 
(B) Histogram of engulfment, defined as the time taken between contact and full enclosure of the fungus 
set out as percentage of events monitored in each minute. (C) Representative frame series illustrating the 
definition of contact and full enclosure. (D) Cumulative percentage of A. fumigatus and A. nidulans spores 
engulfed by J774.A1 macrophages.. All bars and dot plots represent mean ±SEM and * = p<0.05, ** = p<0.01, 
*** = p<0.001 and **** = p<0.0001.
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Phagosome acidification is slower for phagosomes containing A. nidulans
Phagosome acidification has previously been shown to be crucial for the killing of A. 
fumigatus (28). Lysotracker red (LTR) was used to stain the acidic compartments of 
macrophages. Following engulfment, the timing of phagosome acidification was as-
sessed by localization of LTR as a halo around the engulfed spore (figure 4A). Phago-
some acidification of A. nidulans-containing phagosomes was significantly slower than 
phagosome acidification of A. fumigatus-containing phagosomes (figure 4B). Analysis 
of the dynamics reveal that in the case of A. fumigatus 50% of engulfed spores are in 
acidified compartments under 8 minutes after engulfment while for A. nidulans this took 
over 11 minutes (figure 4C). This could indicate faster processing to phagolysosomes, yet 
additional markers are required to verify this.
figure 3: A. fumigatus is more efficiently recognized and phagocytosed than A. nidulans
(A) Percentage of macrophages that show active migration to A. fumigatus or A. nidulans resting spores or 
swollen spores. (B) Representative frames showing measurement of the distance of migration as well as the 
definition of contact between spore and macrophage. (C) Mean distance (mm) measured using velocity soft-
ware from at the moment of initiation of macrophage migration. (D) Migration speed (mm/min) measured by 
velocity software from the moment of movement initiation to the moment of contact between macrophage 
and spore. All bars and dot plots represent mean ±SEM and * = p<0.05, ** = p<0.01, *** = p<0.001 and **** = 
p<0.0001.
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A. fumigatus induces significantly stronger oxidative burst than A. nidulans.
The oxidative burst is thought to be essential for successful killing of Aspergillus conidia, 
since previously NADPH induced ROS was found to regulate LC3 associated phagocy-
tosis (13, 29); a mechanism that is essential for fungal killing and antigen presentation 
(29-32) Therefore the capacity to induce an oxidative burst was compared between A. 
fumigatus and A. nidulans (Figure 5 A-D) In line with previously studies (27), we could 
confirm that A. nidulans shows a significantly impaired capacity to induce an oxidative 
burst in human PBMCs (Figure 5 C,D)).
figure 4: A. nidulans containing phagosomes show delayed phagolysosomal fusion
(A) Representative image series showing lysotracker red (LTR) staining of acidic compartments and appear-
ance of a LTR-halo surrounding the conidia at 5 minutes post engulfment. (B) Histogram illustrating the 
distribution of the time after engulfment that LTR halo co-localized with the engulfed spore and a plot of the 
average time of LTR-halo co-localization compared between A. fumigatus and A. nidulans engulfed spores. 
(C) Cumulative dynamics of LTR halo co-localization. All bars and dot plots represent mean ±SEM and * = 
p<0.05, ** = p<0.01, *** = p<0.001 and **** = p<0.0001.
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A. nidulans-induced cytokine levels are significantly higher compared to 
A. fumigatus
Previously a defective ROS production has been associated with a higher cytokine in-
ducing capacity in CGD patients (33). Therefore, we investigated whether the reduced 
capacity of A. nidulans to induce an oxidative burst correlated with an increased cy-
tokine response by stimulating human PBMCs of healthy volunteers with heat-killed 
and live conidia of A. fumigatus or A. nidulans. A. nidulans-induced cytokine production 
was indeed significantly higher for the innate cytokines IL-6, TNFα, IL-β and IL-1Ra after 
stimulation with both live and heat-killed conidia (Figure 6A-D). Only the induction of IL-
1Ra and TNFα by live conidia did not significantly differ, although the same trend towards 
a higher immune induction could be observed.
figure 5: A. fumigatus induces significantly higher ROS in human PBMCs compared to A. nidulans.
(A-D) Human PBMCs (5x105 cells/well) of healthy volunteers (n=6) were pre-incubated with luminol before 
(A) Zymosan and RPMI, (B) heat-killed conidia of A. fumigatus and A. nidulans (1x107/ml), (C) live resting co-
nidia of A. fumigatus and A. nidulans (1x107/ml), and (D) live germinated conidia of A. fumigatus and A. nidu-
lans (1x107/ml were added. Total integrated ROS production is depicted for two independent experiments. 
All bars and dot plots represent mean ±SEM and * = p<0.05, an ** = p<0.01 Statistical analysis was performed 
with two way ANOVA for ROS assays and the Mann-Whitney-U test for cytokine data.
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DIsCussIon
In this study, various aspects of the innate immune response against A. fumigatus and A. 
nidulans were compared, to identify differences in phagocytic and immune-stimulatory 
capacities that might further explain their differential pathogenicity in certain patient set-
tings such as CGD. Although macrophage phagocytosis and activation were comparable 
at a fixed end point of 6 hours, both species differed markedly in their engulfment and 
uptake kinetics during interactions with host cells: A. fumigatus was recognized and taken 
up much faster compared to A. nidulans. Strikingly, phagosomes containing A. fumigatus 
were significantly faster acidified compared to spores of A. nidulans. This could indicate 
faster processing to phagolysosomes, yet additional markers are required to verify this. 
Although A. nidulans spores are less efficiently phagocytosed, human PBMCs exposed 
to this species responded in a stronger pro-inflammatory manner, reflected by the high 
cytokine induction, yet its capacity to induce an oxidative burst was significantly lower 
than for A. fumigatus (Figure 7).
This is one of the first studies to investigate the dynamics of Aspergillus phagocyto-
sis. Using live cell imaging to compare the phagocytic dynamics of the two species A. 
figure 6: A. fumigatus induces significantly lower innate cytokines in human PBMCs compared to 
A. nidulans.
(A-D) PBMCs of healthy volunteers (n=7-16) were stimulated with live or heat-killed conidia of A. fumigatus 
and A. nidulans. The innate cytokines (A) IL-6, (B) IL-1β, (C) TNFα or (D) IL-1Ra were measured in the cell-
culture supernatant by ELISA. All bars and dot plots represent mean ±SEM and * = p<0.05, an ** = p<0.01 
Statistical analysis was performed with two way ANOVA for ROS assays and the Mann-Whitney-U test for 
cytokine data.
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nidulans and A. fumigatus lead to some general observations that could be of broader 
interest. We observed that macrophages migrated poorly to resting spores of either A. 
fumigatus or A. nidulans, while following germination of the spores macrophages mi-
grated more actively towards the fungi. This is different from other fungi, for example live 
cell imaging with Candida albicans revealed active migration towards the fungi irrespec-
tive of whether they are as yeast or hyphae (34). A potential explanation for the slower 
phagocytosis of resting Aspergillus spores might be the hydrophobin sheet that masks 
molecules on the surface of the cell wall (35, 36), and upon germination (when the hydro-
phobin layer is removed) immune-stimulatory molecules on the cell wall are recognized. 
An interesting aspect is that macrophages sense the germination over a distance (video 
2), suggesting the macrophages might sense a gradient of secreted fungal molecules. 
Alternatively, macrophages may have superfine projections that are in contact with the 
spores and sense its changing cell wall, as was previously revealed for Candida by scan-
ning electron microscopy (37). Nevertheless, the factors that trigger the macrophages 
to migrate towards germinating spores warrants further investigation. For C. albicans 
it also has been observed that the fungi form hyphae inside the macrophage, thereby 
lysing and escaping from macrophages (38). This phenomenon was not observed during 
phagocytosis of A. fumigatus and A. nidulans, however when intracellular germination 
figure 7: Schematic comparison of the innate immune response against A. fumigatus and A. nidulans
The innate immune response against A. nidulans differs from the immune response against A. fumigatus in 
delayed recognition, delayed phagocytosis, slower macrophage migration, slower phagosome acidification, 
less pronounced oxidative burst and a higher levels of cytokine production.
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occurred the hyphae were expulsed from the cell (video 3) as was previously described 
for Candida and Cryptococcus (39-41). These observations provide new insights into the 
interplay between macrophages and Aspergillus, and highlight the potential of live cell 
imaging as a tool to study dynamics of phagocytosis.
A crucial goal of this study was to understand why the susceptibility to A. nidulans 
in CGD patients is much higher compared to hemato-oncological patients, despite 
the latter having more profound immunosuppression. When discussing this point, the 
environmental distribution and exposure of both patients groups must also be taken into 
account (Figure S1). Although fundamental studies are lacking, it can be assumed that A. 
fumigatus is the more abundant pathogen in the environment (23, 42). While hemato–on-
cological patients are more severely immunocompromised with sometimes a complete 
abolishment of white blood cells but a normal killing activity of residual cells, such as 
residential alveolarmacrophages, CGD patients have normal cell counts with a defect in 
fungal killing by neutrophils, macrophages and monocytes. Although the primary defect 
in CGD patients is an inability to produce NADPH dependent ROS, killing of A. nidulans is 
independent of ROS induction (27). However, the defect in the NADPH complex in CGD 
patients has also been associated with a defect in LC3 associated phagocytosis (29, 43), a 
form of phagocytosis that requires the autophagy machinery for more efficient process-
ing of engulfed pathogens for killing (29-31) and MHCII mediated antigen presentation 
(44). In addition, neutrophils of CGD patients have defective neutrophil extracellular trap 
(NET) formation. Restoration of either LC3 associated phagocytosis (13) or NET formation 
by gene therapy (45) in CGD mice/patient was successful for controlling aspergillosis 
respectively. We demonstrated that in addition to the defects in a CGD cell, A. nidulans 
phagocytosis is already delayed in a healthy phagocytic cell. In addition to the fungal 
clearance defects in cells of CGD patients (that account for both A. fumigatus and A. 
nidulans), there is a delayed phagocytosis and processing of A. nidulans spores. This 
might help to explain the incidence of A. nidulans in this disease, but also the higher 
mortality associated with A. nidulans infections in CGD (9, 21, 22). Hemato–oncological 
patients experience a relatively short period of time at risk for Aspergillus infections, 
while CGD patients are exposed to environmental conidia over years. Therefore, the net 
result of an already defective Aspergillus phagocytic machinery characteristic for CGD 
plus the slower phagocytic rate of A. nidulans might explain why A. nidulans infections 
are only seen in CGD and not in other diseases setting where this severe threshold of 
defective phagocytosis for A. nidulans is not reached. In severely immunocompromised 
patients the epidemiological distribution of infections follows the burden of spores in the 
environment, which seems to be the result of the chance of inhalation of environmental 
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spores. In contrast, in CGD patients the delayed and less efficient engulfment of A. nidu-
lans might be more important for explaining their increased susceptibility to A. nidulans.
The higher immunostimulatory capacity of A. nidulans compared to A. fumigatus is in 
line with earlier studies. These studies observed a higher cytokine stimulatory capacity 
with A. nidulans compared to A. fumigatus using different strains than in this study (33). 
Interestingly, CGD patients, in which A. nidulans is much more prevalent compared to 
hemato-oncological patients, demonstrated a pro-inflammatory phenotype (46-49). This 
hyper inflammation in CGD patients with high interleukin-1 responses (13, 33) has been 
associated with colitis (13). On top of the hyper inflammation in CGD patients, we observe 
that A. nidulans induces much more potent cytokine responses than A. fumigatus. During 
an infection the higher immunostimulatory capacity of A. nidulans could lead to even 
higher pro-inflammatory immune responses. Failure to control excessive inflammatory 
responses has been associated with a poor clinical outcome and increased mortality 
from aspergillosis (50, 51). It is therefore tempting to suggest that the higher mortality 
observed with A. nidulans could also be as a result of excessive inflammatory reactions 
leading to immunopathology.
It remains to be determined why A. nidulans is more capable of inducing pro-
inflammatory cytokines, although differences in cell wall architecture between A. 
nidulans and A. fumigatus certainly exist. Galactosaminogalactan (GAG) is an important 
anti-inflammatory polysaccharide of the cell wall of A. fumigatus that induces the anti-
inflammatory cytokine IL-1Ra (52). The absence of GAG in the cell wall of A. nidulans (53) 
could potentially explain its higher capacity to stimulate pro-inflammatory cytokines.
Furthermore, a high immunostimulatory capacity associated with high levels of the 
pro-inflammatory IL-1β or TNFα can be the result of continuous extracellular signaling 
via pattern recognition receptors and activation of the subsequent signaling pathways. 
Frustrated phagocytosis of long filaments is a known phenomenon associated with the 
production of high levels of pro-inflammatory cytokines (54, 55). Although these filaments 
were much bigger than conidia, we observed differential phagocytosis of the fungi, and 
a continuous presence of extracellular filaments might drive more pro-inflammatory 
responses.
Collectively, our data provides novel insights in the dynamics of Aspergillus phagocyto-
sis and illustrates clear differences between Aspergillus species, with, A. nidulans spores 
being much less efficiently engulfed by macrophages. Alternatively, A. nidulans shows 
a higher capacity to stimulate cytokine responses. These findings might contribute to 
explain why A. nidulans infections are specifically observed in CGD and are associated 
with a higher mortality.
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video 1:
Representative video of J774.A1 macrophages engulfing A. fumigatus spores at 1000x 
magnification captured at 1 image per minute and played back at 12 frames per second.
video 2:
Representative video of J774.A1 macrophages targeting germinating A. fumigatus spores 
at 1000x magnification captured at 1 image per minute and played back at 12 frames 
per second.
video 3:
Representative video of J774.A1 macrophages engulfing A. fumigatus spores and expuls-
ing them following intracellular germination. Captured at 1000x magnification captured 
at 1 image per minute and played back at 12 frames per second.
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figure s1: Differences in causative pathogens for aspergillosis between CGD and other patients
(A) Distribution of Aspergillus species in aspergillosis cases in CGD patients versus cases in non-CGD patients 
based on literature search (8, 9, 14-22). (B) Mortality rate in CGD patients due to the fungal infection stratified 
on causative pathogen. The bars represent mean percentage ±SEM and * = p<0.05. Statistical analysis was 
performed with an unpaired t test with Welch’s correction.
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AbsTRACT:
background: Fungal skull base osteomyelitis (SBO) is a severe complication of otitis 
externa or sinonasal infection, and is mainly caused by Aspergillus species. Here we 
investigate innate and adaptive immune responses in patients with Aspergillus SBO to 
identify defects in the immune response that could explain the susceptibility to this 
devastating disease.
Methods: Peripheral blood mononuclear cells isolated from six patients with Aspergillus 
SBO and healthy volunteers were stimulated with various microbial stimuli, among which 
also the fungal pathogens Candida albicans and Aspergillus fumigatus. The proinflam-
matory cytokines IL-6, TNFα and IL-1β, and the T-helper cell-derived cytokines IFNγ, 
IL-17 and IL-22 were measured in cell culture supernatants by ELISA.
Results: Proinflammatory cytokine responses did not differ between SBO patients and 
healthy volunteers. The Candida- and Aspergillus-specific Th17 response (production of 
IL-17 and IL-22) was significantly decreased in the SBO patients compared to healthy 
individuals, while Th1 cytokine response (IFNγ production) did not differ between the 
two groups.
Conclusions: We show that patients with Aspergillus skull base osteomyelitis infection 
have specific defects in Th17 responses. Since IL-17 and IL-22 are important for stimulat-
ing antifungal host defense, we hypothesize that strategies that have the ability to im-
prove IL-17 and IL-22 production may be useful as adjuvant immunotherapy in patients 
with Aspergillus SBO.
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bACkGRounD
Skull base osteomyelitis (SBO) is a rare but life-threatening infection, which originates ei-
ther from the external ear canal or the paranasal sinus. Infiltrative growth from the external 
acoustic duct into the temporal bone is also termed malignant or invasive otitis externa 
[1]. This aggressive infection is usually caused by Pseudomonas aeruginosa, sometimes 
by fungal pathogens (mainly Aspergillus spp.), and in a minority of cases by other bac-
teria (such as Staphylococci, Proteus and Klebsiella) [2-4]. Besides an otologic origin of 
infection, sinusitis is the second major cause of skull base osteomyelitis. Although this 
is a rare complication, infections of the frontal, ethmoid, sphenoid and maxillary sinus 
can spread to the orbital and frontal bone, clivus and petrous apices. A distinct form of 
sinusitis is fungal rhinosinusitis. This has a broad clinical spectrum ranging from chronic 
forms with gradually progressing osteomyelitis to necrotizing angioinvasive disease. 
Aspergillus, Rhizopus and Fusarium are the most commonly identified fungi. Fungal skull 
base osteomyelitis due to Aspergillus is an infection with considerable morbidity and 
mortality rates up to 50%. In addition to aggressive surgical debridement and systemic 
antifungal therapy, the mainstay of therapy includes, whenever possible, correction of 
the underlying immunologic defect.
Spores of Aspergillus are continuously inhaled and therefore fungal colonization of the 
upper airways is common. Despite this continuous exposure, invasive disease caused by 
Aspergillus in an immunocompetent host is very rare. Although some degree of immu-
nosuppression may be present in patients with fungal SBO, often the only apparent risk 
factor identified is a chronic external otitis or an anatomical obstruction of the sinuses 
(e.g. nasal polyps or chronic inflammation of the mucosa). The extent of tissue invasion 
in these patients may vary depending on the underlying immune status of the host. In 
the present study we present six cases of skull base osteomyelitis due to Aspergillus 
fumigatus and Aspergillus flavus, in whom we investigated whether the innate and adap-
tive immune responses known to be important for antifungal host defense are defective.
MeTHoDs
Volunteers and Patients
We describe six patients who were admitted to the Radboud University Medical Center 
with a culture-proven invasive Aspergillus osteomyelitis of the skull. All patients were 
diagnosed between September 2007 and July 2010. Charts were reviewed for data on 
demographics, risk factors, presenting symptoms, treatment, side effects, microbiology 
results, and clinical outcome. Response was defined according to the revised MSG/
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EORTC consensus group definition [5]. Patients and healthy volunteers, who served as 
healthy controls in the immunological experiments, were asked for blood donations. The 
blood samples were collected from patients and healthy volunteers after informed con-
sent was obtained in accordance to Good Clinical practice, the Declaration of Helsinki, 
and the approval of the Arnhem-Nijmegen Ethics Committee (nr.2010/104).
Stimuli
E.coli lipopolysaccharide (LPS) (10 ng/ml) (TLR4 ligand, E. coli serotype O55:B5, Sigma-
Aldrich St. Louis, MO USA); heat-killed Staphylococcus aureus clinical isolate (S. aureus) 
(1x107 /ml); heat-killed Candida albicans yeast ATCC MYA-3573 (UC820) (C. albicans) 
(1x105 /ml); heat-killed Aspergillus fumigatus clinical isolate V05-27 (A. fumigatus) co-
nidia (1x107 /ml) were cultured and isolated as described previously [6].
Peripheral blood mononuclear cells (PBMCs) isolation
Fresh venous blood was drawn in 10 ml EDTA tubes from patients and controls and 
processed in parallel continuously from PBMC isolation to cytokine measurement. 
Every patient gave blood only once. The blood was diluted 1:1 with Phosphate Buffered 
Saline (PBS). Subsequently PBMCs were isolated using Ficoll-paque (GE Healthcare, 
Zeist, The Netherlands) density gradient centrifugation. The PBMCs layer was collected 
and washed twice in cold PBS. Cells were reconstituted in RPMI-1640 culture medium 
(Dutch modification, Gibco, Invitrogen, Breda, The Netherlands) supplemented with 10 
µg/ml gentamicin, 10 mM L-glutamine and 10 mM pyruvate (Gibco). The cells were 
counted with a particle counter (Beckmann Coulter, Woerden, The Netherlands) and the 
concentration was adjusted to 5x106 cells/ml.
PBMCs stimulation
PBMCs were plated in a 96-well plate (Corning, NY, USA) at a final concentration of 
2.5x106/ml in an end volume of 200 μl per well. Either medium or stimuli were added. 
Cells were incubated at 37°C with 5% CO2, after 24 or 48 hours or 7 days supernatants 
were collected and stored at -20°C. Seven-day stimulations were performed in the pres-
ence of 10% pooled human serum. All stimulations assays were performed in duplicates.
Cytokines measurements
Cytokines were measured in the cell culture supernatants using a commercial ELISA 
kit (IL-1β, TNFα, IL-17 and IL-22: R&D Systems; IL-6 and IFNγ: Sanquin) according to the 
instructions supplied by the manufacturer. Proinflammatory cytokines production was 
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measured after 24 hours, IFNγ after 48 hours and the T helper cytokines IL-22 and IL-17 
after 7 days of incubation.
Statistical analysis
The Mann-Whitney-U test was used to detect differences between healthy controls and 
patients. A p-value of < 0.05 was considered statistically significant (*=p < 0.05, ** = p < 
0.01 and *** = p < 0.001). Graphs represent cumulative results of all performed experi-
ments and are presented as mean ± standard error of the mean. Data were analyzed with 
GraphPad Prism v 5.0.
ResulTs
Demographic characteristics of patients and controls
Patients: Three male and three female patients were included in the study with age 
ranging from 37 to 87 years (mean: 59.5 years). Infections were located in the sphenoid, 
mastoid or ethmoid bones with partial affection of sinus cavernosus, frontal or temporal 
lobe or orbita. All patients presented with cranial nerve palsy. In four cases the diagnosis 
was additionally confirmed by a positive histology. One patient developed Aspergillus 
osteomyelitis following trans-sphenoidal surgery for pituitary adenoma with a chronic 
myeloid leukemia (CML) in the past; two had a history of diabetes; all other patients had 
primary fungal infection of sinus or mastoid.
Controls: Three male and three female healthy volunteers were included in the control 
group; the age ranged from 24 to 60 years (mean: 42.7 years). Three of the patients were 
recruited from the blood bank via the blood donor service (Sanquin, Nijmegen, The 
Netherlands) and three were recruited directly to our department for blood donation. All 
volunteers were healthy and did not have an immunologically relevant medical history.
Microbiology
Culture and molecular identification confirmed the fungal infection and susceptibility to 
antifungal drugs was tested (Table 1). Galactomannan assay was performed in all patients 
on serum and in 4 patients on cerebrospinal fluid. All results were negative (index < 0.5).
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Treatment, clinical outcome and blood sampling
Surgical debulking was performed in all patients. All patients were initially treated with 
systemic antifungal drug therapy. Voriconazole was first line treatment in all patients. 
Four patients were treated with voriconazole monotherapy. One patient was con-
comitantly treated with liposomal amphotericine B during the first months of treatment. 
Posaconazole was used after induction treatment in two patients. Duration of therapy 
(from 4.5 to 35 months) was guided by clinical response and imaging, with follow-up 
from 8 to 38 months. Four patients had a complete response, one had a relapse, and 
one died due to respiratory failure. During infection the leukocytes count was normal in 
five of six patients, ranging from 6.6 x 109/l to 9.1 x 109/l. One patient had a decreased 
leukocyte count of 3.1 x 109/l and slightly decreased numbers in the differential blood 
count. Three patients had normal and three patients had increased CRP values (11 mg/l, 
14 mg/l and 32 mg/l). Blood samples for immunological assays were taken after clinical 
improvement and response to the therapy: in three patients during the first month after 
onset of the antifungal therapy, while in three patients blood was collected after the 
pharmacological therapy had been finished and the infection did not recur.
Patients with Aspergillus SBO do not differ from healthy controls in their 
production of proinflammatory cytokines
To investigate the innate immune response, PBMCs isolated from six patients with 
Aspergillus SBO were stimulated with Aspergillus fumigatus, E. coli LPS and different 
pathogens and compared with healthy controls (Figure 1 A-C). Neither the unspecific 
LPS-stimulated, nor the pathogen-specific C. albicans, S. aureus, and disease-specific 
Table 1: Anti-fungal susceptibility of microbiological isolates.
MIC values of fungal isolates tested for Amphotericin B (AMT), Itraconazole (ITC), Voriconazole (VOR), 
Anidulafungin (Anidula), Posconazole (POSA) and Caspofungin (CASPO) are listed.
Case Isolate AMT (mg/L) ITC (mg/L) VOR (mg/L) Anidula 
(mg/L)
POSA (mg/L) CASPO (mg/L)
1 A. fumigatus *
2 A. fumigatus 1 1 2 0.063 0.25
3 A. fumigatus 0.5 0.063 0.125 < 0.016 0.5
4 A. fumigatus 1 0.25 1 0.031 0.063
5 A. fumigatus **
6 A. flavus 1 0.063 1 0.031 0.5
*MIC impossible because of poor sporulation. Analysis of Cyp51A-gene: no TR/L98H
**No isolate available for susceptibility testing
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A. fumigatus stimulations showed differences in the production of the inflammatory 
cytokines IL-1β, TNFα and IL-6.
Patients with Aspergillus SBO are deficient in Aspergillus-induced IL-17 and IL-
22 but not in IFNγ production
While the recognition and initiation of inflammatory cytokine responses revealed to be 
intact, we wanted to address the question whether defects in the acquired immune re-
sponse might explain the high susceptibility to the fungal infection of the six fungal SBO 
patients included in this study. PBMCs were stimulated with C. albicans and S. aureus, 
serving as positive controls for the induction of IFNγ, IL-17 and IL-22, and A. fumigatus, 
to investigate pathogen-specific deficiencies. The Th1 response, shown by IFNγ produc-
tion, did not differ between patients with Aspergillus SBO and healthy controls (Figure 
1D). In contrast, IL-22 and IL-17 production was significantly reduced after stimulation 
with both fungal pathogens C. albicans and A. fumigatus (Figure 1E-F).
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figure 1: SBO patients have an intact innate immune response, but are defective in IL-17 and IL-22 
production.
PBMCs stimulated with E. coli LPS, heat killed C. albicans yeast, S. aureus and A. fumigatus were cultured 
for 24 hours 48 hours or 7 days respectively. The innate cytokines IL-1β (A), TNFα (b), IL-6 (C) (after 24 hours) 
and adaptive cytokines IFNγ (D) (after 48 hours) and IL-17 (e) /IL-22 (f) (after 7 days) were measured in the 
cell culture supernatant by ELISA. Controls (black bars, n=6) compared with SBO patients (white bars, n=6).
184  |  Chapter  8
DIsCussIon
In this study, we describe the clinical presentation and immunological features of six 
patients with Aspergillus SBO. None of the patients were neutropenic at the time of the 
infection or had a known primary immunodeficiency. We hypothesized that specific 
defects in Aspergillus-specific innate and/or adaptive immune response would contrib-
ute to the unsuccessful fungal clearance and extent of the Aspergillus infection in our 
patients. Therefore, we investigated host responses in six patients with Aspergillus-SBO. 
While the innate responses were not different from a healthy control group, Th17 cyto-
kines induced by fungal pathogens such as C. albicans and A. fumigatus were shown to 
be defective in the patients with Aspergillus SBO.
Aspergillus spp. can cause several forms of diseases dependent on the site of infection 
and immune status of the host. Aspergillus osteomyelitis is increasingly being reported 
[7] with approximately 15% of the cases affecting the skull base [7, 8]. Aspergillus SBO is 
a severe complication of otitis externa or invasive sinonasal aspergillosis, in which most 
patients become infected via the tympanic cavity or the sinus [2].
The main risk factors described for invasive Aspergillus-SBO are systemic immuno-
suppression [7] and hematologic malignancies (12%) [7, 9]. One patient included in this 
study suffered from chronic myeloid leukemia, and he was treated with the tyrosine 
kinase inhibitor imatinib at the time of the infection. Two patients had diabetes mellitus 
and three suffered from sinusitis, which have been reported in previous studies as risk 
factors [7, 9]. Although almost all patients had normal leukocyte counts (one was slightly 
decreased), additional factors influencing the immune response such as the imatinib 
treatment, diabetes or the high age of one patient might affect the IL-17 response as well. 
Normal monocyte-derived cytokine levels point to a specific T-cell defect.
Early recognition and therapeutic intervention in invasive sinonasal aspergillosis with 
systemic antifungal therapy and surgical resection and/or debridement is important. In 
accordance with the current guidelines, all patients included in the present study were 
treated with surgical debridement of the infected bone and systemic antifungal drug 
therapy, of which voriconazole was the drug of first choice. We observed a mortality of 
1 out of 6 in the patients included in the present study, which is in line with the reported 
poor clinical outcome of Aspergillus osteomyelitis, which has a 25% 12-weeks mortality 
[10].
Why did our patients without an apparent severe immunodeficiency get invasive 
aspergillosis? Aspergillus spp. are an occasional commensal of the external ear and 
paranasal sinuses [11], but invasive disease is very rare. Chronic infection leading to 
damage of the epithelial barrier is an important entry for the fungus to infect the host. 
Recognition of Aspergillus will result in the production of proinflammatory cytokines that 
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will recruit immune cells to clear the infection [12]. In the present study, patients with 
Aspergillus SBO showed normal production of the cytokines TNFα, IL-1β and IL-6 after 
stimulation with A. fumigatus, C. albicans, the Gram-positive bacterium S. aureus, and 
the Gram-negative cell wall component E. coli LPS. Therefore, a defect in the produc-
tion of monocyte-derived proinflammatory cytokines is unlikely to be the cause of the 
susceptibility of fungal SBO in our patients. Acquired adaptive T-helper responses also 
play an important role in anti-Aspergillus host defense. The protective role of IFNγ in the 
Aspergillus-specific host response has been reported previously [13]. We did not observe 
a difference in Aspergillus-specific IFNγ production; Candida-specific IFNγ production 
showed a trend towards a lower IFNγ production, but this was not significant. However, 
the Aspergillus-specific Th17 response was significantly lower in SBO patients compared 
to the healthy control group. In addition, this was also observed, when the cells were 
stimulated with Candida. IL-17 is a characteristic cytokine produced by Th17 cells. Th17 
cells are crucial for neutrophil recruitment and controlling fungal invasion at the level of 
mucosae and skin. [14]. Similar to IL-17, the IL-22 production was significantly decreased 
in SBO patients compared to healthy controls in the present study. IL-22 is also pro-
duced by Th17 cells [15] and shares many effector functions with IL-17 [16]. IL-22 plays 
a predominant role in mucosal host defense [17] by inducing anti-microbial peptides 
produced by epithelial cells, which can kill microorganisms directly [18].
In a previous study we have identified that IFNγ treatment had beneficial effects on 
the immune status including IL-17 and IL-22 responses in a case series of patients with 
invasive fungal infections [19]. This suggests that adjuvant therapy with recombinant 
IFNγ may improve the outcome of patients with a severe fungal SBO. Another treat-
ment option would be to increase the differentiation into Th1 and Th17 cells by GM-CSF 
[20]. GM-CSF was shown to enhance the secretion of inflammatory cytokines [21] and 
antigen-presentation [22] under inflammatory conditions. It also induces the differentia-
tion of progenitors cells into monocytes and granulocytes [23]. Therefore, GM-CSF might 
have beneficial effects on immune cells in the skin even in the setting of an IL-17/IL-22 
deficiency [24]. One might speculate about supplementary therapy with recombinant 
IL-22, since IL-22 was shown to have beneficial effect in wound healing processes and 
pre-clinical studies have shown good toleration of administration of the drug [25].
We are aware of the fact that the sample size of six patients is inevitably small. A type 
I error of 5%, meaning the likelihood to accept the hypothesis that Aspergillus SBO pa-
tients and control do not differ in their Aspergillus-specific IL-17 response was assumed. 
Using the calculated means, standard deviations of the experimental measurements 
and sample size of both groups we calculated a statistical power of 81%. Thus, the Type 
II error, meaning the hypothesis that patients and controls differ in their IL-17 response 
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is neglected, lay with 19% in an acceptable range for medical tests. Retrospectively, due 
to the differences observed, the sample size of 6 donors was the minimal size needed 
to detect statistically relevant differences. Further sample size independent calculation 
revealed an effect size of 1.5, which indicates that Aspergillus SBO has a statistically 
strong effect on the Aspergillus-specific IL-17 production.
Nevertheless, there are also some limitations of the study. One note of caution is 
that while patients and controls matched regarding their gender, the patients were in 
average older, although the 15 years difference is unlikely to explain the significant dif-
ferences observed. Further, it remains unknown whether the defective IL-17 and IL-22 
production was the consequence of a primary defect (e.g. genetic) or was secondary 
to a predisposing factor of the Aspergillus SBO patients (e.g. the antifungal treatment). 
Nevertheless, the present study contributes to understanding the specific defective 
host defense mechanisms underlying SBO due to Aspergillus.
This is the first study describing a deficiency in fungal-induced Th17 responses in 
patients with Aspergillus skull base osteomyelitis. Future studies are needed to validate 
this observation and its clinical implication, especially the potential beneficial effects of 
immunotherapy aimed to boost Th17 responses.
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AbsTRACT:
background: STAT1 mutations cause Chronic Mucocutaneous Candidiasis (CMC), while 
STAT3 mutations cause Hyper IgE syndrome (HIES). CMC and HIES patients have T 
helper(Th)17 defects suffering from mucosal Candida infections, but only HIES patients 
show an allergic phenotype with eczema, eosinophilia and high IgE levels.
objective: We investigated whether differential Th2 and Th9 responses may explain the 
clinical differences.
Methods: Peripheral blood mononuclear cells of CMC patients (n=4), HIES patients (n=4), 
atopic dermatitis patients (n=4) and healthy volunteers (n=13) were stimulated with Can-
dida and Staphylococcus aureus, with and without IL-4. The cytokines IL-5, IL-13, IL-9, 
IL-17 and TGFβ and regulatory T cells were measured in cell culture supernatants by 
ELISA or flowcytometry, respectively.
Results: PBMCs of CMC patients showed a significantly impaired production of the Th2 
cytokines IL-5 and IL-13, especially in the presence of IL-4. Moreover, IL-9 production 
was significantly lower in CMC patients compared to healthy controls. In contrast, HIES 
patients and AD patients showed normal IL-5 and IL-13 production, while IL-9 produc-
tion was significantly lower in HIES patients compared to healthy controls. Although 
TGFβ was involved in the IL-4-induced IL-9 production, TGFβ levels and the frequency 
of regulatory T cells did not differ between HIES patients and controls. Flowcytometry 
analysis demonstrated an IL-9+IL-17+CD4+ subset in healthy controls after stimulation with 
Candida which was less present in HIES patients.
Conclusion: CMC patients have a general Th defect including Th2 and Th9, while HIES 
patients have normal Th2 cytokines. These differences are in line with their clinical pre-
sentation. Surprisingly, the allergic cytokine IL-9 was deficient in both HIES and CMC, 
suggesting a Th-17 derived origin.
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InTRoDuCTIon
Atopic diseases such as asthma or atopic dermatitis are classically driven by an elevated 
T helper (Th) 2 response, characterized by the cytokines Interleukin (IL) -4, IL-5 and IL-13. 
These cytokines mediate a type 1 immediate hypersensitivity reaction associated with 
IgE class switch and eosinophil recruitment that is followed by a late phase allergic 
reaction caused by infiltrating allergen-specific T cells that lead to persistent allergic 
symptoms (1, 2). Next to the Th2 cells, other T helper cell subpopulations have been 
identified as important players driving pathological atopic reactions. This includes not 
only an imbalance between Th1 and Th2 cells (3) or between Th2 cells and regulatory 
T cell (4), but also disturbed immune responses of the more recently identified Th17 
and Th9 cells. IL-17A (hereafter named IL-17), produced by Th17 cells, is an important 
pro-inflammatory cytokine in the host defence against extracellular pathogens, espe-
cially against Candida (5), but can also drive pathology in allergic airway inflammation, 
where IL-17 was identified to induce IgE-mediated late-phase asthmatic response (6) 
and granulocyte influx (7). IL-9, another pro-inflammatory cytokine derived from Th9 
cells after differentiation from a naïve T cell in the presence of IL-4 and transforming 
growth factor (TGF) β, leads to mast cell activation, eosinophil recruitment and IgE class 
switch during allergic inflammation (8, 9). Neutralization of IL-9 in an ovalbumin-induced 
asthma model was shown to significantly reduce allergic symptoms (10) . Interestingly, 
next to the distinct Th lineage of Th9 cells, Th17 have also been described to be a source 
for IL-9. TGFβ and IL-1β were thereby identified as the main inducers of IL-9 and IL-17 
co-expressing cells and mainly driving pathology in auto-immune diseases (11, 12).
A Th17 deficient immunological phenotype does not implicitly lead to altered allergic 
immune responses. The recently identified gain-of-function (GOF) mutation in STAT1 
leads to deficient IL-17 production (13, 14). Patients with STAT1 GOF-mutation display next 
to recurrent infections and a higher incidence of auto-immune diseases or oesophageal 
cancer also chronic mucocutaneous candidiasis (CMC), manifesting as fungal infections 
on skin, nails and mucous membranes (14), but an atopic constitution is not a feature of 
the clinical presentation in these patients. In contrast, patients with the autosomal domi-
nant loss-of-function (LOF) STAT3 mutation, also leading to a deficient IL-17 production, 
present with an atopic phenotype with eczema, eosinophilia and high IgE levels, as well 
as recurrent staphylococcal skin, pulmonary abscesses accompanied by bronchiectasis 
and also CMC (15, 16). In the present study we wanted to elucidate whether the clinical 
allergic phenotype in HIES correlates with alterations in Th2 and Th9 immune responses, 
and compare this with patients without allergic symptoms that share many features of 
HIES including a Th17 deficiency, namely CMC.
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MeTHoDs:
Volunteers and patients
Blood was collected from healthy volunteers or patients by venous blood puncture after 
informed consent. Healthy volunteers between 20 and 40 years of age with no chronic 
disease or allergic disease in their history as well as without any medication were asked 
for blood donation. Four CMC patients with an autosomal dominant mutation in the 
STAT1 gene donated blood, two of them twice at two different time points. Four patients 
diagnosed with HIES with an autosomal dominant mutation in the STAT3 gene were 
asked for blood donations; two of them donated blood twice at different time points 
(demographic characteristics, Table I). Four patients with atopic dermatitis (AD) recruited 
from the department of dermatology and diagnosed according to their clinical presenta-
tion were included into the study (demographic characteristics, Table II).
Stimuli, recombinant cytokines and blocking antibodies
Staphylococcus aureus isolated form a clinical case was cultured by the department of 
microbiology, heat killed and provided to us (S. aureus) (1x107 /ml).; Candida albicans 
ATCC MYA-3573 (UC820) yeast (Ca yeast) (1x106 /ml) were grown overnight in Sabouraud 
broth at 37°C, cells were harvested by centrifugation, washed twice, and resuspended 
in culture medium. Ca yeast was heat-killed for one hour at 95 °C. The lack of viability 
was tested by culturing heat-killed yeast over night at 37°C and used, when no growth 
was observed (17). Aspergillus fumigatus clinical isolate V05-27 (Asp con), resting conidia 
(1x107/ml) were cultured and isolated as described previously (18). Briefly, A. fumigatus 
was cultured on Sabouraud glucose agar supplemented with chloramphenicol for 7 
days at 37°C. Conidia were harvested by gently scraping the surface of the slants and 
suspending them in PBS with 0.05% Tween 80. To remove hyphae and debris, the co-
nidial suspension was filtered through 4 layers of sterile gauze. The Tween of the mixture 
of conidia and PBS was removed by washing 3 times with PBS, resuspended into cell 
culture medium and adjusted to a concentration of 4x108/ml. Conidia were heat-killed at 
95°C for 30 minutes. The lack of viability was checked by culture in Sabouraud glucose 
broth. Conidia were stored at -80°C until used for the experiment.
Recombinant human IL-4 (10ng/ml), IL-1β (10ng/ml) and IL-23 (50ng/ml) were all 
purchased from R&D Systems. The anti-TGFβ I neutralizing antibody (10μg/ml) and its 
isotype control monoclonal IgG1 mouse anti-human antibody (10μg/ml) were purchased 
from R&D Systems.
9Th2 and Th9 responses in patients with CMC and HIES  |  195 
Ta
b
le
 I:
 D
em
og
ra
ph
ic
 c
ha
ra
ct
er
is
tic
s 
of
 C
M
C
 a
nd
 H
IE
S 
pa
tie
nt
s
Ag
e 
at
 ex
p.
Ge
nd
er
Se
ru
m
 Ig
E 
(IU
/m
l)
Eo
sin
op
hi
l 
co
un
t 
(x
10
9 /l
)
Cl
in
ici
al
 p
re
se
nt
at
io
n 
– a
lle
rg
ic 
ph
en
ot
yp
e
Tr
ea
tm
en
t
M
ut
at
io
n
CM
C 
1
70
m
al
e
< 
2
0.
02
Ch
ro
ni
c m
uc
oc
ut
an
eo
us
 ca
nd
id
ia
sis
, r
ec
ur
re
nt
 
pu
lm
on
ar
y i
nf
ec
tio
ns
, C
OP
D,
 sq
ua
m
ou
s c
el
l c
ar
cin
om
a, 
au
to
-im
m
un
e 
he
m
ol
yt
ic 
an
em
ia
Al
le
rg
ie
s :
 n
o 
at
op
ic 
ec
ze
m
a
Co
lis
tin
, A
ni
du
la
fu
ng
in
, A
zit
hr
om
yc
in
, C
ita
lo
pr
am
, 
Ci
de
so
ni
d,
 C
al
ciu
m
ca
rb
on
at
, A
m
ph
ot
er
ici
n 
B,
 
Pr
ed
ni
so
lo
n 
(1
0m
g/
d)
R2
74
W
CM
C 
2
43
m
al
e
N/
A
0.
04
Ch
ro
ni
c m
uc
oc
ut
an
eo
us
 ca
nd
id
ia
sis
, r
ec
ur
re
nt
 
pu
lm
on
ar
y i
nf
ec
tio
ns
, b
ro
nc
hi
ec
ta
sis
Al
le
rg
ie
s: 
no
 at
op
ic 
ec
ze
m
a
Flu
co
na
zo
le
, A
m
ox
icl
av
QT
26
7R
CM
C 
3
31
m
al
e
< 
2
0.
20
Ch
ro
ni
c m
uc
oc
ut
an
eo
us
 ca
nd
id
ia
sis
, t
yp
e 
I d
ia
be
te
s, 
hy
po
th
yr
eo
di
sm
, r
ec
ur
re
nt
 p
ul
m
on
ar
y i
nf
ec
tio
ns
, S
LE
Al
le
rg
ie
s :
 n
o 
at
op
ic 
ec
ze
m
a
Pr
ed
ni
so
lo
ne
 (s
to
p 
5 
m
on
th
 b
ef
or
e 
te
st
in
g)
, 
Itr
ac
on
az
ol
e, 
Fu
ro
se
m
id
, D
ox
yc
yc
lin
e, 
L-T
hy
ro
xin
, 
In
su
lin
D2
3V
CM
C 
4
40
m
al
e
-
0.
18
Ch
ro
ni
c m
uc
oc
ut
an
eo
us
 ca
nd
id
ia
sis
, r
ec
ur
re
nt
 
pu
lm
on
ar
y i
nf
ec
tio
ns
 w
ith
 ab
sc
es
s, 
re
cu
rre
nt
 si
nu
sit
is
Al
le
rg
ie
s: 
no
ne
, n
o 
at
op
ic 
ec
ze
m
a
An
id
ul
af
un
gi
n,
 Fl
uc
ox
ac
illi
n,
 Ib
up
ro
fe
n
R2
74
W
HI
ES
 1
43
fe
m
al
e
27
02
0.
21
Hy
pe
r I
gE
 sy
nd
ro
m
e, 
re
cu
rre
nt
 st
ap
hy
lo
co
cc
al
 sk
in
 
ab
sc
es
se
s
Al
le
rg
ie
s: 
no
ne
, n
o 
at
op
ic 
ec
ze
m
a
M
ico
na
zo
l, F
lu
clo
xa
cil
lin
, V
al
cic
lo
vi
r
S5
60
de
l
HI
ES
 2
45
m
al
e
39
42
0.
14
Hy
pe
r I
gE
 sy
nd
ro
m
e, 
re
cu
rre
nt
 p
ne
um
on
ia
 w
ith
 S.
 au
re
us
, 
br
on
ch
ie
ct
as
is,
 p
ul
m
on
ar
y a
sp
er
gi
llo
m
a
Al
le
rg
ie
s: 
ha
yf
ev
er
, n
o 
at
op
ic 
ec
ze
m
a
M
ox
ifl
ox
ac
in
, B
ac
itr
ac
in
, C
ip
ro
flo
xa
cin
, 
Am
ox
ici
llin
, M
ico
na
zo
l, D
ox
icy
cli
n
R3
82
W
HI
ES
 3
49
fe
m
al
e
45
24
0.
13
Hy
pe
r I
gE
 sy
nd
ro
m
e, 
re
cu
rre
nt
 st
ap
hy
lo
co
cc
al
 an
d 
st
re
pt
oc
oc
ca
l u
pp
er
 ai
rw
ay
s i
nf
ec
tio
ns
, r
ec
ur
re
nt
 
m
uc
om
yc
os
is 
an
d 
sk
in
 ab
sc
es
se
s, 
ch
ro
ni
c m
uc
ou
ta
ne
ou
s 
ca
nd
id
ia
sis
, k
id
ne
y a
bs
ce
ss
Al
le
rg
ie
s: 
no
ne
, n
o 
at
op
ic 
ec
ze
m
a
Am
ox
icl
av
R3
82
Q
HI
ES
 4
33
fe
m
al
e
74
93
0.
33
Hy
pe
r I
gE
 sy
nd
ro
m
e
Al
le
rg
ie
s: 
no
ne
, a
to
pi
c e
cz
em
a
Flu
clo
xa
cil
lin
, It
ra
co
na
zo
l
V4
73
de
l
196  |  Chapter  9
Ta
b
le
 II
: D
em
og
ra
ph
ic
 c
ha
ra
ct
er
is
tic
s 
of
 A
D
 p
at
ie
nt
s
Ag
e 
at
 ex
p.
Ge
nd
er
Se
ru
m
 Ig
E 
(IU
/
m
l)
Eo
sin
op
hi
l 
co
un
t (
x1
09
/l)
Cl
in
ici
al
 p
re
se
nt
at
io
n 
– a
lle
rg
ic 
ph
en
ot
yp
e
Tr
ea
tm
en
t
AD
 1
30
Fe
m
al
e
89
9
0.
86
At
op
ic 
ec
ze
m
a
Or
al
: p
ro
m
et
ha
zin
e, 
Lo
ca
l: C
et
om
ac
ro
go
l s
al
ve
, C
lo
be
ta
so
n 
sa
lve
, 
co
al
 ta
r, v
as
el
in
e/
pa
ra
ffi
ne
AD
 2
28
Fe
m
al
e
<4
,7
N/
A
At
op
ic 
ec
ze
m
a
Lo
ca
l: v
as
el
in
e/
pa
ra
ffi
ne
AD
 3
28
Fe
m
al
e
30
2
N/
A
At
op
ic 
ec
ze
m
a
Lo
ca
l: v
as
el
in
e/
pa
ra
ffi
ne
AD
 4
38
Fe
m
al
e
69
N/
A
At
op
ic 
ec
ze
m
a
Lo
ca
l: v
as
el
in
e/
pa
ra
ffi
n,
 b
et
am
et
ha
so
ne
, c
lo
be
ta
so
l, t
ac
ro
lim
us
, 
co
al
 ta
r
A
ll 
ex
p
er
im
en
ts
 w
er
e 
p
er
fo
rm
ed
 a
nd
 c
on
d
uc
te
d
 in
 a
cc
or
d
an
ce
 t
o 
G
oo
d
 C
lin
ic
al
 p
ra
ct
ic
e,
 t
he
 D
ec
la
ra
tio
n 
of
 H
el
si
nk
i, 
an
d
 t
he
 a
p
p
ro
va
l 
of
 t
he
 A
rn
he
m
-
N
ijm
eg
en
 E
th
ic
al
 C
om
m
itt
ee
 (n
r.2
0
10
/1
0
4)
.  
9Th2 and Th9 responses in patients with CMC and HIES  |  197 
Peripheral blood mononuclear cell (PBMC) isolation
Venous blood was drawn in 10 ml EDTA tubes. The blood was diluted 1:1 with Phos-
phate Buffered Saline (PBS). Subsequently PBMCs were isolated using Ficoll-paque 
(GE healthcare, Zeist, The Netherlands) density gradient centrifugation, as described 
previously (19). The PBMCs layer was collected and washed twice in cold PBS. Cells 
were reconstituted in Iscove’s modified Dulbecco’s Medium (IMDM) (life technologies) 
supplemented with 10 µg/ml gentamicin, and 10 mM pyruvate (Gibco, life technologies). 
The cells were counted with a particle counter (Beckmann Coulter) and the concentra-
tion was adjusted to 1x107 cells/ml.
PBMCs stimulation
PBMCs were plated in a 96-well plate (Corning) at a final concentration of 2.5x106 /ml 
in an end-volume of 200 μl per well. All stimulations were performed in the presence 
of 10% human pooled serum. Cells were incubated at 37°C with 5% CO2, after 7 days 
supernatants were collected and stored at -20°C.
Cytokine measurements
IL-5, IL-9, IL-13, IL-17, IL-22 and TGFβ were measured in the cell culture supernatants 
using commercial ELISA kits (IL-5, IL-13, IL-17, IL-22 and TGFβ: R&D Systems; IL-9: Biole-
gend) according to the instructions supplied by the manufacturer.
Intracellular staining and flowcytometry
After 7 days incubation in the presence of the pathogen with or without additional IL-4, 
cells were re-stimulated for 4-6 hours with PMA (50 ng/ml) (Sigma-Aldrich) ionomy-
cin (1 μg/ml) (Sigma-Aldrich), in 200 μl of IMDM medium supplemented with 10 µg/
ml gentamicin, and 10 mM pyruvate (Gibco) and 10% human serum in the presence of 
Golgiplug (BD Biosciences, Breda, the Netherlands). Cells were stained extracellular us-
ing PE-Cy7–conjugated anti-CD4 (ITK Diagnostics BV) and ECD–conjugated anti-CD45 
(Beckman Coulter). Fixation and permeabilization was performed with Cytofix/Cytoperm 
solution (eBioscience) according to the instructions supplied by the manufacturer. Cells 
were stained intracellular with anti-IL-4 (PE conjugated, BD Pharmingen), anti-IL-17A 
(FITC conjugated, ITK Diagnostics BV) and anti-IL-9 (Alexa 647 conjugated, ITK Diag-
nostics BV). Regulatory T cells (T-regs) were stained with anti-CD25 (PE-Cy7 conjugated, 
eBioscience) and anti-Forkhead Box Protein (FOX) P3 (APC conjugated, eBioscience). 
Fixated cells were measured with a FC500 flowcytometer (Beckman Coulter) and the 
data were analyzed using CXP analysis software v2.2 (Beckman Coulter).
198  |  Chapter  9
Statistical analysis
The Mann-Whitney-U test was used to detect differences between healthy controls 
and patients. The Wilcoxon-Signed Rank test was used to detect differences between 
isotype control and blocking antibody. A p-value of < 0.05 was considered statistically 
significant (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001). Graphs represent cumulative 
results of all performed experiments and are presented as mean ± standard error of the 
mean. Data were analyzed with GraphPad Prism v 5.0.
ResulTs
CMC and HIES patients have reduced IL-17A and IL-22 responses
Stimulation of PBMCs from CMC and HIES patients showed a significant defect in IL-17 
and IL-22 production (Figure 1). CMC patients demonstrated significantly lower IL-17 and 
IL-22 production after stimulation with Aspergillus, Candida and S. aureus, while HIES 
patients still produced significant amounts of IL-17, especially after S. aureus stimula-
tion. HIES patients produced significantly less IL-22 after stimulation with all different 
pathogens. To further validate this, flowcytometry analysis was performed and in both 
patient groups a lower frequency of IL-17+ CD4+ cells was observed.
Th2 response is deficient in CMC but not in HIES and AD patients
Next, we investigated whether the Th2 responses can be induced in STAT1 GOF or 
STAT3 LOF patients which both lack optimal Th17 responses. Stimulation with diseases-
associated pathogens Aspergillus, Candida or S. aureus showed decreased IL-5 and 
IL-13 production in CMC patients (Figure 2A and B), but not in HIES patients. We did 
not explore classical mitogenic stimulation with aCD3/aCD28 because it did not induce 
IL-5 and IL-13 in healthy volunteers (data not shown). Since the induction of IL-5 and 
IL-13 was relatively low, stimulation in the presence of IL-4 was performed to shift the 
Th responses towards an allergic phenotype. CMC patients demonstrated a significant 
defect in IL-5 and IL-13 production, while cells isolated from HIES patients responded 
normally when stimulated with different pathogens in the presence of IL-4 (Figure 2 C 
and D). To explore Th2 responses in another patients group with allergic phenotype, 
we included another control group of patients with AD. Except for one outlier in the 
AD patients group, comparable IL-5 and IL-13 levels were measured in the cell culture 
supernatants of PBMCs of AD patients and healthy controls using the same stimulation 
assay (Figure 3).
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figure 1: CMC and HIES patients have reduced IL-17A and IL-22 responses
PBMCs of healthy volunteers (n=13), CMC patients (n=4) and HIES patients (n=4) stimulated with heat-killed 
Aspergillus (Asp) conidia, Candida (Ca) yeast and Staphylococcus (S.) aureus and (A) IL-17 and (B) IL-22 mea-
sured in the cell-culture supernatant by ELISA or (C) stained for intracellular IL-17 and measured by fl owcy-
tometry (controls n=7, CMC n=2, HIES n=3). The Mann-Whitney-U test was used to determine, whether the 
means were signifi cantly diff erent (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001, ns = not signifi cant).
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figure 2: The Th2 response of CMC patients but not of HIES patients is defi cient
PBMCs of healthy volunteers (n=13), CMC patients (n=4) and HIES patients (n=4) stimulated with heat-killed 
Aspergillus (Asp) conidia, Candida (Ca) yeast and Staphylococcus (S.) aureus (A+B) in the absence (C+D) or 
presence of IL-4. (A+C) IL-5 and (B+D) IL-13 measured in the cell-culture supernatant by ELISA. The Mann-
Whitney-U test was used to determine, whether the means were signifi cantly diff erent (*=p < 0.05, ** = p < 
0.01 and *** = p < 0.001, ns = not signifi cant).
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IL-9 is induced by Candida and increased in the presence of IL-4 and IL-1/IL-
23 in healthy controls
IL-9 has been described to be produced by Th17 cells under certain conditions; there-
fore we wanted to investigate IL-9 responses in patients with a defective Th17 response. 
Stimulation of PBMCs with diff erent fungal pathogens or S. aureus demonstrated that 
Candida was the most potent inducer of IL-9 production (Figure 4A). The production 
increased steadily during stimulation for 7 days (Figure 4B). In the presence of the 
Th2-polarizing cytokine IL-4 and Candida, IL-9 production was further increased, while 
IL-4 stimulation alone did not induce detectable IL-9 production (Figure 4C). The IL-17-
inducing cytokine cocktail IL-1β and IL-23 also increased Candida-induced IL-9 but to 
a lesser extend then IL-4 (Figure 4C). We next wanted to identify which T helper subset 
displayed IL-9+ cells. Candida stimulation induced IL-9+ cells, which were either single 
positive or present in the IL-17+ subset. No IL-9+ cells were detected in the IL-4+ subset 
(Figure 4D). Since the frequency of IL-9+ cells was very low, additional analysis was per-
formed in the presence of IL-4 (Figure 4E). The percentage of IL-9+ cells remained low 
even after IL-4 stimulation, and again IL-9 was almost absent in IL-4+ cells, but present in 
the Th17 subset and IL-9 single positive cells.
figure 3: The Th2 response of AD patients is comparable to healthy controls
PBMCs of healthy volunteers (n=4) and AD patients (n=4) stimulated with heat-killed Aspergillus (Asp) conidia, 
Candida (Ca) yeast and Staphylococcus (S.) aureus (A+B) in the absence (C+D) or presence of IL-4. (A+C) IL-5 
and (B+D) IL-13 measured in the cell-culture supernatant by ELISA. The Mann-Whitney-U test was used to 
determine, whether the means were signifi cantly diff erent (*=p < 0.05, ns = not signifi cant).
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HIES patients have a striking defect in IL-4 induced IL-9 production
Stimulation of PBMCs isolated from CMC and HIES patients resulted in signifi cant lower 
Candida-specifi c IL-9 concentrations in CMC, while HIES cells produced IL-9, albeit 
lower (Figure 5). Interestingly, we observed that the addition of IL-4 to Candida stimula-
tion resulted in signifi cant lower IL-9 production in cells isolated from patients with HIES 
(Figure 5). Next, we measured IL-9 in the serum of HIES patients, AD patients and healthy 
controls; no IL-9 was detectable (data not shown).
figure 4: IL-9 is induced by Candida and increased in the presence of IL-4
PBMCs of healthy volunteers (n=6) stimulated with (A) diff erent pathogens, (B) Candida yeast, or (C) Candida 
yeast in the presence of medium, IL-4or IL-1β/IL-23 . (A-C) IL-9-measured in the cell-culture supernatant by 
ELISA. (D+E) PBMCs of healthy volunteers stimulated with Candida yeast with and without IL-4. Intracellular 
cytokine combinations in percentage on all CD4+ cells measured by fl owcytometry.
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This made us explore the underlying mechanism. Since TGFβ contributes to the induc-
tion of IL-9, and TGFβ expression of circulating activated T cells of HIES patients has 
been described to be low (20), we investigated whether TGFβ was responsible for this 
observed defi ciency of IL-9 in HIES. The total IL-9 production was partially dependent on 
TGFβ in PBMCs of healthy controls. However, the synergistic eff ect of IL-4 on Candida-
induced IL-9 was still present, when TGFβ was blocked in PBMCs of healthy controls 
(Figure 6A). In addition, TGFβ concentrations in cell culture supernatants of PBMCs 
isolated from HIES patients were comparable to healthy controls (Figure 6B).
TGFβ induces regulatory T cells (Tregs), which are able to modulate Th2 responses, 
therefore we measured the frequency of Tregs in HIES patients (21). The percentage of 
FOXP3+ CD25+ T-reg cells of total CD4+ cells was not diff erent between healthy controls 
and HIES patients (Figure 6C). In contrast, intracellular staining with fl owcytometry 
analysis of cells from HIES patients demonstrated a decreased percentage of overall 
CD4+ IL-9+ cells that was mainly due to a decrease in the IL-17+/IL-9+ cells compared to 
controls (Figure 6D).
figure 5: CMC and HIES patients are defi cient in IL-9 responses
PBMCs of healthy volunteers (n=13), CMC patients (n=4) and HIES patients (n=4) stimulated with heat-killed 
Aspergillus conidia, Candida yeast and S. aureus in the absence or presence of IL-4 and IL-9-measurement 
in the cell-culture supernatant by ELISA. The Mann-Whitney-U test was used to determine, whether the 
means were signifi cantly diff erent (*=p < 0.05, ** = p < 0.01 and *** = p < 0.001, ns = not signifi cant).
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DIsCussIon
The present study investigated Th2 and Th9 responses in patients with CMC and HIES. 
CMC patients had defi cient Th2 response, while HIES patients were capable to produce 
IL-5 and IL-13, such as AD patients. Since both CMC and HIES patients are defi cient in Th17 
responses, this suggests that Th2 responses are initiated and regulated independently 
from IL-17. In addition, CMC patients were completely defi cient on Candida-induced IL-9 
production, with only a partial defect in HIES patients.
An interesting observation was a defect in IL-4-induced IL-9 production after stimula-
tion with Candida in the HIES patients. IL-9 was co-expressed in a Th17 subset in healthy 
controls, and the percentages of this subset was lower in HIES patients, suggesting that 
figure 6: HIES patients are IL-9 defi cient not due to diff erences in TGFβ production or T-regs, but due to 
a lower frequency of IL-17+ IL-9+ CD4+ cells
(A) Blocking of TGFβ in PBMCs of healthy volunteers (n=6) stimulated with Candida yeast, with and without 
IL-4. (B) TGFβ-measurement in cell-culture supernatants of PBMCs of healthy controls (n=8) or HIES patients 
(n=4) stimulated with medium, Aspergillus conidia, Candida yeast and S. aureus. The Mann-Whitney-U test 
was used to determine, whether the means were signifi cantly diff erent (*=p < 0.05, ns = not signifi cant). (C) 
T-reg-measurement by fl owcytometry of healthy controls (n=2) or HIES patients (n=3) stimulated with stimu-
lated with medium, Aspergillus conidia, Candida yeast and S. aureus with and without IL-4. (D) Measurement 
of the intracellular cytokines IL-4, IL-9 and IL-17 of healthy controls (n=3) or HIES patients (n=3) by fl owcytom-
etry after stimulation with Candida yeast
9Th2 and Th9 responses in patients with CMC and HIES  |  205 
a robust IL-9 response is dependent on an intact Th17 subset that can produce IL-9. The 
intact Th2 response in HIES and a completely deficient Th2 response in CMC correlate 
with the clinical symptoms seen in CMC and HIES, because allergic responses are not 
a key feature of CMC, while atopic constitution with eczema, eosinophilia and high IgE 
levels are classical symptoms of HIES. Since we have not assessed the expression levels 
of IL-4R in CMC and HIES we cannot rule out that the IL-4R expression is significantly 
lower in CMC compared to HIES , which might explain our observations.
Th2 responses in HIES and CMC patients have been little studied until now. Here we 
describe a significant defect of IL-5 and IL-13 only in CMC patients, but not only after 
stimulation with Th2 inducing pathogens, but also after skewing these responses towards 
Th2 by the addition of IL-4. This is in line with a study investigating cytokine responses 
of eight CMC patients from Brazil, in whom no elevated Th2 responses were observed 
after mitogenic stimulation (22); it is important to note that in these patients the presence 
of STAT1 GOF mutations has not been tested. Khosravi et al. speculate about increased 
Th2 responses without having measured IL-4, IL-5 or IL-13 (23). However, Eyerich et al. 
had observed low interferon (IFN) γ and higher IL-10 in CMC patients and attributed the 
deficient Th responses to the elevated IL-10 response. One hypothesis is that STAT1 
hyperphosphorylation (13) results in increased IFNγ signaling, subsequently leading to 
a strong inhibition of the Th17 differentiation resulting in an IL-17 production defect (24). 
This mechanism could also underlie the deficient IL-5, IL-13 and IL-9 production, since 
they are all inhibited by IFNγ (3, 25). One other explanation why all T helper subset are 
deficient in CMC would be a general defect in T helper cell proliferation. However, we 
observed that the T cell proliferation capacity of CMC patients was intact (Supplemental 
Figure 1), which is in line with previously published data (26). Nevertheless, a lower per-
centage of CD4+ on CD45+ cells as seen in CMC patients could also partially contribute 
to the low production of T helper derived cytokines (Supplemental Figure 2). In contrast, 
HIES patients displayed a selective IL-9 deficiency, while the Th2 cytokines IL-5 and IL-13 
were produced in normal amounts. Intact Th2 responses were anticipated since HIES 
patients can present with an atopic constitution. AD patients presented with a robust 
Th2 response comparable to a non-allergic control group, suggesting that the Th2 as-
say used in this study is rather a qualitative assay than a quantitative assay for allergic 
responses. On the one hand, Boos et al. had described higher frequencies of Th2 cells 
in AD patients compared to healthy controls. On the other hand, they described compa-
rable Th2 responses of HIES patients and healthy controls (27). Furthermore, these data 
are in line with previous reports describing normal frequencies of CD4+ IL-4+ cells, but 
elevated CD4+ IL-13+ cells (28), and normal Th2 responses (27, 29) in STAT3-HIES patients. 
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Collectively these data suggests that a disturbed immune balance causes the atopic 
pathology rather than a strictly isolated increased Th2 response.
Several studies suggest that T-regs, IL-10, and TGFβ are main players in regulating Th1/
Th2 balance (30, 31). Interestingly, IL-10-treated dendritic cells derived from HIES pa-
tients have an impaired capability to induce FOXP3+ T-regs (31). However, we observed 
a normal frequency of peripheral T-regs in patients with HIES, which is in line with previ-
ously reported data (31). TGFβ is a cytokine of great interest in the context of our findings, 
since it is on the one hand a T-reg inducing cytokine (32), but in the presence of IL-4 
it is a significant inducer of IL-9, and initiates the differentiation of naïve CD4+ T cells 
towards Th9 cells (33). Since we observed a deficient Candida-induced IL-9 response in 
the presence of IL-4 in HIES patients, we hypothesized that lower TGFβ concentration in 
HIES patients might be a possible mechanism. TGFβ concentrations were however not 
significantly different after stimulation in the patients. This is in line with the study of Saito 
et al., who also showed an intact TGFβ response in HIES patients (31), but in contrast with 
a study of Ohga et al., who described low TGFβ expression of circulating activated T cells 
of HIES patients (20). Interestingly, Candida induced more IL-9+IL-17+ co-expressing CD4+ 
cells than IL-9+ single positive cells in healthy volunteers. Secondary signals such as the 
IL-1 family cytokines IL-1α and IL-1β (34) have been described to potentiate IL-9 produc-
tion. Candida is a strong IL-1 and IL-17 inducer (35), which is reflected by the relatively 
high frequency of IL-9+IL-17+ co-expressing CD4+ cells in response to Candida compared 
to other stimuli. Here we show that HIES patients, most likely due to their deficient Th17 
response due to their STAT3 LOF mutation, also have a lower Th17 subset that is able to 
produce IL-9. Therefore it is likely that the lower IL-9 response in response to IL-4 in HIES 
patients is due to a deficiency to induce a subset of Th17 cells that are able to produce 
IL-9.
Since HIES patients suffer from cold staphylococcal abscesses, chronic mucocuta-
neous candida infection as well as from pulmonary aspergillosis, mainly in preformed 
bronchiectatic cavities causing aspergilloma or even invasive pulmonary aspergillosis, 
specific immune responses against these three pathogens have been investigated 
and compared to CMC patients (36). Interestingly, both fungal pathogens Candida and 
Aspergillus did not cause different immune responses, although Candida had a stronger 
cytokine inducing capacity. This matches with their clinical presentation, since it has 
recently been published that also CMC patients can suffer from Aspergillus and S. aureus 
infections (37) making HIES and CMC syndromes very similar in terms of susceptibility to 
fungal infections due to their Th17 deficiency.
In conclusion, CMC and HIES patients share several immunological defects, but differ 
in their capability to induce Th2 and Th9 responses. CMC patients have a completely 
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abolished Th2 and IL-9 response, while HIES patients have normal Th2 responses and 
only lack an IL-4-induced IL-9 response. These data might explain both the similarities 
and differences in clinical presentation seen between HIES and CMC patients; sharing 
an increased susceptibility to mucocutaneous candidiasis due to a Th17 deficiencies on 
the one hand, but displaying clear differences in allergic disease due to difference in Th2 
and Th9 responses on the other hand. Why CMC patients present with a more general 
defect in Th subsets, and how the lack of IL-9 further contributes to the immunopathol-
ogy of HIES patients remains to be elucidated.
ADDITIonAl MATeRIAl: MeTHoDs foR suPPleMenTAl fIGuRes:
CFSE proliferation assay
Proliferation of PBMCs was measured using the CFSE kit (Biolegend) according to the in-
structions described by the manufacturer. Briefly, PBMCs were re-suspended to a density 
of 10 x 106 cells/ml in PBS and labeled by adding CFSE in a 1:1 ratio to a final concentra-
tion of 1.25uM. The suspension was mixed gently and incubated for 5 minutes at 37°C. An 
equal volume of 100% human pooled serum was added and incubated for 3 minutes at 
room temperature. Cells were washed two times in RPMI+ (RPMI-1640 culture medium 
- Dutch modification, Gibco, Invitrogen, Breda, The Netherlands - supplemented with 10 
µg/ml gentamicin, 10 mM L-glutamine and 10 mM pyruvate - Gibco) supplemented with 
10% human pooled serum and re-suspended to a concentration of 5x106/ml in RPMI+. 
An unlabeled cell fraction and a labeled cell fraction were measured by flowcytometry 
on day 0 to control for the staining efficacy. Labeled cells were stimulated for 6 days with 
IL-2 (75 U/ml, R&D systems) and different pathogens in the presence or absence of IL-4. 
On day 6 cells were stained with anti-CD3 (PE-Cy5 conjugated, ITK Diagnostics BV) and 
measured by flowcytometry. The percentage of proliferated CD3+ cells were calculated 
as percentage of all CD3+ cells.
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supplemental figure 1: Proliferation assay of CMC patients
Proliferation assay was performed after 7-days stimulation of CFSE-labelled PBMCs with IL-2 and Candida 
yeast or S. aureus with and without IL-4 of healthy controls (n=4) and CMC patients (n=3).
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supplemental figure 2: Frequency of CD4+ cells of CMC and HIES patients
The percentage of CD4+ cells within the CD45+ cells was calculated in PBMCs of healthy controls (n=7) and 
patients with CMC (n =4) or HIES (n=3) after measurement by flowcytometry.
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To the editor
The respiratory tract of patients with cystic fibrosis (CF) is colonized with a high 
diversity of microorganisms. Non-tuberculous-mycobacteria (NTM) show a high and 
increasing prevalence. Forty percent of these positive NTM cultures were caused by My-
cobacterium abscessus (1), one of the rapidly growing NTM present in the environment. 
Patients with M. abscessus infection are difficult to treat due to natural and acquired 
antibiotic resistance (2, 3) and an infection with M. abscessus is controversially discussed 
as contra-indication for lung transplantation (4).
Immune-modulatory treatment strategies might contribute to overcome this problem. 
For their development, a better understanding of the defective immune response ex-
plaining the higher susceptibility of CF patients to M. abscessus is needed. Here we pres-
ent three CF patients with M. abscessus infection, in whom we describe the pathogen-
specific innate and adaptive cytokine production and compare this with non-CF patients 
with pulmonary infection caused by various NTMs: M. abscessus (n=1), M. avium (n=3), M. 
kansasii (n=2), M. intracellulare (n=1).
Case 1 is a 24-year-old female patient with CF (dF508del/dF508del) with pancreatic 
insufficiency and Pseudomonas colonization since 2003. In 2004, she presented with 
allergic bronchopulmonary aspergillosis (ABPA) that was successfully treated with 
corticosteroids. After years of infectious exacerbations she presented with an episode 
of haemoptysis in 2010. Shortly thereafter, M. abscessus was cultured from her sputum. 
In 2011, haemoptysis and clinical deterioration led to hospitalisation and several courses 
of antimycobacterial regimens (combinations of amikacine, clarithromycin, tigecycline, 
meropenem and clofazimine) were given without successful M. abscessus eradication.
Case 2 is a 23-year-old male patient with CF (dF508del/dF508del), pancreatic insuf-
ficiency and Staphylococcus aureus and Aspergillus colonization presented with ABPA. 
After a course of corticosteroids and itraconazole, he improved and serological markers 
for ABPA have remained at low levels ever since. After this episode, M. abscessus was 
consistently cultured and although he had no physical complaints, his pulmonary func-
tion deteriorated, and a CT thorax showed several sub-pleural and intra-parenchymatous 
nodular lesions compatible with mycobacterial disease. No clearance of M. abscessus 
was achieved, despite two courses of treatment with combination regimens of amikacin, 
meropenem, clarithromycin and clofazimine.
Case 3 is a 15-year-old male patient with CF (dF508del/G551D), pancreatic insufficiency 
and Pseudomonas colonization. Since 2011 M. abscessus was consistently cultured and 
he experienced several exacerbations in 2014 in which his pulmonary function dete-
riorated, despite several NTM regimens (including tigecycline, clofazimine, linezolid, 
azithromycin) and treatement with ivacaftor. However, he was non-compliant for the 
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figure 1: Innate and adaptive cytokine responses of three CF patients with M. abscessus infection 
compared with non-CF patients with pulmonary NTM infection.
PBMCs (2.5x106/ml) of a healthy control group (n = 11), non-CF patients with pulmonary NTM infections 
(pNTM) (n=7) and three CF patients with M. abscessus infection were stimulated with heat killed M. absces-
sus (clinical isolate NLA001001395) (1x105/ml), heat killed C. albicans (ATCC MYA-3573, UC820) (1x105/ml), 
E.coli LPS (E. coli serotype O55:B5, Sigma-Aldrich St. Louis, MO USA) (1ng/ml) or A. fumigatus conidia (clinical 
isolate V05-27) (1x107/ml). The innate cytokines TNFα and IL-1β were measured after 24h and the adaptive 
cytokines IFNγ, IL-17.
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treatment and not able to complete several regimens due to side effects and complex 
psychosocial situation. No relevant clearance of M. abscessus was achieved.
PBMCs isolated from the three patients described above were stimulated with M. 
abscessus, isolated and cultured from the second case, C. albicans, E. coli LPS and A. 
fumigatus. CF patients and pulmonary NTM patients did not demonstrate a distinct in-
nate cytokine profile after PBMC stimulation with M. abscessus or C. albicans (Figure 1 
A+B). Interestingly, all NTM patients showed higher TNFα and IL-1β production on LPS 
stimulation compared to the control group, while the A. fumigatus-specific innate im-
mune response was selectively increased in the CF patients infected with M. abscessus 
(Figure 1 C+D).
CFTR-deficient monocytes have been described to be highly reactive to LPS stimula-
tion due to a prolonged sensing period of TLR4 on the cell surface (5). Furthermore, 
previous studies reported a hyper-responsive innate immune system in CF patients, with 
elevated TNFα, IL-1β and IL-6 levels in the sputum (6), which is in line with the elevated 
innate immune profile described in the CF patients of our study. CF patients who are 
often colonized with Aspergillus are on high risk to develop allergic bronchopulmonary 
aspergillos (ABPA) (7.8%) (7), and two out of the three CF patients with NTM infection in 
this study fulfilled the criteria of ABPA. Whether and how the strongly increased innate 
cytokine response after Aspergillus stimulation as seen in all CF patients in this study 
contributes to the development of ABPA or is the result of a hypersensitivity reaction in 
an Aspergillus colonized lung remains to be elucidated.
By contrast, the acquired immune responses revealed pathogen-specific differences. 
To investigate adaptive T helper (Th) cell responses, PBMC were stimulated with M. 
abscessus, C. albicans, which was used as a positive control for IL-17 production, and 
Aspergillus conidia. PBMCs from healthy subjects produced IL-17, IL-22 and IFNγ in re-
sponse to M. abscessus (Figure 1E). Although PBMCs isolated from both patient groups 
were capable of producing IL-17 in response to C. albicans (Figure 1F), IL-17 in response 
to M. abscessus was very low in all CF patients as well as in most of the patients with 
pulmonary NTM infection. By contrast, M. abscessus induced IL-22, and IFNγ was similar 
or even elevated in CF patients infected with M. abscessus, while the pulmonary NTM 
patients demonstrated low IFNγ and IL-22 production on M. abscessus-stimulation. This 
suggests a selective pathogen-specific immunodeficiency in CF patients infected with 
M. abscessus shown by the total absence of M. abscessus-specific IL-17 production. 
Interestingly the Aspergillus-specific T helper (Th) 1 and 17 responses did not show dif-
ferences between the groups.
CF is associated with a high prevalence of M. abscessus infections (1), but the underly-
ing host defects leading to this increased susceptibility are not fully understood. Abnor-
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malities in the IL-12/IFNγ-signalling pathways are a known risk factor for mycobacterial 
infections (8) and decreased IL-17 production in response to Mycobacterium avium has 
been described in PBMCs isolated from patients with NTM lung disease (9). This is in line 
with the low T helper cytokine deficiency of the pulmonary NTM patients in this study. The 
Th17 subpopulation has been described to play a protective role in mucosal immunity 
against extracellular fungal and bacterial infections, especially in the lung (10). Although 
some of the healthy volunteers responded only poorly on M. abscessus-stimulation, in 
most donors a robust Th17 response was induced as described earlier (11). The three 
CF patients in this study demonstrated a M. abscessus-specific IL-17 deficiency, while 
the cells were not intrinsically deficient in IL-17 production. Despite earlier reports that 
described significantly elevated IL-17 level in sputum and airway mucosa of CF patients, 
we propose that M. abscessus-specific IL-17 deficiency can promote the susceptibility to 
chronic NTM infections (12).
Treatment with biological drugs blocking innate cytokines that promote Th17 differentia-
tion is associated with an increased risk of NTM infections (13). Therefore we propose the 
inverse correlation that patients with low IL-17-responses, such as the three CF patients 
in this study, might profit from an IL-17 supporting treatment regimen. Only a few studies 
has been performed to date. Next to treatment with IFNγ, which had beneficial effects 
on the IL-17 and IL-22 production in patients with severe fungal infection (14), one might 
speculate about the supplementation of recombinant IL-17. Low-dose IL-17 has recently 
been shown to be prevent diabetic nephropathy and organ fibrosis (15).
In conclusion, we describe pathogen-specific cytokine signatures in three CF patients 
and M. abscessus infection, two of them with ABPA, which might contribute to their higher 
susceptibility of NTM and Aspergillus-specific responses. The M. abscessus-specific IL-17 
deficiency rather than an IFNγ-defect might play a crucial role in promoting pulmonary 
non-tuberculous mycobacterial infections in CF. This might have direct implementation 
for different immune-modulatory treatment regimens in pulmonary NTM infection in 
patients either with CF or without.
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To the editor
The prevalence of pulmonary NTM (pNTM) disease is increasing (1). The most commonly 
isolated NTM to cause disease belong to the M. avium complex (MAC) (1). Susceptibility 
to and clinical manifestation of NTM disease is largely governed by the immune status of 
a person. Disseminated or extrapulmonary NTM infections are strongly associated with 
severe immunosuppression such as those with frank defects in the interferon-gamma 
(IFNγ)-interleukin-12 (IL-12) axis (2). Isolated pNTM is strongly associated with certain 
underlying conditions, such as cystic fibrosis, chronic obstructive pulmonary disease, 
and primary ciliary dyskinesia (3, 4). However, substantial number of pNTM patients have 
no apparent risk factors and a significant proportion of them exhibit a body morphotype 
characterized by life-long slender body habitus, pectus excavatum (PEX), scoliosis, and 
mitral valve prolapse (5, 6), also called the lady Windermere syndrome. Patients were 
described to have a modest reduction in IFNγ production and an increase in transform-
ing growth factor-beta (TGFβ) levels (7-10). Fowler and co-workers quantified ciliary beat 
frequency of 58 pNTM patients and 40 controls and found reduced ciliary beat frequency 
in the pNTM patients (11). Szymanski et al. recently performed whole exome sequencing 
on patients with pNTM, their unaffected family members and a control group and con-
cluded that pNTM is a multigenic disease, encompassing potential defects in proteins 
encoded by cilia genes, the cystic fibrosis transmembrane conductance regulator gene, 
connective tissue genes, and certain immune-related genes (12).
Since PEX and scoliosis have been described in several genetic disorders that are not 
necessarily notable for increased susceptibility to lung infections, it suggests that pNTM 
patients with this body phenotype may have a more specific genetic basis that could 
not only account for their increased vulnerability to pulmonary NTM infections (13). The 
goal was to determine the genetic basis for patients with lady Windermere syndrome, 
namely the pNTM patients with PEX and scoliosis (pNTMPEX/scoliosis) by performing whole 
exome sequencing in 11 individuals with this phenotype and functional validation of the 
genetic findings.
Eleven individuals with pNTMPEX/scoliosis – one family with two sisters and nine sporadic 
cases – were recruited from National Jewish Health and University of Colorado Anschutz 
Medical Campus, respectively, as part of a previous study (5). In whole exome sequenc-
ing MST1R was the only gene with a previously described role in innate immunity or cilia 
function that harbored rare non-synonymous variants in 3 families.
The two sisters (Patients 1 and 2 in Family 1, Figure 1A) carried a very rare missense vari-
ant (p.V900M) in MST1R with a very low population frequency of 0.0004794 or 28/58,406 
public exomes based on Exome Aggregation Consortium (ExAC) (14). Co-segregation 
analysis in their extended family revealed that three siblings and three children are 
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Family'1:'pa+ents'1'&'2'
Individual! Complaints!
MST1R'
muta+on!
I.I! Unknown!! DNA!N/A!
I.II! Unknown!! DNA!N/A!
II.I!
Pectus!excavatum,!
occasional!pneumonia,!
throat!clearing!with!phlegm! V900M/wt!
II.II'(Pa+ent'1)!
pNTM,'pectus'excavatum'
and'scoliosis'! V900M/wt!
II.III! unaﬀected! wt/wt!
II.IV! Chronic!cough!! V900M/wt!
II.V'(Pa+ent'2)!
pNTM,'pectus'excavatum'
and'scoliosis'! V900M/wt!
II.VI! Unaﬀected! V900M/wt!
III.I! Unaﬀected!! wt/wt!
III.II! Unaﬀected!! wt/wt!
III.III! Unaﬀected!! V900M/wt!!
III.IV! Unaﬀected!! V900M/wt!!
III.V! Unaﬀected!! wt/wt!!
III.VI! Unaﬀected!! V900M/wt!!
III.VII! Unaﬀected!! wt/wt!!
Family'2:'pa+ent'3'
Individual! Complaints! MST1R'muta+on!
I.I!(Mother)! Unaﬀected! wt/wt!!
I.II!(Father)!
Frequent!severe!bronchiJs,!
throat!clearing!with!phlegm! DNA!N/A!(p.M1383T/wt)*!
II.I'(Pa+ent'3)'''''!
pNTM,'pectus'excavatum'and'
scoliosis'! p.M1383T/wt!
II.II!!
Pneumonia,!suscepJble!to!
chest!infecJons;!throat!
clearing!!!! p.M1383T/wt!
III.I! Unaﬀected!! DNA!N/A!!
Family'3:'pa+ent'4'
Individual! Complaints! MST1R'muta+on!
I.I!(Mother)! Unaﬀected! wt/wt!
I.II!(Father)!
Pronounced!cough!>20y!,!
raspy!hoarse!voice!! p.D176N/wt!!
II.I!! Unaﬀected! wt/wt!
II.II'(Pa+ent'4)!
pNTM,'pectus'excavatum'and'
scoliosis'! p.D176N/wt!
III.I! Unaﬀected!! p.D176N/wt!!
''''''' '''''''
Family'1! Family'3!Family'2!(A)
       Medium       LPS       S. epidermidis      M. intra 
0
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500
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1500
controls (n=52)
pNTMPEX/scoliosis (n=4)            
0.1491p = p = *0.1602
*     pNTMPEX/scoliosis/ΔMST1R               
       (n=2)
IF
N
γ 
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g/
m
l)
(B)
heat killed M. avium
coIgG αMST-1r
0
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1500
0.0977p =
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live M. avium 
coIgG αMST-1r
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4000
6000
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10000 *
heat killed M. avium + IL-12
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0
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20000
30000 *
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0
10000
20000
30000
40000 ns
(F)(E)(D)(C)
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carriers of the same MST1R variant (Figure 1A). Two of the nine sporadic pNTMPEX/scoliosis 
cases also have missense variants in the MST1R gene. Patient 3 had a private missense 
variant not previously reported (p.M1383T) and patient 4 possessed a rare missense vari-
ant (p.D176N) with a very low population frequency of 0.0009082 or 53/58,360 public 
exomes (14). Co-segregation analyses within the respective families showed that in both 
Patients 3 and 4 of Family 2 and 3, the MST1R variant was paternally inherited (Figure 1A). 
Sanger sequencing revealed that all 29 pNTM patients without PEX or scoliosis were 
negative for rare MST1R variants.
We next addressed cytokine production of pNTMPEX/scoliosis patients. Whole blood stimu-
lation experiments revealed significantly lower M. intracellulare-induced IFNγ production 
in all pNTM patients compared to the control group as previously reported (5) (Figure 1B). 
IL-10 production in the pNTMPEX/scoliosis patients was also lower after stimulation with LPS, 
S. epidermidis, or M. intracellulare (data not shown). The mean concentrations of IL-6 were 
not significantly different between pNTMPEX/scoliosis patients and controls (data not shown). 
In contrast, the anti-inflammatory cytokine TGFβ was significantly increased in pNTMPEX/
scoliosis patients compared to controls (data not shown), also shown in a recent study (7). 
Comparing pNTMPEX/scoliosis patients with and without the variant in MST1R revealed as low 
or even lower levels of IFNγ in whole blood stimulation (Figure 1B).
To investigate the immunological relevance of MST1R, we stimulated PBMCs from 
healthy individuals with heat-killed M. avium, live M. avium, heat-killed M. avium + IL-12, or 
IL-12 + IL-18 in the absence or presence of a MST1R neutralizing antibody, and measured 
IFNγ levels (Figure 1D-F). Blocking MST1R resulted in a significantly lower level of IFNγ in 
figure 1: (A) Family 1: The two sisters with pNTMPEX/scoliosis carry a mutation in MST1R. Three of their 
siblings also have DMST1R and two of them have chronic respiratory symptoms. Family 2 The index 
patient with pNTMPEX/scoliosis has DMST1R. One brother of the index patient also has the same MST1R 
mutation and has frequent chest infections. *Because two of his children carry the MST1R mutation, 
the deceased father of the family is the expected carrier of the mutation, although his DNA was 
not available. Family 3 The index patient with pNTMPEX/scoliosis has DMST1R. Both the father and 
daughter of the index patient also carry the MST1R mutation but only the father has a chronic cough 
whereas the daughter has no health issues or complaints. (B) Whole blood of healthy controls (black 
squares), patients with pNTMPEX/scoliosis (open squares) and pNTMPEX/scoliosis patients carrying the MST1R 
mutation (pNTMPEX/scoliosis/ ΔMST1R, open circles) was stimulated with a medium control, LPS, heat-killed 
S. aureus and M. avium. IFNγ was measured in the supernatant by ELISA. The Mann-Whitney-U test 
was used to determine, whether the means were significantly different. (C-F) PBMCs of healthy 
donors were stimulated for 48 hours with (C) heat killed M. avium (n=6), (D) live M. avium (n=6), (E) 
heat killed M. avium + IL-12 (n=6), or (F) IL-12/IL-18 (n=7) in the presence of a MST1R neutralizing 
antibody (γMST1R) or its isotype control. IFNγ was measured in the cell culture supernatant by ELISA. 
The Wilcoxon Signed Rank test was used to determine whether the mean values were significantly 
different.
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response to live M. avium ± IL-12 and a trend toward reduced IFNγ production with heat-
killed M. avium (Figure 1C-E). However, with IL-12+IL-18 stimulation of the PBMCs, there 
was no difference in IFNγ production with or without anti-MST1R antibody (Figure 1F). 
Furthermore, blocking MST1R had no effect on M. avium (heat-killed or live) stimulation 
of IL-10, IL-6, or TGFβ by the PBMCs (data not shown). This reveals a previously unde-
scribed potential mechanism by which MST1R plays a host defense role against NTM.
Interestingly, MST1R variants were also recently reported in three pNTM patients in a 
cohort of 77 NTM patients (12). While this is consistent with our findings, it is interesting 
to speculate that the higher frequency of MST1R variants in our smaller cohort may be 
due to more stringent selection of patients with both PEX and scoliosis. To evaluate 
this possibility, we performed Sanger sequencing in 29 patients without these physical 
characteristics and found no rare genetic variation in MST1R. How MST1R variants might 
be related to the presence of PEX/scoliosis is unknown; furthermore, because PEX/sco-
liosis are also present in some patients without MST1R mutation raises the strong pos-
sibility that PEX/scoliosis are associated with anomalies of more than one gene. Indeed, 
this notion is supported by the finding that PEX/scoliosis is not only seen with Marfan 
syndrome but also several other connective tissue disorders such as Loeys-Dietz and 
Shprintzen-Goldberg syndromes (13). Interestingly, all these connective tissue disorders 
are due to increased TGFβ signaling albeit through different mechanisms.
MST1R is highly expressed on airway epithelial cells and functions to increase muco-
ciliary function; i.e., binding and activation of MST1R by its ligand macrophage-stimulated 
protein (MSP) leads to a significant increase of the ciliary beat frequency (15). Thus, a 
defect in the mucociliary transport due to a MST1R mutation could lead to impaired 
clearance of NTM, resulting in a vicious cycle of airway inflammation and infection lead-
ing to the bronchiectasis typically seen in patients with pNTM. These genetic findings 
are consistent with the study showing that adult patients with pNTM and without known 
predisposing factors have reduced ciliary beat frequency (11). Thus, defects in MST1R 
function can specifically attenuate IFNγ production as well as decrease airway ciliary 
function, with both defects increasing susceptibility to pNTM. The decrease in IFNγ 
production was specific for the stimulation with live M. avium, since blocking MST1R did 
not decrease IL-12 + IL-18-induced IFNγ production. The reason for this phenomenon is 
not known; it might be speculated that M. avium has a direct ligand for MST1R.
In conclusion, we have identified rare variants in MST1R in four of 11 pNTMPEX/scoliosis pa-
tients, and suggest that these genetic variants contribute to lady windermere syndrome 
by decreasing airway ciliary function and reducing IFNγ production in response to NTM.
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Fungi are environmental microorganisms that make a valuable contribution to the 
ecosystem. Humans are in permanent contact with fungi and a healthy immune sys-
tem can deal with the fungal contact easily: either by tolerating commensals such as 
Candida which resides on the human mucosal surface or by clearing fungal pathogens 
such as airborne Aspergillus, of which we inhale more than several hundred spores 
on a daily basis without developing any signs of illness. However in patients lacking 
efficient defence mechanisms the fungus can invade the tissue and cause disease. 
While chemotherapy is the most common cause for a severe immunodeficient status 
of humans, many genetic defects have been identified over the past decades that also 
play a key role. This ranges from single nucleotide polymorphisms being associated with 
a higher susceptibility for fungal infections under immunocompromised conditions, to 
monogenetic mutations leading to severe fungal diseases. In contrast, a hyper-reactive 
immune system triggered by fungi can cause allergic disease. Aspergillus has a potent 
allergenic capacity and can cause allergic bronchopulmonary aspergillosis, especially 
in patients with severe asthma or cystic fibrosis. Treatment options are still limited for 
both invasive and allergic fungal disease and a better understanding of the molecular 
mechanisms underlying the antifungal host response is the basis for the development 
of novel target-specific and immunomodulatory treatment regimens.
ASPERGILLUS ReCoGnITIon AnD InITIATIon of T HelPeR ResPonses
Studying fungal immunology always has totake into account both sides, the fungus and 
the host. Different morphologies of the fungus will lead to the exposure of a fundamen-
tally different range of associated molecular patterns. The first step of an efficient innate 
immune response is the recognition of these different structures by pattern recognition 
receptors that subsequently initiate a strong adaptive immune response [1]. In Chap-
ter 2 I present an overview of the range of pattern recognition receptors recognizing 
the two most commonly isolated pathogenic fungi, namely Aspergillus fumigatus and 
Candida albicans. Although only a certain number of the pattern recognition receptors 
and downstream signalling cascades are described for the antifungal host response, the 
crosstalk and conditional interaction between these pathways allow the immune system 
to establish a tailored innate and adaptive immune response [2]. The synergistic effects 
of Dectin-1 and TLR2, the activation of the required dectin-1-mediated phagocytosis 
and signals and the subsequent activation of the NLRP3 inflammasome, are some of 
the most important innate immune mechanisms responsible for the antifungal immune 
response [3, 4]. A complex interplay of different immune cells ranging from neutrophils, 
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monocytes, macrophages, NK-cells, T-cells to innate lymphoid cells and even epithelial 
and endothelial cells orchestrate the anti-fungal immune response.
Polysaccharides of the fungal cell wall serve as receptor ligands for PRRs. Wer per-
formed a set of studies to elucidate their corresponding receptors in order to better un-
derstand the molecular mechanism of fungal recognition. In Chapter 3 we investigated 
immunomodulatory properties of the Aspergillus cell wall component chitin. Different 
immune functions have been attributed to chitin to date: while Bueter et al. described 
chitin as an inert particle, Wagener et al. observed a strong anti-inflammatory capacity of 
chitin mediated by mannose receptor, TLR9 and NOD2 [5, 6]. Interestingly, the variation 
inpurity, size, shape,  preparation and experimental setup can explain the important dif-
ferences between the results described in the literature [7]. In this study we used Asper-
gillus chitin with a high grade of acetylation and a particle size of < 0,5μm, proceeded by 
short time ultrasonication; we ensured high purity due to removing remaining β-glucan 
by β-glucanase treatment. By stimulating human PBMCs in the presence of human 
serum we identified the Fcγ/Syk/PI3K pathway, through which chitin can induce strong 
anti- and pro-inflammatory immune responses. We also described that the Aspergillus 
cell wall component chitin is a trigger of a potent anti-flammatory response by inducing 
IL-1Ra in human PBMCs, while no other pro-inflammatory cytokine was induced by chitin. 
We identified immunoglobulins in human serum as necessary opsonins to activate the 
Fcγ/Syk/PI3K pathway, which is the key pathway involved in chitin-specific IL-1Ra re-
sponse, while the chitin particles themselves were immunologically inert. In contrast, in 
the presence of bacterial cell wall components, chitin induced potent pro-inflammatory 
immune responses via the same signalling pathway. Cross-activation of Fcγ-receptor 
with TLR2, TLR4 or NOD2 resulted in a synergistic pro-inflammatory immune response. 
Translating this immunomodulatory function of chitin into pathogenesis of fungal infec-
tions must take various influencing factors into account: on the one hand, chitin can 
dampen immune responses and control cytokine overproduction by the stimulation of 
the antiinflammatory IL-1Ra in the presence of immunoglobulins that are abundant in 
the serum. In addition, the strong anti-inflammatory signal facilitates the fungus to sup-
press the human defence mechanism and might even facilitate fungal invasion. On the 
other hand, although the exact fungal ligand is not known yet, TLR2, TLR4 and NOD2 are 
important for the antifungal host response since TLR2-/-, TLR4-/- and NOD2-/-mice 
were highly susceptible for invasive aspergillosis [8, 9] (Gresnigt et al., submitted). This 
means that chitin can augment the immune system by amplification of TLR2-, TLR4- 
or NOD2-mediated signals activated either by fungal or bacterial pattern recognition 
receptor ligands. How this integrative concept of receptor-crosstalk changes during the 
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course of infection remains speculative, since littleis known about the cell wall structure 
and its composition change during germination and its interaction with host defense.
Although recognition is the first crucial step in successful antifungal host response, 
a strong T helper response is key for mediating effector functions to efficiently clear 
the fungus and establish an immunological memory. Pattern recognition receptors build 
the bridge by inducing the release of different innate cytokines that in turn activate the 
differentiation of naïve T cells towards specific T helper subsets. While invasive aspergil-
losis has been associated with a deficient Th1 and Th17 response, allergic aspergillosis is 
caused by increased and dysregulated Th2 responses. In Chapter 4 and 5 we elucidated 
pattern recognition receptors, pathways and T helper subpopulations that are triggered-
by Aspergillus fumigatus. Aspergillus can induce various specific T helper cytokines, but 
especially IL-22 has gained attention due to its protective role in invasive aspergillosis 
[10], in contrast to its detrimental role in allergic aspergillosis [11]. In Chapter 4 we iden-
tified that the Aspergillus-specific IL-17 and IL-22 responses triggered by conidia and 
hyphae were dependent on TLR4, while blocking TLR2 increased these responses. IFNγ 
production was independent of TLR2 and TLR4. Interestingly, complement receptor 3 
(CR3) was crucial for the initiation of the Th1 and Th17 subset, while the dectin-1 receptor 
was redundant. This was rather unanticipated, since dectin-1 is one of the main receptors 
in the recognition of Candida albicans and Aspergillus hyphae that abundantly express 
β-glucan on their surface [3]. By studying the cytokine co-expressing cells induced by 
Aspergillus, we identified that IL-22 was not restricted to a specific Th subset, but that 
these cells are able to co-express IL-17 as well as IFNγ. This indicates that Aspergillus 
does not induce one specific type of T helper response, but rather induces a diverse 
plastic T helper response. This T helper plasticity might contribute to a  faster and more 
efficient defence of Aspergillus. The induction of IL-17 and IL-22 induced by Aspergillus 
conidia and hyphae was dependent on IL-1β and TNFα. This is an important finding given 
the widespread use of biologicals that target these cytokines. A few clinical reports have 
described the development of invasive aspergillosis after treatment with TNF blockers 
[12, 13]. This should raise the clinicians’ awareness for a better fungal surveillance during 
treatment with biologicals that target cytokines that are important for the anti-Aspergillus 
host defence
In Chapter 5 we investigated the pattern recognition pathways leading to Th2 re-
sponses induced by Aspergillus, and used this knowledge to discover potential novel 
corticosteroid-sparing therapeutic options. Aspergillus conidia were unique in trigger-
ing Th2 responses in human PBMCs, while no bacteria or fungi other than Aspergillus, 
or single fungal cell wall components, showed the capacity to induce IL-5 and IL-13. 
Interestingly, also Aspergillus hyphae failed to induce IL-5 or IL-13 despite their potent 
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IL-17- and IL-22-inducing capacity. We identified complement receptor 3 recognition and 
phagocytosis as key pathways involved in Aspergillus-specific Th2 responses. Surpris-
ingly, none of the well-known PRRs such as TLR2/4 or dectin-1 were involved in the 
Aspergillus-specific Th2 response. This mechanism might prevent us from triggering an 
allergic response just by inhalation of fungal spores that loose their melanin and rodlets. 
ABPA patients show a unique Aspergillus-specific elevated Th2/Th1-ratio that could be 
restored by recombinant IFNγ, but not by other biologicals such as anti-TNFα or IL-1R 
antagonist. This is in line with some reports that describe an association of exaggeration 
of ABPA with TNFα blockers [14]. These data give a rationale to investigate IFNγ treat-
ment in ABPA patients since it will supplement the Aspergillus-specific IFNγ deficiency 
on the one hand, and dampen the elevated Aspergillus-induced Th2 response on the 
other hand.
Several studies suggest that ABPA shares the same  pathophysiologicalmechanisms 
as asthma. Interestingly, ABPA is more common in India compared to Europe, although 
asthma  has a much higher prevalence in Europe compared to India. Furthermore, only a 
small percentage of people exposed to the high environmental fungal burden develop 
ABPA [15]. This might indicate a strong genetic factor influencing the susceptibility and 
pathogenesis of ABPA. Previous genetic studies have investigated candidate genes and 
confirmed important pathways of the already known antifungal host response, but this 
approach lacks the opportunity to find novel gene associations and has mainly been 
performed in patients with European descent. In Chapter 6 we recruited patients with 
ABPA or asthma from India and performed a gene wide association study (GWAS). We 
used a systems biology approach to combine RNA expression analysis and functional 
genomics to investigate the pathogenesis of ABPA in India.  Unexpectedly we did not 
find classical genes associated with the pathogenesis of asthma and allergy. Suggestive 
associations were found however in genes that interacted with the transcription factor 
STAT3, in genes that regulate the expression of type I interferons, and the vitamin D re-
ceptor. Functional validation confirmed the role of STAT3 in the Aspergillus-specific T cell 
response, especially during IL-17 differentiation. Further, we observed elevated IL-6 and 
IL-17 levels in the serum of ABPA patients, and ABPA serum had the capacity to skew the 
immune response of healthy PBMCs towards a pro-inflammatory profile. These findings 
are in contrast to earlier studies that have described ABPA as a classical Th2-disease, 
and suggest an important role of Th17 as well. Our data are reminiscent of a severe 
corticosteroids-resistant asthmatic phenotype, in which Th2/Th17 double-positive cells 
have been found in bronchoalveolar fluid [16] and blocking the STAT3 pathway had 
beneficial effects in airway inflammation in a multi-allergen challenged mouse model 
[17]. Taken together these findings suggest that the pathophysiology of ABPA might be 
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dependent on dysregulated Th17 responses in addition to an exaggerated Th2 response. 
How the modulation of these cytokines might be a beneficial  adjuvant treatment option 
remains to be elucidated.
Our study could also confirm known pathophysiological mechanisms: vitamin D 
supplementation prevented the development of ABPA in CF patients that has been 
demonstrated in a clinical trial [18]. Therefore, modulation of type I interferons, STAT-3 in-
hibition or vitamin D supplementation might represent treatment options in ABPA which 
could prevent the use of conventional corticosteroid treatment regimen and might lead 
to a more personalized treatment.
The species A. fumigatus is the most common cause for invasive aspergillosis in pa-
tients with hemato-oncological malignancies, while A. nidulans is only a disease-causing 
organism in chronic granulomatous disease. [19]. This observation brought us to ques-
tion how the host defence mechanisms between these two Aspergillus species differ. 
This might lead to an explanation why there is a higher prevalence of A. nidulans in an 
immune system lacking NADPH-oxidase activity. In Chapter 7 we observed that A. nidu-
lans had a lower capacity to induce reactive oxygen species in healthy immune cells, but 
could induce a significant higher pro-inflammatory response compared to A. fumigatus 
conidia. Moreover, A. nidulans was phagocytosed at a slower rate. Although we did not 
perform these experiments in NADPH-oxidase deficient settings, the different kinetics of 
innate immune recognition and phagocytosis might help us to explain why the epide-
miological distribution differs so significantly. Hemato-oncological patients are deeply 
immunocompromised and are deficient in several protective immune mechanisms, such 
as phagocytosis and cytokine responses; thus they are susceptible to any Aspergillus 
species explaining why the species distribution of invasive aspergillosis follows the 
environmental distribution. In contrast, CGD patients have an isolated defective phago-
cytic machinery and ROS production in neutrophils and monocytes, while other immune 
mechanisms such as recognition, cytokine signalling pathways and T cell responses 
are not defective. CGD patients are exposed to the fungal pathogens  for many years, 
which means that an accumulative exposure to A. nidulans in a defective phagocytic 
system can shift the distribution towards an increase to the less efficiently phagocytosed 
species, such as A. nidulans. Although the mechanism remains speculative our observa-
tions might contribute to explain the unique susceptibility of CGD patients to A. nidulans 
infections, and the higher mortality of A. nidulans infections. Further research needs to 
be performed to elucidate the exact reason why patients with CGD are susceptible to A. 
nidulans.
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DefICIenT T HelPeR ResPonses In ClInICAl seTTInGs
In Chapters 4 to 6 we demonstrate the importance of T helper responses for the Apergil-
lus-specific host response with special emphasis on the recognition pathways that drive 
the immune response towards a certain Th response. The second part will focus on the 
role of T helper responses in different clinical settings. We selected patients with  Asper-
gillus osteomyelitis of the skull base, patients with chronic mucocutaneous candidiasis 
and hyper IgE syndrome, as well as patients with other opportunistic infections such as 
non-tuberculous mycobacteria (NTM). NTMs play an important role in ABPA patients: 
like Aspergillus they are opportunistic pulmonary pathogens and chronic colonizers of 
the ABPA lung. Moreover, both are often present concomitantly. 
Local Aspergillus infection, such as Aspergillus skull base osteomyelitis (SBO), is  rare 
, especially in seemingly immunocompetent patients [20]. We studied the Aspergillus-
specific T cell responses in six apparently immunocompetent patients with SBO due to 
Aspergillus in Chapter 8 and observed a specific defect in their Th17 response. While 
the innate immune response did not differ between patients and healthy volunteers, 
the adaptive Th17 responses were significantly decreased after stimulation with fungal 
pathogens in the patients with SBO. This might help to explain why the seemingly im-
munocompetent patients were susceptible for the Aspergillus skull base infection, since 
Th17 plays a protective role in preventing invasive fungal disease. This observation could 
help to explore immunomodulatory treatment strategies next to the common antifungal 
treatment that would induce optimal Th17 responses in these patients.
The IL-17 deficiency associated with Aspergillus SBO was a new finding. In contrast, 
probably the best-studied patients with IL-17 deficiency are patients with chronic mu-
cocutaneous candidiasis (CMC) and hyper IgE syndrome (HIES), both highly susceptible 
to fungal infections [21]. Less is known about their capability to differentiate towards T 
helper responses other than Th17. Interestingly, their predisposition to develop aller-
gies differs tremendously: while allergies are only rarely reported in CMC patients, HIES 
patients can present with atopic eczema, eosinophilia and high IgE levels. In Chapter 
9 we investigated the cytokine profiles of allergic T helper (Th) 2 and 9 responses in 
CMC and HIES patients. Since IL-9 can be derived from the Th17 population, we also 
focused on IL-9 and explored the capacity of IL-9 induction by fungi in the setting of 
Th17 deficiency. We described the induction of Th2 and Th9 responses of four CMC and 
four HIES patients and the capability of these Th responses to be augmented by IL-4 
to skew towards an allergic phenotype. CMC patients were completely deficient in al-
lergic responses, namely IL-5, IL-13 and IL-9 production. In contrast, HIES patients were 
able to respond with a robust Th2 response. However their IL-9 production, especially in 
the presence of IL-4 co-stimulation was defective. Flowcytometric analysis revealed a 
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lower frequency of IL-9+ cells derived from the Th17 population, suggesting that the IL-9 
deficiency is caused by a loss of the Th17 subset in HIES. These data provide evidence 
that the Th17 subset is important for optimal IL-9 responses induced by fungi. How these 
data can directly be translated to the clinical setting remains to be elucidated. Restoring 
IL-9 responses and thereby supporting the IL-17 response might be beneficial for the 
control of the fungal pathogen, a strategy that has been unexplored to date.
Our studies suggest that IL-17 and IL-22 are very important cytokines to control fungal 
pathogens at the site of the mucosa. But, what about other environmental bacteria 
that are facultative pathogens? Patients with cystic fibrosis that are defective in ciliary 
clearance and optimal innate immune responses are also often chronically colonized 
or infected with NTMs. Especially M. abscessus is very difficult to diagnose and to treat 
and moreover might be a reason why a CF patient is rejected for lung transplantation 
[22, 23]. In CF patients diagnosed with a chronic M. abscessus infection we observed 
a complete M. abscessus-specific IL-17 deficiency, in contrast to patients that were 
infected with other NTMs. This might be one of the reasons why these patients had 
a specific increased susceptibility to M. abscessus. In Chapter 10 we deciphered the 
general and pathogen-specific immune cytokine profiles of two CF patients with chronic 
M. abscessus infection and ABPA. Compared to healthy controls, the CF patients showed 
a general exaggerated innate immune response. The Aspergillus-specific T helper re-
sponse was skewed towards Th2, which is in line with their underlying ABPA. Notably, the 
M. abscessus-specific Th17 response of the CF patients was entirely deficient, despite 
their ability to produce IL-17 in response to C. albicans. These data are the first to report 
a possible important role for IL-17 in the human host defense against M. abscessus in 
patients with CF.
Patients with a unique body phenotype with scoliosis and pectus excavatus have been 
described to have a higher prevalence of non-tuberculous mycobacterial (NTM) infec-
tions. This association has been known for quite some time and is also called the Lady 
Windermere syndrome [24]. We performed whole exome sequencing in eleven patients 
with Lady Windermere Syndrome and their family members to identify a new molecular 
mechanism explaining the higher prevalence and susceptibility for NTM infections. In 
Chapter 11, we identified novel mutations in the MST1R gene in 4 out of the 11 patients. 
MST1R has been shown to be important for optimal bronchial cilia function. In addition, 
we demonstrate a second role for the MST1R in this syndrome, since patients carrying 
the mutation were deficient in IFNγ production, an important cytokine in the host defence 
against NTM infection. In further functional analysis, a specific defect in IFNγ production 
in response to NTM was observed when MST1R was blocked, while blocking MST1R 
did not alter other innate cytokines and IL-10. This suggests a dual role for MST1R in the 
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pathogenesis of Lady Windermere Syndrome by playing a role in optimal pulmonary 
cilia function, as well as anti-NTM host defence. It remains to be elucidated whether 
MST1R is involved in the IFN responses via its natural ligand MSP, or whether it is a direct 
PRR. Thus, we describe a genetic association with MST1R with the long known enigmatic 
Lady Windermere Syndrome, and provide novel functional insights into MST1R function 
in this disease that can be clinically relevant for adjunctive immunotherapy.
GeneRAl ConClusIons AnD fuTuRe PeRsPeCTIves
The field of fungal immunology is very dynamic and much knowledge has been gained 
due to the research that has been performed during the last decade. Since fungal infec-
tions are complex in many ways, there are still many challenges ahead of us. Diagnostic 
tools and treatment regimens are limited, antifungal drugs can come with severe side 
effects and high costs, and invasive fungal infections still have an unacceptable high rate 
of mortality. A thorough understanding of the molecular mechanisms underlying the 
anti-fungal host response is urgently needed to develop target-specific and immune-
modulatory treatment strategies to support the conventional treatment in order to 
improve patient outcome.
A healthy immune system is able to control the inhaled Aspergillus conidia. We de-
scribed the Fc-γ pathway as one of the underlying mechanisms recognizing the fungal 
cell wall polysaccharide chitin and playing a role in the initiation of an immune response 
against Aspergillus. The fact that patients with hypogammaglobulinemia suffer from 
recurrent respiratory infections emphasizes the importance of immunoglobulins in 
control and defence of pulmonary pathogens [25]. Chitin-binding antibodies can me-
diate immunomodulatory effects of chitin as described in this thesis. Vaccination with 
antigens and development of antigen-specific antibodies is one of the most resounding 
achievements in the prevention of infections. Up to date, vaccination against fungal 
infections was only successfully proven in mouse models, and no fungal vaccine is on 
the market for humans. Future research must be performed to decipher fungal antigens 
that are most protective against aspergillosis [26]. Chitin is certainly a promising vaccine 
candidate not only as an antigen itself, but also due to its immunomodulatory function; 
it has syngergistic effects with several pathogen associated molecular patterns such 
as LPS providing the rationale to study the effects of chitin together with immunogenic 
Aspergillus proteins in further studies.
Notably, patients with fungal infections are severly immunocompromised lacking 
neutrophils or antigen-specific T helper responses that most likely makes a vaccination 
inefficient. To overcome this problem, more studies need to be performed to elucidate, 
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how either active vaccination before the start of chemotherapy or hemato-oncological 
stem cell transplantation, or passive immunisation with fungal-specific antibodies during 
immunosuppression can help to compensate the deficiency. Moreover, adoptive trans-
fer of Aspergillus-specific T cells has never been successfully performed in a patient 
with invasive aspergillosis, although experimental data look promising. Therapeutic or 
prophylactic adoptive transfer of Aspergillus-specific T cells from the stem cell donor to 
the recipient needs to be improved and should be part of future research.
Aspergillus has the capacity to induce a variable set of T helper responses, ranging from 
protective Th1 and Th17 responses to allergic Th2 responses. A balanced IL-1 response 
is crucial for a successful anti-Aspergillus host response [27] and especially for the dif-
ferentiation towards adaptive immune responses that is a fine-tuned process influenced 
by IL-1. On the one hand, IL-1Ra is beneficial by dampening allergic responses, on the 
other hand IL-1Ra suppresses the beneficial Th1 response as well. Unexpectedly, we 
observed a possible Th17-driven pathogenesis of ABPA in functional genomic studies. 
This gives a rationale to explore the efficacy of anakinra (recombinant IL-1Ra) treatment 
in ABPA patients since IL-17 responses can be inhibited by anakinra. Moreover, patients 
with ABPA were shown to have also defective Th1 responses. The rationale to treat with 
IFNγ would have two sides: on the one hand it supplements the IFNγ deficiency and on 
the other hand it will dampen exaggerated Th2 responses. These two immunomodula-
tory strategies for ABPA are currently under investigation.
The field of immunodeficiencies is very broad and far from being entirely understood. 
Different approaches were used in this thesis to decipher some of the defective mecha-
nisms in these patients. First, we wanted to decipher the pathological mechanism in 
patients with rare infections explaining their higher susceptibility to a specific pathogen. 
We observed a pathogen-specific IL-17 deficiency in patients with Aspergillus SBO 
and CF patients with M. abscessus. This points to a unique interaction of pathogen and 
immune cells and treatment should not be targeted only at eliminating the pathogen 
with antibiotics, but should also be focussed on restoring this defect. Adjuvant immu-
notherapy by augmenting a cytokine deficiency or blocking an exaggerated immune 
response remains a promising treatment option for the future, such as IFNγ or IL-1Ra. 
Secondly, we used immune cells isolated from patients with primary immunodeficien-
cies as an experimental setup. The natural IL-17-deficient setting as seen in CMC and 
HIES patients was used to decipher the allergic Th2 and Th9 responses. This strategy of 
using cells from patients with primary immunodeficiencies helps to investigate specific 
research hypotheses that arise from clinical observations and brings these findings back 
to the patients and even patients with diseases other than fungal infections.
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Innovative diagnostic, prevention and immune-modulatory treatment options are 
strongly needed to overcome our limited possibilities in the management of fungal and 
other opportunistic infections.
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en conclusie
Schimmels zijn eukaryote micro-organismen die overal in de natuur voorkomen, waar ze 
een waardevolle bijdrage leveren aan het ecosysteem door het afbreken van organische 
stoffen. Mensen worden permanent blootgesteld aan schimmels, maar gelukkig heeft 
een gezond afweersysteem verschillende mechanismen om infecties met schimmels 
te controleren. De gist Candida komt als commensaal voor op de menselijke mucosa 
en wordt getolereerd door het immuunsysteem in samenwerking met het microbioom. 
Sporen van de schimmel Aspergillus worden door de lucht verspreid en op een dage-
lijkse basis in grote aantallen geïnhaleerd, echter heeft de mens efficiënte mechanismen 
om deze sporen uit de long te elimineren.
In patiënten met een verstoord afweersysteem, kunnen deze schimmels patho-
gene capaciteiten ontwikkelen en ernstige infecties veroorzaken. Chemotherapie voor 
behandeling van kanker is een van de meest frequente oorzaken van verworven im-
munodeficiëntie. Daarnaast zijn verschilde genetische defecten geïdentificeerd die een 
verhoogde gevoeligheid voor schimmelinfecties kunnen veroorzaken. Deze genetische 
variaties variëren van polymorfismen die de kans op schimmelinfecties vergroten in een 
immuun gecompromitteerde context, tot monogenetische mutaties die geassocieerd 
zijn met een aangeboren immunodeficiëntie.
In tegenstelling, een hyperreactief immuunsysteem kan ook bijdragen aan ontwikke-
ling van allergische infecties. Aspergillus heeft potente allergenen die een hyperreactief 
immuunsysteem kunnen triggeren en bijdragen aan ontwikkeling van ernstig astma met 
schimmelsensitisatie. De allergische reactie kan in ernstige gevallen leiden tot allergi-
sche bronchopulmonale aspergillosis, in het bijzonder in patiënten met ernstig astma of 
cystische fibrose.
Therapeutische mogelijkheden voor behandeling van zowel invasieve en allergische 
schimmelinfecties zijn gelimiteerd. Immuun-modulerende therapieën worden gezien 
als een aantrekkelijke strategie om de behandeling van schimmelinfecties te verbete-
ren. Echter, voor de ontwikkeling van deze nieuwe immuun-modulerende therapieën 
is het van cruciaal belang dat we de moleculaire mechanismen van schimmelinfecties 
beter begrijpen.
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HeRkennInG vAn ASPERGILLUS en InDuCTIe vAn De 
T-HelPeRResPons
Bij het bestuderen van de interactie tussen gastheer en schimmels moet men altijd twee 
kanten in overweging nemen: (1) hoe de schimmel probeert te overleven in de gastheer, 
en (2) hoe de gastheer de schimmel onder controle houdt om infectie te voorkomen.
Bij invasieve schimmelgroei ondergaat de schimmel een verandering van morfolo-
gie, namelijk het uitgroeien tot een filamenteuze vorm genoemd hyphae waarmee de 
schimmel het lichaam kan indringen en een infectie kan veroorzaken. Om verschillende 
morfologische vormen te kunnen herkennen heeft het afweersystem verschillende 
pattern regocognition receptors (PRRs) om een immuunrespons op te wekken (1). In 
hoofstuk 2 geven wij een overzicht van die meest bekende PRRs, die betrokken zijn 
bij de herkenning van de twee meest voorkomende pathogene schimmels, namelijk 
Candida en Aspergillus. Slechts een klein aantal van PRRs en de daarmee verbonden 
signaalcascaden betrokken bij de afweer tegen schimmels zijn bekend. De interactie en 
crosstalk tussen verschillende signaalmoleculen is de reden, waarom het afweersystem 
een specifieke aangeboren en adaptieve immuun respons kan opwekken (2). Het syner-
gisme tussen dectin-1 en TLR2, de activatie van de dectin-1 gemedieerde fagocytose en 
activatie van het NLRP3 inflammasoom zijn de best beschreven mechanismen hoe de 
immuunrespons tegen schimmels gepolariseerd wordt (3, 4). Er is een complexe interac-
tie tussen de verschillende immuuncellen. Neutrofielen, monocyten, macrofagen, NK-
cellen, T-cellen, innate lymphoid cellen, epitheelbarrières en endotheel werken samen 
voor een effectieve immuunrespons tegen schimmels. Polysachariden van de celwand 
van de schimmel zijn liganden voor de PRRs. Verschillende studies hebben onderzocht 
welke receptoren de verschillende schimmel polysacchariden kunnen herkennen, met 
als doel de moleculaire mechanismen van de schimmelherkenning beter te begrijpen 
en betere therapeutische strategieën te kunnen ontwikkelen. In hoofdstuk 3 hebben 
we de immunomodulatoire capaciteit van chitin onderzocht. Chitin is een moelucuul 
van de celwand van Aspergillus. Verschilde aspecten van de capaciteit van chitin om het 
immuun systeem te activeren zijn reeds beschreven. Bueter et al. hebben beschreven 
dat chitin een partikel is zonder immunologische functie, maar Wagener et al. hebben 
gevonden, dat chitin een sterke anti-inflammatoire capaciteit bezit, wat gemedieerd 
wordt door mannosereceptor, TLR9 en NOD2 (5, 6). Een interessante gedachte is dat 
verschillen in de experimentele setup in samenhang met zuiverheid, grote, vorm en ook 
de isolatie van chitinpartikels een verklaring kunnen zijn voor de conflicterende resulta-
ten met betrekking tot de immunogeniciteit van chitin tussen verschillende publicaties 
(7). In onze studie hebben we chitinpartikels van Aspergillus met een partikelgrootte 
van < 0,5 μm gebruikt. Deze partikels hebben een hoge graad aan acetylatie en zijn 
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kortdurend gesonificeerd middels ultrasonicatie. Mogelijke contaminatie van β-glucan is 
verwijderd door degradatie met het enzym β-glucanase. Middels stimulatie van PBMCs 
met deze partikels in de aanwezigheid van humaan serum hebben we de Fcγ/Syk/PI3K 
cascade geïdentificeerd, welke geïnduceerd wordt door chitin, om een sterke anti- en 
pro-inflammatoire immuunrespons te induceren. Ten eerste, hebben we gevonden dat 
Aspergillus-chitin een sterke activator van een anti-inflammatoire immuunrespons is, 
gekarakteriseerd door productie van de anti-inflammatoire cytokine IL-1Ra, maar geen 
pro-inflammatoire cytokines. Immuunglobulines in het humane serum zijn belangrijke 
opsonines, om de Fcγ/Syk/PI3K cascade te activeren. Wij hebben gevonden dat deze 
cascade cruciaal is voor de chitinspecifieke IL-1Ra-inductie.
Ten tweede hebben we laten zien dat chitin in aanwezigheid van andere immuno-
logisch actieve bacteriële celwandcomponenten een potente pro-inflammatoire im-
muunrespons kan induceren. Hierbij maakt chitin gebruik van dezelfde cascade, echter 
door een samenwerking tussen de Fcγ-receptor met TLR2, TLR4 of NOD2 wordt er een 
synergistische pro-inflammatoire immuunrespons geïnduceerd. Samengenomen, weten 
we nu verschillende mechanismen waarmee chitin zijn immuunmodulerende functie 
uitoefent. Chitin kan, in de aanwezigheid van immunoglobulinen, de immuunrespons 
dempen door IL-1Ra te induceren. Als gevolg van dit sterke anti-inflammatoire signaal, 
is het mogelijk voor de schimmel om de humane immuunrespons te onderdrukken en 
daardoor mogelijk schimmelinvasie te faciliteren. Ondanks dat de exacte schimmel-
liganden voor TLR2, TLR4 en NOD2 nog onbekend zijn, is er voor deze receptoren aan-
getoond dat ze een belangrijke rol spelen in de inductie van de immuunrespons tegen 
schimmels (8, 9) (Gresnigt et al., submitted). In tegenstelling tot de anti-inflammatoire rol 
van chitin zou dit kunnen betekenen dat chitin bijdraagt aan een adequate inductie van 
de antifungale immuunrespons door TLR2-, TLR4- of NOD2-gemedieerde signalen te 
amplificeren.
Hoe de crosstalk tussen receptoren verandert gedurende het verloop van infectie 
blijft speculatief, omdat niet veel bekend is over hoe de Aspergillus-celwand verandert 
tijdens de groei van de schimmel en hoe dit een interactie met de immuunrespons heeft. 
Herkenning van schimmelmoleculen is de eerste cruciale stap van een succesvolle 
afweerreactie tegen de schimmel. Daarnaast is een sterke T-helperrespons de sleutel 
voor inductie en versterking van immunologische effectormechanismen die op een 
efficiënte manier de schimmel opruimen en een immunologisch geheugen generen. 
Pattern recognition receptoren slaan de brug tussen het aangeboren immuunsysteem 
en de adaptieve immuunrespons. Dit doordat deze receptoren de uitscheiding van cyto-
kines in cellen van het aangeboren immuunsysteem induceren, deze cytokines induce-
ren op hun beurt naïeve T-helpercellen die vervolgens differentiëren om een specifieke 
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T-helperrespons genereren. Aan de ene kant is invasieve aspergillosis geassocieerd met 
een deficiënte van de Th1- en Th17-respons, anderzijds wordt allergische aspergillosis 
veroorzaakt door een verhoogde en foutief gereguleerde Th2-respons.
In hoofdstukken 4 en 5 hebben we onderzocht welke pattern recognition receptoren, 
signaaltransductie en T-helpersubpopulaties door Aspergillus fumigatus geactiveerd 
worden. Aspergillus kan verschillende specifieke T-helpercytokines induceren, maar 
vooral de inductie van IL-22 wordt belangrijk geacht door de protectieve rol in invasieve 
aspergillosis (10), in tegenstelling tot een destructieve rol in allergische aspergillose (11). 
In hoofdstuk 4 hebben we geïdentificeerd welke receptoren de Aspergillus-specifieke 
IL-17- en IL-22-respons induceren. We hebben kunnen laten zien dat deze respons 
afhankelijk is van TLR4, maar in tegenstelling het blokkeren van TLR2 resulteerde in 
een versterking van deze T-helperrespons. Enigszins verrassend was dat complement 
receptor 3 (CR3) cruciaal was voor de inductie van een Th1- en Th17-respons, maar dat 
de dectin-1 receptor overbodig bleek te zijn. Dit was een onverwachte bevinding, omdat 
dectin-1 geïdentificeerd is als een van de belangrijkste receptoren voor de herkenning 
van Candida albicans en Aspergillus hyphae (3). Verder hebben we de co-expressie van 
verschillende cytokines in Aspergillus-geïnduceerde T-celpopulaties bestudeerd, en 
vonden dat IL-22 niet door een specifieke T-helpersubklasse geproduceerd wordt, maar 
dat er een grote plasticiteit is in het cytokinerepertoire van Aspergillus-geïnduceerde 
T-celpopulaties. Dit betekent dat Aspergillus niet de specifieke T-helperpopulaties zoals 
Th1 en Th17 induceert, maar eerder een diverse plastische T-helperrespons. Deze T-
helperplasticiteit zou kunnen bijdragen bij een snellere een efficiëntere immuun respons 
tegen Aspergillus. Die inductie van IL-17 en IL-22 door Aspergillus conidia en hyphae is 
sterk afhankelijk van de cytokines IL-1β en TNFα. Dat belangrijke informatie met de blik op 
het wijdverspreid gebruik van biologicals voor de behandeling van inflammatoire ziekten 
die specifiek deze cytokineresponsen beïnvloeden. Verschillende casus beschrijven de 
ontwikkeling van een invasieve aspergillosis na behandeling met TNFα blokkers (12, 13). 
De associatie tussen verschillende cytokinecascades en een effectieve inductie van de 
afweerreactie tegen Aspergillus, is een belangrijk aspect dat belangrijk is voor de kliniek. 
Bijvoorbeeld patiënten die met specifieke biologicals behandeld worden, zouden inten-
sief gemonitord moeten worden voor de ontwikkeling van schimmelinfecties.
In hoofdstuk 5 hebben we de PRRs geanalyseerd die betrokken zijn bij de inductie 
van een Th2-respons door Aspergillus. Kennis met betrekking tot de moleculaire mecha-
nismen van de Th2-respons kan gebruikt worden, om nieuwe gerichte therapeutische 
opties te ontwikkelen die de Th2-respons kunnen remmen. Dit zou een aanlokkelijke 
strategie zijn om de huidige veel bredere immunosuppressieve therapie in de vorm van 
corticosteroïden te vervangen. Aspergillus conidia zijn uniek in hun potentie om een 
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Th2-respons in humane PBMCs te induceren. Andere bacteriën, schimmels, of zelfs 
opgezuiverde celwandcomponenten van de schimmel hadden niet de capaciteit om 
een IL-5 of IL-13 respons te induceren. Daarnaast is het heel interessant dat wij vonden 
dat de hyphae van Aspergillus ook geen IL-5 of IL-13 kunnen induceren, ook als zij wel 
in staat een sterke IL-17 en IL-22 respons te induceren. Deze observatie ligt in de lijn der 
verwachting, namelijk specifiek de inhalatie van schimmel sporen wordt gezien als de 
belangrijkste trigger van een astmatische respons in ABPA. We hebben geïdentificeerd 
dat complement receptor 3 en fagocytose van de sporen cruciaal is voor de inductie 
van de Aspergillus-specifieke Th2-respons. Onverwacht was dat geen van de PRRs die 
betrokken zijn bij een efficiënte afweer tegen invasieve aspergillosis (zoals bijvoorbeeld 
TLR2/4 of dectin-1), een rol speelden in de inductie van de Aspergillus-specifieke Th2-
respons. Het feit dat deze receptoren niet betrokken zijn bij de inductie van de Th2-
respons zou een beschermend mechanisme kunnen zijn tegen allergische reacties 
geïnduceerd door de schimmel. Wanneer de T-celrespons van gezonde individuen en 
ABPA-patiënten werd vergeleken, observeerden wij dat ABPA-patiënten een unieke 
verhoging hebben van de ratio tussen de Aspergillus-specifieke Th2- en Th1-respons. 
Mogelijk zou deze verstoring van de Th1/Th2 balans een belangrijke rol kunnen spelen 
in de pathogenese van ABPA en astma met schimmelsensitisatie. Daarom hebben we 
getracht deze balans te herstellen met behulp van biologicals die gericht zijn op de 
immuunrespons. Wij vonden dat in vitro toepassing van biologicals zoals anti-TNFα- of 
IL-1R-antagonisten deze balans niet konden herstellen, echter recombinant IFNγ her-
stelde de disbalans tussen Th2 en Th1. Reeds eerder zijn exacerbaties van ABPA door 
het gebruik van TNF-antagonisten beschreven (14). Dit in samenhang met onze data 
pleit voor klinische studies die onderzoeken of het geven van IFNγ-therapie in ABPA-
patiënten potentie heeft om ten eerste een Aspergillus-specifieke IFNγ-deficiëntie te 
compenseren, en ten tweede en verhoogde Aspergillus-geïnduceerde Th2-respons 
kan verlagen, en daarmee het allergische fenotype terug te dringen en exacerbaties te 
voorkomen.
Verschillende studies suggereren dat ABPA en astma een vergelijkbare onderliggende 
pathogenese hebben. Echter komt ABPA in India duidelijk vaker voor in vergelijking met 
Europa, terwijl de prevalentie van astma veel hoger is in Europa. Slechts een gering 
aantal mensen, dat dagelijks in contact komt met grote hoeveelheden schimmelsporen, 
ontwikkelt hierdoor ABPA (15). Dat duidt op een sterke genetisch factor die gevoelig-
heid voor ABPA beïnvloedt. Eerdere genetische studies hebben genetische kandidaten 
bestudeerd en konden zo van verschillende belangrijke signaalcascades, die al bekend 
waren in de immuunrespons tegen Aspergillus, bevestigen dat ze ook een rol spelen bij 
de pathogenese van ABPA. Deze benadering heeft echter niet geleid tot identificatie 
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van nieuwe genetische associaties. Daarnaast waren deze eerdere studies uitgevoerd 
met een cohort met een Europese genetische achtergrond. In hoofdstuk 6 hebben wij 
ABPA-patiënten uit India gerekruteerd en met behulp van een immunochip assay ge-
genotypeerd. We hebben gebruik gemaakt van systeembiologie, expressie-analyse en 
functionele genetische analyse om de pathogenese van ABPA in de Indische populatie 
te bestuderen. Onverwacht was dat we geen typisch genetisch patroon hebben kunnen 
identificeren dat geassocieerd was met de pathogenese van astma en allergie. Wan-
neer wij de ABPA-patiënten met de controlegroep vergeleken, hebben wij significante 
associaties met genen gevonden, betrokken bij de transcriptiefactor STAT3, genen die 
de expressie van IRF8 reguleren, en een gen, dat de vitamine D-receptorexpressie 
reguleert. Met behulp van functionele validatiestudies hebben we de rol van STAT3 in 
de Aspergillus-specifieke T-celrespons kunnen bevestigen, in het bijzonder in de Th17-
differentiatie. Verder hebben wij gezien dat naast een verhoogde Th2-respons ook IL-6 
en IL-17 verhoogd zijn in het serum van ABPA-patiënten. Daarnaast hebben we gevon-
den dat ABPA-serum de capaciteit heeft om de immuunrespons van PBMCs geïsoleerd 
uit gezonde individuen naar een pro-inflammatoir profiel te brengen. Deze bevindingen 
staan in tegenstelling tot vroegere studies die ABPA als een typische Th2-gerelateerde 
ziekte beschrijven. In de bronchoalvelolaire lavage van ABPA-patiënten zijn Th2/Th17-
dubbelpositieve celen gevonden (16), en het blokkeren van het STAT3-signaal heeft een 
positief effect op de luchtweginflammatie in allergiemuismodellen (17). Samenvattend 
suggereren deze resultaten dat the pathofysiologie van ABPA afhankelijk is van een 
slecht gereguleerde pro-inflammatoire Th1- respons in samenhang met een verhoogde 
Th2-respons. Verder zijn type I interferonen geassocieerd met chronisch mucocutane 
candidiasis en betrokken bij de pathogenese van ABPA (18). Hoe de modulatie van 
cytokines kan bijdragen als een aanvullende therapie moet nog nader onderzocht 
worden in toekomstige studies. Onze studie heeft verschillende bekende pathologische 
mechanismen kunnen bevestigen. Een klinische trial heeft aangetoond, dat vitamine D-
suppletie een beschermend effect heeft op de ontwikkeling van ABPA in CF-patiënten 
(19). De modulatie van type I interferonen, STAT3-inhibitie of vitamine D-suppletie zou-
den mogelijke nieuwe therapeutische opties zijn voor ABPA.
Die species A. fumigatus is de meest voorkomende Aspergillus-soort, die invasieve as-
pergillosis in patiënten met haemato-oncologische onderliggende ziekten veroorzaakt. 
In tegenstelling, A. nidulans veroorzaakt zelden infecties in deze patiëntengroep en 
veroorzaakt alleen infecties in patiënten met chronische granulomateuze ziekte (CGD) 
(20). In hoofdstuk 7 hebben wij gezien dat A. nidulans een lagere capaciteit heeft om 
reactieve zuurstofmoleculen te induceren in immuuncellen van gezonde individuen, 
echter induceert A. nidulans significant meer pro-inflammatoire cytokines in vergelijking 
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met A. fumigatus. Verder hebben we geobserveerd dat A. nidulans minder efficiënt 
gefagocyteerd wordt dan A. fumigatus. Ondanks dat deze experimenten niet in NADPH-
oxidase deficiënte cellen zijn uitgevoerd, de verschillen in de kinetiek van aangeboren 
immuunherkenning en fagocytose kan mogelijk de verschillende epidemiologische 
verdeling te verklaren zijn. Hemato-oncologische patiënten hebben een sterk verzwakt 
afweersysteem en zijn deficiënt voor verschillen immuunfuncties, zoals fagocytose 
en het induceren van een cytokinerespons; dus zijn deze patiënten vatbaar voor As-
pergillus-species. Dit verklaart mogelijk ook waarom de prevalentie van verschillende 
geïsoleerde Aspergillus-species in deze patiënten de verdeling in de omgeving volgt. 
In tegenstelling, CGD-patiënten hebben een geïsoleerd fagocytosedefect en deficiënte 
ROS-productie in neutrofielen en monocyten. Echter zijn andere immuunfuncties zoals 
pathogeenherkenning, cytokineproductie en T-celresponsen intact. CGD-patiënten 
zijn gedurende hun hele leven aan schimmels blootgesteld, wat betekend dat ze een 
cumulatieve blootstelling hebben aan A. nidulans. In patiënten met een levenslange 
gevoeligheid voor aspergillosis zal de verdeling verschuiven richting meer A. nidulans 
infecties, gezien de minder efficiënte fagocytose van deze schimmel. Onze observatie 
zou kunnen bijdragen aan de verklaring waarom GCD-patiënten een unieke vaatbarheid 
voor A. Nidulans-infecties hebben en zou daarnaast kunnen verklaren waarom infecties 
met A. nidulans geassocieerd zijn met een hogere mortaliteit. Er is zeker nog meer on-
derzoek nodig om dee exacte reden te vinden, waarom CGD patiënten zo gevoelig voor 
A. nidulans infecties zijn.
DefICIënTe T-HelPeRResPons In klInIsCHe seTTInG
In hoofdstukken 4 tot 6 hebben we gedemonstreerd dat de T-helperrespons belangrijk 
is voor de Aspergillus-specifieke immuunrespons. Het eerste deel van dit werk is gefo-
cusseerd op het ontrafelen van liganden, receptoren en cytokines die betrokken zijn in 
de Aspergillus-specifieke immuunrespons in in vitro-modellen; daarentegen hebben we 
in het tweede deel de focus gelegd op de rol van T-helperresponsen in een klinische 
setting. We hebben verschillende patiënten onderzocht, zoals onder andere patiënten 
met lokale Aspergillus-infecties in de schedelbasis, patiënten met chronische mucocu-
tane candidiasis en hyper-IgE-syndroom, maar ook patiënten met andere opportunisti-
sche infecties, zoals patiënten met infecties met niet-tuberculoze mycobacteriën (NTM). 
Opmerkelijk is dat de NTM-infecties veel overeenkomst delen met schimmelinfecties: 
beide zijn opportunistisch, veroorzaken infecties in de long en ABPA-patiënten zijn chro-
nisch gekoloniseerd met Aspergillus en NTMs.
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Lokale Aspergillus-infecties, zoals Aspergillus-schedebasisosteomyelitis (SBO) zijn 
uiterst zeldzaam (21). In hoofdstuk 8 hebben wij de Aspergillus-specifieke T-celrespons 
in schijnbaar immuuncompetente patiënten met Aspergillus-SBO bestudeerd. Hierbij 
hebben we een specifiek defect in de Th17 respons gevonden. De stimulatie van cel-
len van zes patiënten met Aspergillus-SBO met bacteriële en schimmelantigenen heeft 
aangetoond dat de aangeboren immuunrespons tussen patiënten en controles niet ver-
schillend is. Echter hebben deze patiënten wel een significant verlaagde Th17-respons 
na stimulatie met schimmelantigenen. Dit zou kunnen verklaren, waarom schijnbaar 
immuuncompetente patiënten gevoelig zijn voor Aspergillus-SBO, omdat de Th17-
respons een belangrijke rol speelt in de verdediging tegen invasieve schimmelinfecties. 
Onze observatie zou kunnen helpen bij de ontwikkeling van een immuunmodulerende 
therapeutische strategie die gericht is op het induceren van een optimale Th17-respons.
De IL-17-deficiëntie geassocieerd met Aspergillus-SBO was een onverwachte bevin-
ding. In tegenstelling, is IL-17-deficiëntie een van de best bestudeerde mechanismen 
in patiënten met chronische mucocutane candidiasis (CMC) en hyper-IgE-syndroom 
(HIES). Beide patiëntengroepen zijn extreem gevoelig voor het ontwikkelen van schim-
melinfecties (22). Er is echter minder bekend over de andere T-helperresponsen die 
naast de Th17-respons ook een belangrijke rol in de gevoeligheid voor schimmelinfec-
ties zou kunnen spelen. De predispositie om een allergie te ontwikkelen verschilt enorm 
tussen deze twee patiëntengroepen: allergieën zijn bijna nooit in CMC-patiënten gerap-
porteerd, maar HIES-patiënten zijn bekend met presentatie van atopisch eczeem, eosi-
nofilie en hoge IgE-levels. In hoofdstuk 9 hebben we de cytokineprofielen van Th2- en 
Th9-responsen in CMC- en HIES-patiënten bestudeerd. Omdat IL-9 geproduceerd kan 
worden door Th17-cellen, hebben we specifiek op IL-9 gefocust, en hebben onderzocht 
of CMC- en HIES-patiënten met een IL-17 deficiëntie wel IL-9 kunnen produceren.
We hebben de inductie van Th2- en Th9-responsen van vier CMC- en vier HIES-
patiënten onderzocht. Om de capaciteit van deze cellen om specifiek een allergisch 
fenotype te induceren beter te kunnen beoordelen hebben wij IL-4 toegevoegd aan 
het kweekmedium. CMC-patiënten waren compleet deficiënt in het induceren van 
Th-responsen die geassocieerd zijn met allergie, namelijk IL-5, IL-13 en IL-9 met en 
zonder IL-4-toevoeging. In tegenstelling, HIES-patiënten hadden wel de capaciteit om 
een robuuste Th2-respons te induceren. Echter was de IL-9-productie in beide groepen 
deficiënt. Met behulp van flowcytometrie hebben we aangetoond dat IL-9+-cellen in de 
Th17-populatie te vinden zijn en HIES-patiënten een kleinere populatie van IL-9+-IL-17+-
cellen hebben. Dat betekent dat de Th17-populatie ook belangrijk is voor de inductie 
van een optimale IL-9 respons. Hoe deze data direct naar een klinische setting vertaald 
kunnen worden, moet nog nader onderzocht worden. Het herstellen van een sterke 
Nederlandse samenvatting en conclusie   |  261 
13
IL-9-respons en daarbij ook de Th17-populatie zou nuttig kunnen zijn voor een betere 
controle van schimmelinfecties.
Onze studies suggereren dat IL-17 en IL-22 belangrijke cytokines zijn in de afweer 
tegen schimmels op de mucosa. Patiënten met cystische fibrose (CF) hebben een defi-
ciënte ciliaire clearance en zijn vaak chronisch gekoloniseerd of geïnfecteerd met NTMs. 
Vooral M. abscessus is een moeilijk te diagnosticeren en te behandelen mycobacterium 
en vaak een reden waarom patiënten afgewezen worden voor longtransplantatie (23, 
24). We hebben in CF-patiënten die een chronische M. Abscessus-infectie hebben, een 
M. abscessus-specifieke IL-17-deficiëntie gevonden, in tegenstelling tot patiënten met 
andere NTM-infecties. Dit zou mogelijk een reden kunnen zijn waarom deze patiënten 
een verhoogde gevoeligheid voor M. abscessus hadden. In hoofdstuk 10 hebben we 
het algemene en pathogeen-specifieke cytokineprofiel van twee CF-patiënten met 
chronische M. Abscessus-infectie en ABPA onderzocht. In vergelijking met de gezonde 
controles hebben de CF-patiënten een verhoogde aangeboren immuunrespons. De 
Aspergillus-specifieke T-helperrespons was richting Th2 gepolariseerd, wat past bij 
hun ABPA-fenotype. Wij vonden echter dat de M. abscessus-specifieke Th17-respons 
compleet deficiënt was, desondanks dat deze individuen wel de capaciteit hadden om 
IL-17 te produceren in respons op Candida. De M. abscessus-specifieke IL-17-defichientie 
kan mogelijk een rol spelen in de gevoeligheid van CF=patiënten om chronisch gekolo-
niseerd te zijn met M. Abscessus.
Een hogere prevalentie van NTM-infecties is ook beschreven bij patiënten met een 
unieke lichaameigenschappen zoals scoliose en pectus excavatus. Deze associatie is al 
lang bekend en word ook het Lady Windermere Syndrome genoemd (25). We hebben 
een ‘whole exome sequencing’ studie in 11 patiënten met Lady Windermere syndrome 
en hun familieleden gedaan om mogelijke onderliggende genetische defecten te 
identificeren die de hogere prevalentie en gevoeligheid voor NTM-infecties in deze 
patiëntengroep zou kunnen verklaren. In hoofdstuk 11 beschrijven we een mutatie in 
het MSTR gen dat werd gevonden in 4 van de 11 patiënten. Het MSTR1 gene is belangrijk 
voor een optimale bronchiale ciliare functie. Daarnaast hebben we een tweede rol voor 
MSTR1 in dit syndroom aangetoond, de patiënten met deze mutatie lieten een spe-
cifieke deficiënte IFNγ-productie zien. Verdere functionele analyse heeft aangetoond 
dat IFNγ-productie defect was na stimulatie met NTM in de aanwezigheid van een 
MST1-receptorblokker. Echter andere cytokines geproduceerd door het aangeboren im-
muunsysteem werden niet door deze blokkade beïnvloed. Deze bevinding suggereert 
een tweeledige rol voor MST1R in de pathogenese van Lady Windermere syndroom: 
ten eerste, de optimale controle van de pulmonale ciliaire functie en ten tweede een 
belangrijke rol in de immuunrespons tegen NTMs.
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Het veld dat de immunologie in schimmelinfecties onderzoekt is zeer dynamisch en er 
is veel nieuwe kennis opgedaan in de laatste jaren. Omdat schimmelinfecties zeer com-
plex zijn, liggen er nog vele aantal uitdagingen voor ons. Diagnostische mogelijkheden 
en therapeutische strategieën zijn gelimiteerd, antimykotische medicatie heeft serieuze 
bijwerkingen en is duur, en invasieve schimmelinfecties hebben steeds nog een zeer 
hoge mortaliteit. Een breed inzicht in die moleculaire mechanismen van de immuun-
respons tegen schimmels is dringend nodig om doelgerichte immuun-modulerende 
therapeutische strategieën te ontwikkelen. Deze nieuwe therapeutische strategieën zijn 
nodig om de conventionele therapie te ondersteunen en mortaliteit van deze infecties 
terug te brengen. Een gezond immuunsysteem kan ie geïnhaleerde Aspergillus-sporen 
gemakkelijk controleren. We hebben beschreven dat de Fc-γreceptor Aspergillus-chitin 
herkent en de immuunrespons tegen Aspergillus initieert. Het feit dat patiënten met 
hypogammaglobulinemia recidiveerde respiratorische infecties hebben, ondersteunt 
het belang van immunoglobulinen in de afweer tegen pulmonale pathogenen [25]. 
Het immuunmodulerende effect van chitin was gemedieerd door chitinbindende anti-
lichamen. Vaccinatie met antigenen en ontwikkeling van specifieke antilichamen is een 
van de meest geweldig ontwikkelingen in preventie van infecties. Vaccinaties tegen 
schimmels zijn tot nu toe alleen nog in muismodellen succesvol getest. Toekomstig 
onderzoek dient de meest protectieve antigenen tegen Aspergillus identificeren [26]. 
Chitin is met zekerheid een veelbelovend vaccinatiekandidaat niet alleen als antigen 
zelf, maar het zou ook door zijn immuunmodulerende functie als adjuvant kunnen 
dienen. Bij de ontwikkeling van vaccinatiestrategieën moeten we niet vergeten dat 
patiënten met schimmelinfecties vaak immuuncomprimeerd zijn en geen neutrofielen 
of antigen-specifieke T-helperresponsen kunnen opwekken. Dit maakt een vaccinatie 
heel moeilijk en inefficiënt. Om dit probleem te overkomen zouden toekomstige studies 
zich er op kunnen richten om uit te zoeken, of een actieve vaccinatie voor een che-
motherapie of stamceltransplantatie, of passieve vaccinatie met schimmelspecifieke 
antilichamen tijdens immuunsuppressie een voordelig effect kunnen hebben op het 
terugdringen van de incidentie en mortaliteit van schimmelinfecties in deze patiënten. 
Adoptieve transfer van Aspergillus-specifieke T-cellen is nooit succesvol in een patiënt 
met invasieve aspergillosis uitgevoerd, terwijl de experimentele data er veelbelovend 
uitzien. Therapeutische en profylactische adoptieve transfer van Aspergillus-specifieke 
T-cellen van donor naar zijn ontvanger moet nog sterk verbeterd worden. Aspergillus 
heeft de capaciteit een breed scala aan van T-helperresponsen te induceren. Dit reikt 
van de protectieve Th1respons tot de Th2-respons die betrokken is bij ontwikkeling van 
allergie. Een gebalanceerde IL-1-respons is cruciaal voor een succesvolle afweer tegen 
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Aspergillus [27] en in het bijzonder voor de differentiatie en polarisatie van de adaptieve 
immuunrespons. Ten eerste, IL-1Ra is een goede kandidaat voor het dempen van de al-
lergische immuunrespons die een rol speelt bij ABPA, echter ten tweede kan IL-1Ra ook 
die nuttige Th1-respons onderdrukken. Enigszins onverwacht hebben we de observatie 
gemaakt dat ABPA-patiënten ook verhoogde IL-17-respons hebben, een sterke pro-
inflammatoire respons die zou kunnen bijdragen aan de pathogenese van ABPA. Deze 
observatie zou een goede rationale zijn om de effectiviteit van Anakinra (recombinant 
IL-1Ra) therapie in ABPA-patiënten te onderzoeken, omdat de mogelijk schadelijke IL-
17-respons door Anakinra sterk geremd kan worden.
Het veld van immuundeficiënties is zeer breed en veel immuundeficiënties zijn nog 
slecht bestudeerd. In dit proefschrift zijn verschillende strategieën toegepast om enkele 
immuundeficiënties verder te ontrafelen. Onze intentie was om de pathologische me-
chanismen in patiënten met zeldzame infecties te onderzoeken, vooral met het doel te 
verklaren waarom deze patiënten gevoelig zijn voor specifieke zeldzame pathogene. We 
hebben pathogeen-specifieke IL-17-deficiënties gevonden in patiënten met Aspergillus-
SBO en CF-patiënten met een M. Abscessus-infectie. Dit wijst op een unieke interactie 
tussen pathogeen en het immuunsysteem die resulteert in pathogeen-specifieke 
immuun responsen. De therapie bij deze immuundeficiënties moet niet alleen op de 
eliminatie van het pathogeen door antimicrobiële medicatie focussen, maar vooral op 
de compensatie van de onderliggende cytokinedeficiëntie. Als experimentele setup 
hebben we primaire immuuncellen geïsoleerd van immuundeficiënte patiënten. De 
IL-17-deficiëntie zoals gezien in patiënten met CMC en HIES hebben we gebruikt, om 
de allergische Th2- en Th9-respons te onderzoeken. Deze strategie kan bijdragen om 
specifieke onderzoek hypothesen te bevestigen en zal het bijdrage aan nieuwe kennis 
die direct vertaald kan worden naar de behandeling van de patiënt.
Innovatieve diagnostische, preventieve en immuunmodulerende therapeutische 
opties zijn dringend nodig, om de gelimiteerde mogelijkheden van de behandeling van 
schimmelinfecties en andere opportunistische infecties te overkomen.
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koffie pausen, de lunch of bij de talrijke borrels. Jullie hebben bijgedragen, dat ik die 
drie jaar in Nijmegen heel erg heb genoten. Nooit was eer iemand, die niet zijn hulp 
heeft aangeboden! Ajeng, Anca, Anne J, Anne A, Arjan, bas b, bas H, Daniela, Diana, 
Duby, floor, Hedwig, Inge, Jaap, James, Janna, Jesicca, Johanneke, kathrin T, khutso, 
kiki, lilly, lisette, Maartje, Marije, Mariska, Mark s, Martin, Megan, Michelle, Monique, 
Reinout, Richard, Rinke, Rob A, Rob t H, Ruud, sandra, sanne, shan, siroon, Teske, 
274  |  Chapter  13
Theo, vesla, wouter. Beste Cor, ik was nog een van die laatste, die van jouwen dropjes 
voorraad op het lab kunde genieten. Maar vooral wil ik je danken voor die uren, die je met 
mij bij het FACS hebt gezeten, om nieuwe dinge op te zetten op data te interpreteren. 
Beste Heidi en Helga, beste Ineke en Anneke, bedankt voor jullie hulp met alles. Nooit 
was iets niet mogelijk! Beste Trees en liesbeth, bedankt voor jullie hulp met stimulatie 
experimenten en die goede samenwerking in het ELISA coating team. 
Dear xiaowen, it was a pleasure to work together with you for one year in Nijmegen. 
Although we live now on opposed parts of the globe, many common things connect us! 
Prof. dr. Willem Melchers, dear willem, thank your very much for being my mentor!
Liebe Conni, meine treue Hamburger Deern! Du hast immer dafür gesorgt, dass wir auch 
mal vom Lab abschalten konnten. Danke für all die schönen Stunden beim Kochen, Chor 
oder Radfahren! Beste Alphons Diepenbrook studentenkoor, bedankt voor twee pret-
tige jaren met repetities en concerten met jullie; het was ontzettend leuk!
Meine lieben Freundinnen aus Schul- und Studienzeit, Julia, Jule, kathrin, Melly, Melitta 
und verena. Auch wenn uns schon lange nicht mehr der tägliche Schulbus verbindet, 
versuchen wir doch, uns an sämtlichen Flecken der Erde zu besuchen oder zu Hause in 
Bubenreuth zu treffen. Vielen Dank für immer offene Ohren, eure Unternehmungslustig-
keit, legendäre durchzechte Nächte und dass es euch gibt! 
Liebe Mama, lieber Papa, danke, dass ihr mir beigebracht habt und mir jeden Tag aufs 
Neue vorlebt, dass man sich nicht unterkriegen lassen darf. Ihr habt immer an mich 
geglaubt und mich in allem unterstützt! Papa, dein unendlicher Idealismus und die Be-
geisterung für die Forschung haben mich immer fasziniert. Lieber Chris, liebe bettina, 
schon lange seid ihr nicht mehr „nur“ meine kleinen Geschwister, sondern zusammen 
mit Doro und Robin und dem kleinen benjamin auch sehr gute Freunde. Auch wenn wir 
in drei verschiedenen Himmelsrichtungen wohnen, probieren wir doch immer, so oft wie 
möglich nach Hause zu kommen und am Leben der anderen teilzuhaben. Danke, dass 
ihr immer für mich da seid. 
Liebe Dörte, lieber Claus, liebe(r) karsten, Anke, sönke, nina, Helge und steffi mit allen 
neun Nichten und Neffen, vielen Dank, dass ich ein Teil der Gößling’schen Großfamilie 
werden durfte. Mit viel Interesse habt ihr die letzten Jahre verfolgt und Enno und mich 
bei jeder Gelegenheit unterstützt!
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Lieber enno. Schon lang ist’s her, dass ich dir per skype– du in Ghana im PJ – und ich in 
Nijmegen für ein Praktikum – total angefixt von Idee berichtet habe, in Nijmegen einen 
PhD zu machen. Du hast mich immer ermuntert, meine Träume und Ziele zu verfolgen, 
auch wenn es viel Entbehrung bedeutet hat. Wenn ich gestresst war, hast du es geschafft, 
mich runterzuholen, und wenn ich glaubte, alles würde mal wieder nicht gelingen, hast 
du es immer geschafft, die Probleme ins rechte Licht zu rücken und mich aufzubauen. 
Ich bin dir unglaublich dankbar für alles! Ich freue mich riesig auf die vielen schönen 
Dinge und Herausforderungen, die das Leben noch für uns bereithält! 
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